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CHAPTER I: INTRODUCTION 
Overview 
This introductory chapter will supply background information necessary to situate and understand the 
original research contained in this dissertation. The chapter is divided into two sections: the first is focused on 
clinical background, namely, lung adenocarcinoma; the second is focused on the biology of the epidermal 
growth factor receptor (EGFR)a. The first section will detail the cellular and molecular pathology of lung 
adenocarcinoma, explain the transition from the historical histological characterization of the disease to the 
modern molecular characterization, and, finally, describe EGFR-mutant lung cancer, a molecular subtype of 
lung adenocarcinoma. The second section will concentrate on the biology of EGFR, including the receptor’s 
structure, function, and aberrant activation in lung cancer. 
Clinical Background 
Lung Adenocarcinoma 
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for over 160,000 
deaths per year in the United States (2). Despite advances in the molecular characterization of tumors, the 
histopathology of lung cancer remains the basis for diagnosis and treatment of the disease. As such, lung 
cancer remains broadly divided into histologically-defined non-small cell lung cancer (NSCLC; 85% of lung 
cancers) and small cell lung cancer (SCLC; 15% of lung cancers) (Figure 1.1A) (3). NSCLC can further be 
divided into several histological subtypes, of which adenocarcinoma is the most common—comprising nearly 
half of all lung cancers (Figure 1.1B) (4).  
Although lung adenocarcinoma accounts for under 5% of cancer diagnoses every year, it accounts for 
over 10% of all cancer-related deaths (5). The prognosis remains poor for patients with lung adenocarcinoma 
because the cancer most commonly is detected at an advanced stageb. The majority of symptomatic patients 
with lung adenocarcinoma have advanced disease. In fact, more patients with lung adenocarcinoma present 
with vague symptoms of metastatic disease (such as headache, visual changes, or seizures) or nonspecific 
constitutional symptoms (such as anorexia, fatigue, and weight loss) than with symptoms related to the primary 
tumor (such as cough or dyspnea) (8-12). 
Treatment of lung adenocarcinoma is commensurate with the stage of the disease. Surgery provides 
the best chance for cure in the setting of early stage disease (13). Multimodal treatments, which can include 
combinations of surgery, radiotherapy, and/or chemotherapy, are used successfully in intermediate stage 
disease (14). However, because patients commonly present with advanced or unresectable disease, 
chemotherapy is the mainstay of treatment for lung adenocarcinoma. Until recently, two agent mixes of 
cisplatin or carboplatin and paclitaxel, docetaxel, gemcitabine, or pemetrexed—called platinum doublets—were 
used to treat the majority of patients with lung adenocarcinoma (15)c. Irrespective of the mix of agents used, 
objective response rates (ORRd) of lung adenocarcinoma treated with platinum doublets ranged from 20–35% 
and overall survival (OSe) plateaued at 8–10 months (21,22). The advent of immunotherapy, emerging as the 
standard of care for most patients with NSCLC (23), is likely to change these dire outcomes. 
From Phenotype to Oncogene Addiction 
Nearly all lung cancers exhibit features of epithelial cells and are accordingly classified as carcinomas. 
The histological features that distinguish adenocarcinomas from other lung cancers are glandular 
differentiation and mucin production (24). The glandular elements and mucin vacuoles of adenocarcinomas 
may be arranged in several aberrant patterns, and these various arrangements form the basis for the division 
of adenocarcinomas into several different subtypes (Figure 1.1C) (4). Historically, the classification of lung 
adenocarcinoma relied on the expertise of individual pathologists to identify these patterns—leading to differing 
diagnoses, treatments, and prognoses. To rectify this issue, the World Health Organization (WHO) created, 
and has updated and maintained (3), a standard nomenclature for the classification lung cancer based on 
precise histology and/or cytology.  
Although histological subtypes still influence tumor classification and treatment, the recognition that 
lung cancer is a genetic disease has prompted a push to reconfigure cancer taxonomies according to 
molecular criteria (3,25). While there are, on average, more than 300 non-synonymous mutations per lung 
adenocarcinoma (26), mutations in only 140 or so of these genes can promote or ‘drive’ lung tumorigenesis 
(27). The products of these mutated cancer driving genes—drivers (28)—can be mapped onto a limited set of 
cell signaling pathways (29), which themselves can be grouped into a couple of cellular processes that define 
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Figure 1.1: Progressive subtyping of lung cancer 
A, classical view of tumors arising in the lung including non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC) (3). Rare tumor types include NUT carcinoma, defined by the presence of BRD-NUT fusion protein. B, histological 
subtypes of NSCLC (5). Rarer tumor types include large cell neuroendocrine carcinoma (LCNEC). C, histological 
subtypes of lung adenocarcinoma (4,30). D, molecular subtypes of lung adenocarcinoma (31). EGFR, KRAS, FGFR1, etc. 
correspond to the dominant driver (gene) alteration.
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the selective advantage of cancer cells: altered cell fate and survival (27). Though there is still some debate, 
just a few key driver mutations are sufficient to transform normal human lung cells to a tumorigenic state: P53 
or RB inactivation and MYC, RAS, and/or TERT activation (32-36). Inhibition of any of these key drivers can 
lead to loss of the malignant phenotype (37), hinting that these drivers may not only be sufficient, but also 
necessary for lung tumor formation. Indeed, many data accumulated over the past decades show that cancers 
are ‘addicted to’ (that is, physiologically dependent) on the continued activity of a few specific activated or 
overexpressed drivers for their malignant phenotype (38,39). Nearly all lung adenocarcinomas contain genetic 
alterations in—at least some of— the arbiters of cell fate (P53, RB, MYC, TERT) leading to a selective growth 
advantage by favoring cell division over differentiation (26). Where lung adenocarcinomas seem to differ from 
one another is in the way that they activate cell survival signaling (typified by RAS activation) (40,41). 
Therefore, despite the enormous histological variation (over 10 subtypes (42)) and genetic complexity (over 10 
mutations per megabase (43)) present in lung adenocarcinoma, one can ‘simply’ classify tumors by the way in 
which their cell survival signaling is driven.  
 As such, lung adenocarcinoma can now be considered a cluster of discrete molecular diseases, with 
most being defined by a single driver alteration that effects cell survival (Figure 1.1D) (44). The defining 
molecular alterations used to subtype adenocarcinomas are all involved in cell survival for two reasons: firstly, 
lung adenocarcinomas otherwise share a similar cell fate (highlighted by some combination of P53, RB, MYC, 
TERT alterations); and, secondly, the alterations involved in cell survival, as opposed to cell fate, are currently 
actionable—that is, potentially responsive to an available targeted therapy (45). Such known and/or putative 
(cell survival) drivers in lung adenocarcinoma include mutated AKT1, BRAF, DDR, EGFR, HER2, KRAS, 
MEK1, MET, NRAS, PIK3CA, PTEN; re-arranged ALK, EGFR, NTRK1, RET, ROS1; and amplified FGFR1 and 
METf (31). Alterations in any of these driver genes effects cell survival—mainly via modulation of the MAPK 
and/or PI3K/AKT signaling pathways—and are, or may be, amenable to available targeted therapy (50). Rather 
than empiric treatment based on histological classification (an approach whose benefits have plateaued; ORR 
20–35% (21)), molecular classification of lung adenocarcinoma by driver alterations has revolutionized the 
prognosis and treatment of the disease. It is now standard for tumors to be genotyped and for patients to be 
given a driver-targeted therapy, to which they will likely respond (ORR ≥ 60% (51)). Such advancements have 
made lung adenocarcinoma the poster child for precision medicine, which is most apparent in EGFR-mutant 
(EGFR-driven) lung adenocarcinoma. 
 
EGFR-mutant lung cancer 
 As soon as EGFR, a receptor tyrosine kinase (RTK), was connected with lung cancer (52), much effort 
was spent in attempts to therapeutically block the protein’s aberrant signaling, first with antibodiesg, and then 
with small molecule EGFR tyrosine kinase inhibitors (EGFR-TKIs). Ever since phase III studies demonstrated 
their efficacy (57,58), the first EGFR-TKIs, erlotinib (59) and gefitinib (60), have been in clinical use. However, 
during initial clinical studies against NSCLC, the ORR of EGFR-TKIs varied greatly, from 7 to 70%, and 
averaged ≤ 25%—comparable to standard chemotherapy (24). Retrospective analyses led to the determination 
that response to an EGFR-TKI was dependent on specific clinical factors including smoking history (never-
smokers responded 38% of the time vs. former/current smokers 10%), gender (men 13% vs. women 36%), 
histological subtype (adenocarcinoma 27% vs. 7% for all others), and ethnicity (East Asian 29% vs. 8% for all 
others) (61). These observations led to the design of new clinical trials which attempted to evaluate the efficacy 
of EGFR-TKIs in never-smoking East Asian patients with lung adenocarcinoma, leading to more predictable 
and durable responses (62).  
 In seeking to understand why some patients with lung adenocarcinoma had dramatic responses to first-
generation EGFR-TKIs, while others derived little clinical benefit, somatic mutations in EGFR were discovered 
in a subset of NSCLC patients (63-65). These mutations, primarily found as a series of deletions in exon 19 
(ex19del) or as leucine to arginine substitutions at codon 858 (L858R), enable constitutive activation of the 
EGFR tyrosine kinase domain (TKD) and sensitize cancer cells to EGFR-TKIs (66). This information was 
incorporated into clinical trial design, leading to trials comparing EGFR-TKIs to platinum-based chemotherapy 
in select patients with EGFR-mutant (defined as EGFR ex19del or L858R) tumors. Groundbreaking initial 
results demonstrated that patients with EGFR-mutant tumors achieved significantly longer progression-free 
survival (PFSh) with gefitinib as opposed to those receiving platinum doublets (hazard ratioi of 0.48 (62). 
Moreover, ORRs in these patients were over 60% (62). Similar results subsequently were observed in 
populations of differing ethnicities and with different EGFR-TKIs (68-74). As a result, erlotinib, gefitinib and, 
most recently, afatinib (a second generation EGFR-TKI (75)) received approval for first-line treatment of 
EGFR-mutant NSCLC. Furthermore, several multivariate analyses have revealed that EGFR mutation status is 
Figure 1.2: Refinement in the treatment of lung cancer 
Evolution in the progression free survival (PFS, green), overall survival (OS, blue) and objective response rates (ORR, red) of treatment naïve lung cancer. The 
trend towards treating molecularly-defined cohorts of lung adenocarcinoma (LUAD) to achieve better response and survival rates was recently bucked by 
pembrolizumab, an anti-PD1 antibody (17,21,23,62,76,77). This immunotherapy agent holds promise in treating broad swaths of NSCLC without a driver mutation. 
The ORR of pembrolizumab is significantly better than platinum-based chemotherapy against NSCLC, as is its survival benefit—so much so that median OS data 
has yet to be reached and is not shown here.
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the only significant prognostic factor (as opposed to previously identified clinical factors [smoking status, 
gender, histology, and ethnicity]) in predicting response to EGFR-TKIs (78-80). Together, this has led to a 
revolution in the treatment of NSCLC with upfront molecular testing and treatment using an EGFR-TKI for 
patients with EGFR-mutant lung cancer (Figure 1.2) (4,81,82). 
Despite advances in the identification and treatment of patients with EGFR-mutant lung cancer, there 
remain large clinical hurdles. For one, patients with EGFR-mutant lung adenocarcinoma treated with an EGFR-
TKI have a similar OS as patients treated with platinum doublets (83-85)j. Whilst these patients’ PFS and 
quality of life are measurably better (86), increasing OS remains a major goal of cancer therapyk. Secondly, 
almost all patients treated with an EGFR-TKI develop acquired resistance after 10–16 months of treatment 
(88,89). The most common mechanism of resistance to erlotinib, gefitinib, and afatinib is a secondary mutation 
in the EGFR TKD that results in a change from threonine to methionine in codon 790 (T790M) (90,91). Other 
mechanisms of resistance, including EGFR gene amplification, activation of bypass signaling, and histological 
transformation have all been described in the setting of acquired resistance to EGFR-TKIs (92-94). Options are 
available for patients who progress on EGFR-TKIs—such as osimertinib (95); an FDA-approved T790M-
specific EGFR-TKI—but there is still a long way to go in order to make EGFR-mutant lung adenocarcinoma a 
managed chronic disease. 
Molecular Background 
The HER Family of Receptors 
EGFR is a 1210 amino acid (aa) residue nascent polypeptide, and, after processing of the N-terminal 
signal peptide sequence, a 1186 aa, 170 kD, N-linked-glycosylated, membrane-bound RTK (96). The 
processing event has led to two widely used but divergent numbering systems for EGFR’s amino acid 
residues: one for the nascent polypeptide and one for the mature protein. Residues 1–1186 of the mature 
protein numbering system correspond to aa 25–1210 of the nascent peptide number system. Although the use 
of the mature protein numbering system is ingrained in the biochemistry literature, the nascent peptide 
numbering system (1–1210) will be used throughout as it is easier to reference when interconverting between 
nucleic and amino acids. 
While EGFR was the first RTK discovered (97) and used as a model to work out much of the protein 
family’s biochemistry (98), it is not a typical RTK (99). EGFR has been shown to have unique biochemistry 
amongst RTKsl (for one, it has no need for activation loop phosphorylation (102,103)) and its biology has been 
proven to be nuanced: the effects of knocking out the EGFR gene in mice range from embryonic lethality in 
one genetic background to peri-partum mortality in anotherm (105). Partly owing to EGFR’s complexity is its 
wide array of ligands and familial dimerization partners. EGFR was the first of four subsequently discovered 
human epidermal growth factor receptor (HER) family members, which also include HER2 (106), HER3 (107), 
and HER4 (108). Aside from HER2, each HER family member binds ligand, forms 2:2 receptor:ligand 
complexesn, and homo- or hetero- dimerizes with another HER to propagate downstream signal (110,111). 
EGFR binds at least seven different activating ligands in humans: EGF itself, TGFα, BTC, HB-EGF, ARG, 
EPR, and EGN (112). Including all known ligands, receptors, and isoforms, there are 611 possible 
combinations of ligand-activated HER complexes (113). Due to subtle structural differences in the receptors, 
each of these ligand-receptor combinations may elicit distinct but overlapping sets of responses in cells (114).  
Architecture, Activation, and Multimerization of EGFR 
The major structural features of EGFR are its extracellular domain (ECD), transmembrane helix (TM), 
tyrosine kinase domain (TKD), and carboxyl terminus region (C-term) (Figure 1.3A-B). The extracellular 
domain itself is divided into four sub-domains: domains I and III, which are related leucine-rich segmentso that 
participate in ligand binding, and domains II and IV, which contain numerous cysteine residues that participate 
in disulfide bond formation and dimerization (116). The extracellular domain is separated from the EGFR TKD 
by the TM; a single membrane-spanning α-helix. The EGFR TKD catalyzes the transfer of γ-phosphate groups 
from bound ATP onto specific tyrosyl moieties—mainly onto tyrosines located within its own C-term (117)p. In 
addition to the previously mentioned TKD and C-term, the intracellular portion of EGFR contains a 
juxtamembrane segment (JM) that helps promote receptor activation (119,120). While each of these structural 
features has been studied in detail, due to its involvement in cancer, the EGFR TKD has been of particular 
interest to (cancer) researchers. 
The structure of the EGFR TKD resembles that of typical TKDs (98,121-123). The active site is located 
between the two lobes (the smaller N-(terminal) lobe and the larger C-(terminal) lobe) of the TKD. Upon ATP 
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Figure 1.3: Overview of EGFR architecture 
A, schematic representation of EGFR protein domain structure. Numbers correspond to amino acid residues. ECD, 
extracellular domain; TM, transmembrane helix; JM, juxtamembrane segment; TKD, tyrosine kinase domain; C-term, 
carboxyl terminus region. B, general overview of EGFR protein relative to the cell membrane; adapted from (116). I-IV 
indicate ECD sub-domains. C, top: Detailed view of the inactive (left) and active (right) EGFR TKDs; adapted from (116). 
Bottom: ribbon diagram and space filling model of the in/active EGFR TKDs generated using Chimera (124) (active EGFR 
PDB=2GS6; inactive=2GS7 (125)). Throughout: the αC-helix is colored navy, the ATP-coordinating lysine is colored 
purple, the catalytic aspartate is colored orange, and the Asp–Phe–Gly (DFG) motif / activation loop colored red if inactive 
and green if active. D, F, and K stand for the amino acid residues aspartate, phenylalanine, and lysine, respectively.
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binding, a hinge motion changes the relative orientation of these two lobes from a more open state (in the 
inactive conformation) to a more closed state (in the active conformation) (Figure 1.3C). Three secondary 
structures within the kinase domain—the N-lobe αC-helix (αC in=active EGFR; αC out=inactive), the C-lobe 
DFG motif (DFG in=active; DFG in=inactiveq), and the C-lobe activation loop (a-loop open=active; a-loop 
closed=inactive)—control this hinge motion (113). In three dimensional space, the αC, DFG, and a-loop 
combine to form two highly conserved tertiary structures or ‘spines’ (126,127). Residues in the spines that are 
oriented towards the active site are key to the catalytic properties of EGFR (and other TKDs) (128). Of 
particular importance for EGFR are a lysine at position 745 (K745, which forms salt bridges with the α- and β- 
phosphates of ATP) and a catalytic aspartate at position 837 (D837, which accepts a proton from the tyrosine 
substrate’s hydroxide group). Along with several other conserved residues on the spines (123), K745 and 
D837 coordinate the transfer of the γ-phosphate of ATP onto exogenous tyrosyl substrates and/or the C-term 
of EGFR, the latter in a trans manner. While these structural elements of EGFR resemble that of typical TKDs, 
the protein’s mechanism of activation diverges from canonical RTKs (99). 
Because EGFR does not require activation loop phosphorylationr, the classical view of EGFR activation 
involves the monomeric receptor binding to a single ligand (110), the ligand-EGFR complex unfolding from the 
‘tethered’ into the ‘extended’ form (129), and the C-term being trans-autophosphorylated while EGFR is in the 
dimeric form  (111)(Figure 1.4A). As opposed to all other RTKs, dimerization and activation of EGFR are 
driven by receptor-receptor interactions (98), with a ‘dimerization arm’ in domain II providing the majority of 
contacts across the ECD interface (130-132). Without bound ligand (in the monomeric receptor) this 
dimerization arm is buried in a tight intramolecular tether via an interaction with domain IV (133,134), and 
dimerization of the receptor is mostly (auto)inhibiteds (138). Activating ligands, such as EGF, bind to domains I 
and IIIt of the ECD (130,131) and promote a hinge motion in the ECD of the receptor—leading to the extended 
form of EGFR and the exposure of the dimerization arm (domain II). This model of EGFR activation holds that 
dimerization arms from individual ligand-bound HER family members need to interact in order for the receptors 
to form active dimers. However, receptor dimerization is not sufficient for EGFR signaling. The introduction of 
inter-receptor disulfide bonds (leading to constant dimerization) produces both active and inactive dimers, 
demonstrating that downstream signaling require stereospecific ICD interactions (143)u.  
Indeed, activation of the EGFR kinase involves the specific formation of an asymmetric dimer of two 
EGFR TKDs, in which one kinase serves as an allosteric activator of the other (125). This allosteric interaction 
involves the C-lobe of one EGFR TKD (the ‘activator’) forming a tight interface with the N-lobe of another (the 
‘receiver’), which stabilizes the receiver in the active conformation (Figure 1.4B). This mode of activation does 
not require the tyrosine in the activation loop, as with all other RTKs (98); instead, it requires the intact 
asymmetric TKD dimerization interface (125). EGFR variants containing mutations that disrupt the asymmetric 
dimer interface—such as the C-lobe activator-impaired V948R mutant and the N-love receiver-impaired I706Q 
mutant—do not respond to EGF binding. However, together, the activator-impaired and receiver-impaired 
mutants can form an intact asymmetric interface and autophosphorylate EGFR (116). Thus, while ligand 
binding and ECD interactions are important in bringing two EGFR molecules together, specific TKD 
interactions, namely asymmetric dimerization, are needed to activate EGFR and enable trans-
autophosphorylation. 
Additional molecular interactions stabilize the activated form of EGFR and make it possible for EGFR to 
multimerize (Figure 1.4C). While research on EGFR has focused on the inactive monomer to active dimer 
transition, it is known that tetramers (145-147) and clustering (148) are important for signalingv. Inspection of 
the EGFR ECD dimer interface shows that, although the dimerization arm provides the majority of interactions, 
several secondary receptor-receptor contacts also can be made by other parts of domains II and IV and EGFR 
(109,130-132). The transmembrane helix, which connects the ECD and ICD, also dimerizes (154,155), and 
this dimerization is coupled to the asymmetric dimerization of the TKDs (156-158). There also is a key role for 
the juxtamembrane domain in the activation EGFR, whereby this small structure allosterically regulates EGFR 
by locking (latching) the TKD in the active confirmation (119,120,159). Taken together these, and other, 
interactions enable head to tail (C- to N-lobe) EGFR multimerization that is able to increase C-term 
phosphorylation (109,160)w. Whether the highly-active multimeric (as opposed to dimeric) EGFR is the main 
signaling unit remains an active area of investigation (162). 
Signaling Downstream of EGFR 
EGFR propagates intracellular signal by recruiting and activating proteins via the phosphorylated 
tyrosine (pY) residues on its C-term (Figure 1.5A). Binding of effector proteins via their SH2 and PTB (pY- 
Figure 1.4: Activation and multimerization of EGFR 
A, model of ligand-induced dimerization-mediated EGFR activation; adapted from (116). Colors correspond to EGFR protein domains from Figure 1.3. B, ribbon 
diagram and space filling model of the asymmetric dimer of the EGFR TKD (PDB 2GS6 (125)) generated using Chimera (124). The activator kinase is colored 
navy, and the receiver (enzymatically active) kinase is colored dark green. Key contact residues at the asymmetric interface are highlighted in orange (valine 948) 
and magenta (isoleucine 706). C, ribbon diagram and space filling models of the complete EGFR monomer (164), dimer (156), and tetramer (160) generated using 
Chimera(124). Ribbon colors correspond to EGFR protein domains from Figure 1.3, except for additional TKDs in dark green, chartreuse, and sky blue. EGF is 
presented as a space-filling beige model. EGFR-EGFR interactions are highlighted, including the proposed ECD sub-domain III (160) and IV (109) oligomerization 
interfaces.  
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binding) domains onto EGFR’s C-term activates three main signaling pathways: the MAPK, PI3K, and PLC-γ 
signaling pathways (163). The proteins that directly interact with activated (auto-pY) EGFR can generally be 
categorized as: positive regulators of mitogenic signaling, such as the kinase SRC, the phospholipase PLC-γ, 
and the transcription factor STAT3; adaptor/scaffolding proteins with no catalytic activity, but with the ability to 
assemble and regulate protein complexes, such as GRB2 and SHC; and negative regulators of signaling such 
as the E3 ubiquitin ligase CBL and phosphatase SHP1 (163). At least 65 different proteins with SH2 or PTB 
domains have been validated as binding to EGFR’s C-term pYs (165). These interacting proteins are often 
multivalent—having multiple SH2, PTB, SH3, PH, or other domains —and mediate interactions with additional 
proteins or with the cell membrane (166). When the multivalency of adaptor proteins (≥ 65 effectors), the 
possible variety of autophosphorylated sites (~12 tyrosines) on EGFR’s C-term, and the receptor’s regulation 
by different growth factors and oligo/hetero/homo-dimerization (611 possible combinations) are all considered, 
the picture of EGFR signaling becomes complex and nuanced.  
Much work has gone into untangling and simplifying EGFR signaling (167,168). When the entirety of 
the known signaling pathway is mapped out, a notable feature becomes apparent: a bowtie (or hourglass) 
structure (169). The vast ligand–EGFR–SH2/PTB network of receptor signaling complexes converges onto just 
a handful of molecules, which themselves activate a variety of signaling cascades (Figure 1.5B). The critical 
nodes in EGFR signaling are a series of previously mentioned non-receptor tyrosine kinases (non-RTKs), 
small GTPases, and phosphatidylinositol phosphates (PIPs). Specifically, the nodes in EGFR signaling are the 
non-RTKs PYK2 and SRC, the small GTPases RAS and RAC, and the PIPs PI4,5-P2, and PI3,4,5-P3 (169)x. 
As the complexity of EGFR signaling via PYK2 and SRC is being untangled (170,171), the field has forged 
ahead with the simplified view that EGFR signals primarily through the MAPK (RAS node) and or PI3K/AKT 
(PIP node) signaling pathways (172)y. 
Learning from EGFR Mutations to Design Better Therapies 
Since EGFR was recognized as an oncogene due to its homology to v-erb-B, a retroviral protein that 
enables avian erythroblastosis virus to transform chicken blood cells (173), the study of cancer and EGFR 
have inexorably been linked (174,175). EGFR overexpression in brain, head & neck, lung, pancreatic, and 
colorectal cancers led to myriad clinical trials aimed at targeting the protein for therapeutic effects (113). While 
EGFR-TKIs are FDA-approved against cancers in a couple of different body sites (113,176), the inhibitors have 
their most significant effects against EGFR-mutant lung adenocarcinoma. At the same time, cetuximab, the 
anti-EGFR antibody, has been found to be most clinically effective for head & neck (177) and colorectal 
cancers (178). These clinical findings lead to basic questions: why are EGFR-TKIs most effective in lung 
cancer and why are anti-EGFR antibodies most effective in head & neck and colorectal cancers? The answers 
to these questions may have to do with EGFR’s mechanism of activation. Anti-EGFR antibodies are thought to 
be effective in colorectal and head & neck cancers because these cancers express locally high levels of 
EGFR-activating ligands and because anti-EGFR antibodies block ligand binding (175). At the same time, 
EGFR-TKIs are effective against certain lung adenocarcinomas because these cancers harbor recurrent 
mutations in the kinase domain—where TKIs bind (63-65). While EGFR is implicated in colorectal, head & 
neck, and pancreatic cancers, EGFR mutations in these malignancies are not consistently identifiedz. 
Recurrent genetic alterations are useful in cancer biology because they hint at how an oncogene’s product is 
activated. Along these lines, study of lung adenocarcinoma associated EGFR mutations has been critical in 
pushing forward understanding of EGFR biology. 
Studies of the common lung adenocarcinoma associated EGFR mutations (L858R and ex19del) have 
provided further insights into the biology of the receptor. Studies of EGFR-L858R have demonstrated that it is 
≥ 50 times more active than wild-type (WT) EGFR (66) as a result of preferentially adapting the active 
conformation (180). More importantly, studies on EGFR-L858R have added a plethora of evidence to support 
EGFR’s activation via receptor-mediated asymmetric dimerization. While monomeric EGFR-L858R is active in 
the absence of EGF (181,182), the protein is even more active as part of an asymmetric dimer (183), 
especially when it adopts the receiver position (184). In fact, the oncogenic properties of EGFR-L858R may be 
entirely driven by the greater propensity of these mutants to form active dimers (185). The ECD also appears 
to play a key role in the activation of mutant EGFR, even in the absence of ligand (186). Study of EGFR 
ex19del has likewise been generalized to help with the understanding of the mechanism of activation of similar 
deletions in other oncogenes (187). In due turn, increased knowledge about the structure and function of 
EGFR mutations has enabled the development of more potent irreversible second-generation (188) and third-
generation (189,190) EGFR-TKIs for the treatment of lung adenocarcinoma.  
Figure 1.5: Overview of EGFR signaling 
A, graphical representation of phosphotyrosine-mediated recruitment of adaptors to EGFR; lines connect phosphotyrosines to adaptors and provide a quantitative 
protein interaction network for EGFR, adapted from (165). Dark red circles represent phosphopeptides at each indicated EGFR tyrosine residue; clear circles 
represent the non-phosphorylated version of each phosphopeptide; green circles represent SH2 domains; and blue circles represent PTB domains. Lines 
connecting peptides to domains indicate observed interactions, colored according to the affinity of the interaction (see legend). B, simplified bow-tie architecture of 
the EGFR signaling pathway, adapted from (169). Beige = ligands; light blue = signaling intermediaries; orange = critical nodes in EGFR signaling [non-RTKs 
(PYK2 and SRC), small GTPases (RAS and RAC), and PIPs (PI3,4,5-P3 and PI4,5-P2)]; yellow = MAPK signaling pathway (RAS node); and magenta = PI3K/AKT 
signaling pathway (PIP node). 
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There now exist over 20 well-characterized EGFR-TKIs that have undergone some clinical 
development in NSCLC (Table 1.1). First generations EGFR-TKIs were a fallout of attempting to study WT-
EGFR with small molecules (191). Although there is still some controversy (192), the majority of first-
generation EGFR-TKIs are thought to selectively bind the active mode of the TKD (which explains the 
effectiveness in EGFR-mutant lung adenocarcinoma) (180). This has been attributed to two factors: 1) the 
recognition of the active state of the kinase by certain EGFR-TKIs (193,194) and 2) the higher ATP affinity of 
mutant enzyme relative to the WT-EGFR (195). Unlike the ATP-competitive first generation EGFR-TKIs, 
second generation EGFR-TKIs, were designed to bind the TKD irreversibly in attempts to overcome acquired 
resistance. While these agents proved efficacious against models of T790M-mediated EGFR-TKI resistance 
(196,197), they failed to meet endpoints against T790M-positive EGFR-mutant lung adenocarcinoma in clinical 
trials—due to the limited therapeutic window offered by these agents (198,199). As such, third generation 
EGFR-TKIs were developed: irreversible EGFR-TKIs with a puckered ring structure that can bind the TKD 
active site in the presence of T790M (189,190,200). These agents have proven to be active in patients 
(95,201), and one of them, osimertinib, is FDA approved. However, resistance to osimertinib is emerging, 
suggesting that alternative strategies and/or EGFR-TKIs are needed (202). 
Recent work on EGFR mutants in glioblastoma has presented another possible way to inhibit EGFR: by 
using inhibitors selective for the mutant-specific conformation of the receptor (203). TKIs can be categorized by 
generation and mode of binding, but they can also be categorized as whether they bind the active form (Type I 
inhibitors) or inactive form (Type II inhibitors) of EGFR (or their target, in general (204)). EGFR mutations found 
in glioblastoma are more responsive to Type II EGFR-TKIS (the best characterized being lapatinib) than type I 
inhibitors (such as erlotinib) (203). Though head to head data is sparse, it appears that lung adenocarcinoma 
associated EGFR mutations are, dose for dose, more potently inhibited by Type I as opposed to Type II EGFR-
TKIs; however, lapatinib still is able to inhibit certain EGFR-mutant lung cancer cell line models at clinically 
achievable doses (203,205,206). Although clinical development of lapatinib was shifted away from NSCLC (as 
the agent did not meet predetermined ORR in NSCLC), initial trials were performed in heavily pre-treated 
patients and failed to test for EGFR mutation status (205,207,208). Because there is no structural reason why 
EGFR-TKIs could not bind the inactive EGFR TKD effectively (182), more study is needed into Type II 
inhibitors in the setting of EGFR-mutant lung adenocarcinoma. This is especially true as EGFR mutants are not 
all alike and there exists a spectrum of activation between the active and inactive confirmations of the TKD 
(180). Since imatinib (a BCR-ABL TKI) was first recognized as an inactive site TKD binder (209), it has been 
generally recognized that targeting inactive states of TKDs offers clear advantages in terms of target 
selectivity, patient safety, and time to resistance (210-212). In light of the mounting success of Type II TKIsaa, 
the question is whether the inactive state of the EGFR TKD is a better target for drug discovery and therapy. 
Purpose of these Studies 
We now know that EGFR mutations (≥ 85% being L858R or ex19del (179)) afflict ~20% of patients with 
lung adenocarcinoma (214). However, because EGFR mutations historically were interrogated by ‘hot-spot’ 
PCR-based methods, most known mutations are biased to fall between exons 18 and 21 (the regions that 
encodes for L858R and ex19del and which encodes the majority of the TKD). As such, there is an outstanding 
amount of basic science and clinical data regarding mutations in these exons, and there are less data 
regarding mutations elsewhere in the protein—such as in the ECD or C-term—even though hundreds of such 
mutations have been catalogued in NSCLC patients (179,215,216). At the same time, due to the limitations in 
companion diagnostics and sequencing technologies (82,217), it is likely that other EGFR variants exist in lung 
adenocarcinoma. This idea is backed by clinical data: a small proportion (up to 20%, depending on the trial) of 
patients with no detected EGFR-activating mutations show a radiographic response when treated with EGFR-
TKIs (62,218-220). While knowledge about common mutations has allowed for rational treatment of specific 
cohorts (L858R or ex19del) of EGFR-mutant NSCLC, little is known about the remaining 10–15% of EGFR 
mutations in NSCLC. The rest of these mutations—deemed rare or atypical mutations—are primarily scattered 
throughout the EGFR TKD and can mediate either sensitivity or primary resistance to EGFR-TKI therapy (221). 
The goal of these studies is to fill in this knowledge gap: to identify novel EGFR mutations in lung 
adenocarcinoma, to determine the sensitivity of these alterations to therapy, and, along the way, to uncover 
more about the biology of EGFR.  
12 
generation compound name generic name 1º target(s) type class binding furthest clinical development in NSCLC 
1 OSI744 (59) erlotinib EGFR I EGFR reversible FDA-approved (70,71) 
ZD1839 (60) gefitinib EGFR I EGFR reversible FDA-approved (62,68,69) 
GW572016 (194) lapatinib EGFR/HER2 II dual-HER reversible Phase I (208) 
BPI2009H (222) icotinib EGFR I EGFR reversible Phase III (223) 
AZD8931 (224) sapitinib EGFR/HER2/HER4 I pan-HER reversible Phase I (225) 
XL647 (226) tesevatinib EGFR/HER2/VEGFR I multitargeted reversible Phase II (227) 
ZD6474 (228) vandetanib VEGFR/EGFR/RET I multitargeted reversible Phase III (229) 
AEE788 (180,230) — EGFR/HER2 I dual-HER reversible Phase I (231) 
AZD3759 (232) — EGFR I CNS-penetrant reversible Phase I (233) 
BMS599626 (234,235) — EGFR/HER2 I dual-HER reversible Phase I (236) 
BMS690514 (237) — EGFR/HER2/VEGFR I multitargeted reversible Phase II (238) 
CUDC101 (239) — EGFR/HER2/HDAC I multitargeted reversible Phase I (240) 
2 BIBW2992 (188) afatinib EGFR/HER2 I dual-HER irreversible FDA-approved (72,73,75) 
PF299804 (197) dacomitinib EGFR/HER2/HER4 I pan-HER irreversible Phase III (199) 
CI1033 (241) canertinib EGFR/HER2/HER4 I pan-HER irreversible Phase II (242) 
HKI272 (243) neratinib EGFR/HER2/HER4 II pan-HER irreversible Phase II (244) 
EKB569 (245) pelitinib EGFR/HER2 II dual-HER irreversible Phase I (246) 
AST1306 (247) allitinib EGFR/HER2 II dual-HER irreversible Phase I (248) 
HM781 (249) poziotinib EGFR/HER2 I dual-HER irreversible Phase I (250) 
TAK285 (251) — EGFR/HER2 II dual-HER irreversible Phase I (252) 
3 AZD9291 (190,253) osimertinib EGFR T790M I mutant-selective irreversible FDA-approved (95,254) 
CO1686 (189) rociletinib EGFR T790M I mutant-selective irreversible Phase II (201) 
AC0010 (255) avitinib EGFR T790M I mutant-selective irreversible Phase I (256) 
EGF816 (257) — EGFR T790M I mutant-selective irreversible Phase I (258) 
Table 1.1: EGFR-TKIs for the treatment of NSCLC 
Inhibitors are categorized on generation based on their being 1st generation: reversible; 2nd generation: irreversible; and 
3rd generation: mutant-EGFR selective. In cases where compounds have several names, only the most recent compound 
name is listed. 1º targets are the targets which the compound was designed to inhibit (listed in order of cell-free IC50) with 
slashes indicating near-equal potency. The compound type (I=binds active confirmation of EGFR; II=binds inactive 
confirmation (204)) was determined based on available crystal structures and/or whether the compound was designed 
against the structure of active EGFR (PDB 2GS6) or inactive EGFR (2GS7). The inhibitor class refers to the common 
language used to describe the inhibitor. Note that clinical development is specific to NSCLC; some inhibitors, such as 
vandetanib, are FDA-approved for other indications. Not detailed in this table: natural EGFR inhibitors (e.g. erbstatin 
(259)), early tyrphostins (e.g. AG1478 (260)), molecules that never underwent clinical testing (e.g. EAI045 (261), EKI-785 
(262), PD153035 (263), WZ4002 (200)), molecules never developed for their ability to inhibit EGFR in patients with 
NSCLC (e.g. BGB283 (264), brigatinib (265)), named secondary metabolites (AZD5104 (190), OSI420 (266)), and/or 
molecules with only abstract-level data (ASLAN001, ASP8273, CNX2006, epitinib, olmutinib, PD168393,  PF06747775, 
and theliatinib).
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Notes 
a While human gene symbols generally are italicized with all letters in uppercase (EGFR), I will refer to genes 
in uppercase only (EGFR). As opposed to nomenclature guidelines (1), proteins also will be designated in non-
italicized uppercase. This simplified all-caps notation is meant to circumvent the ambiguity related to 
interchanging references of EGFR alterations, constructs, and mutants. 
b Patients usually are asymptomatic in the early stages of the disease because of the sparse pain fiber 
innervation in the lungs and because adenocarcinomas most often originate in the periphery of the lungs—
leaving patients with sufficient respiratory reserve (6,7). This presentation contrasts with that of SCLC and 
squamous NSCLC; cough, dyspnea, and hemoptysis present most frequently in patients with squamous cell 
and SCL carcinomas because of these tumors’ tendency to involve central airways (8-12). 
c The most used platinum doublets against lung adenocarcinoma are cisplatin/carboplatin+pemetrexed and 
carboplatin+paclitaxel (16). The latter is sometimes combined with bevacizumab, an anti-angiogenic 
therapeutic antibody, which helps boost response rates and survival (17). 
d Defined as the percent of patients experiencing objectively decreased tumor size per repeat imaging of the 
same tumor. ORR is typically the combined percentage of patients experiencing a complete response (CR; 
loss of detectable tumor per repeat imaging of the same tumor) and partial response (PR; loss of ≥ 30% of 
tumor per repeat imaging of the same tumor) (18). 
e Defined as the average time between diagnosis (or treatment initiation) and death (19,20). 
f Due to their signaling redundancy and synthetic lethality (46), these mutations are rarely co-occurring. Still, 
there are case reports of co-occurring driver alterations in NSCLC (47,48), especially with PIK3CA (49).  
g Anti-EGFR antibodies have demonstrated efficacy against lung cancer cells in vitro for decades (53). 
However, for reasons that are not completely understood, anti-EGFR therapeutic antibodies have proven less 
efficacious against NSCLC in the clinic (54,55). Still, there may be a place for anti-EGFR antibodies treating 
defined molecular cohorts of NSCLC (56). 
h Also known as time to progression (TTP); defined as the average time between diagnosis (or treatment 
initiation) and recurrence (radiological or clinical) (19,20). PFS is increasingly used as an endpoint in 
molecular-based clinical trials, where demonstration of efficacy is the main goal (67). 
i A measure of how often a particular event happens in one group compared to how often it happens in the 
control group. In this case, the risk of an event—progression or death—while being treated with gefitinib versus 
(control) platinum doublets at 12 months is 0.48—just under 50%. 
j This is to say: patients with EGFR-mutant lung adenocarcinoma treated with a first generation EGFR-TKI 
(erlotinib or gefitinib) have the same overall survival as matched patients (EGFR-mutant lung adenocarcinoma) 
treated with chemotherapy. It is unclear whether this finding is due to patient selection, poor trial design, and/or 
patient crossover (86). It should also be noted that patients with EGFR-mutant NSCLC have a longer OS than 
patients with EGFR-mutant-negative NSCLC, regardless of treatment modality (83-85). 
k Immunotherapy (such as PD/L-1 inhibitors) has shown promising results (23) with respect to increasing OS in 
patients with NSCLC (partly because the trials are designed/powered to test OS); however, the role of these 
agents in EGFR-mutant lung adenocarcinoma remains contentious (87). 
l In fact, in various unsupervised clustering analyses, EGFR is more closely related to ACK or SRC than to any 
RTK (100). EGFR’s inactive confirmation bears striking resemblance to inactive CDK and/or SRC (101). 
m Still, in most mouse models, defects are seen in bone, brain, heart, and various epithelia—notably in the 
skin, hair, lungs, and eyes. Indeed, EGF was originally identified as a protein that induces early eyelid opening 
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and teeth eruption in mice (104). 
n This is the classical view accepted by the field. However, emerging evidence suggests that EGFR may be 
forming higher order multimers (109). 
o Extracellular domains I and III alternatively are referred to as LR1 and LR2—the LR being short for leucine-
rich (115). 
p In other words, the EGFR TKD primarily catalyzes trans-autophosphorylation (118). As such, throughout this 
work, the measurement of EGFR’s phosphotyrosines is used as a readout of EGFR activity. 
q The DFG residues relative orientation (compared to the a-loop) does change; they simply remain in the 
catalytic site in both the in/active confirmations. 
r For this reason, it was thought that EGFR was always in the active conformation and that dimerization of the 
receptor simply enabled trans-phosphorylation of the C-terms of two receptors (101). 
s Although exposure of the dimerization arm is an important part of the HER family activation mechanism, it is 
not sufficient. Mutations that disrupt the domain II–IV inhibitory tether do not activate EGFR (135,136). 
Moreover, deleting domain IV (and thus constitutively exposing the dimerization arm) does not cause ligand-
independent dimerization of EGFR (137). 
t Most of the binding energy between EGF and EGFR is mediated by domain III (139), which is also the binding 
cite for cetuximab, the anti-EGFR therapeutic antibody (140). While cetuximab mainly inhibits EGFR signaling 
by preventing ligand binding and receptor-mediated dimerization, there is also a role for the antibody in 
attenuating signal by causing internalization/downregulation of the receptor and immune-mediated effects 
(141,142). 
u These interactions were postulated to exist long before the crystal structure of EGFR was solved (144). 
v This is not to mention the myriad cellular processes involved in modifying EGFR signaling in the cell including 
receptor internalization (149), miRNA modulation of enzyme levels (150), and/or cross talk with other receptor 
types (151). Beyond phosphorylation, glycosylation, and ubiquitylation, unique post-translational modifications 
also effect EGFR’s activity, with sulfenylation (152) and palmitoylation (153) being but two examples. This is to 
say: EGFR activity is regulated in a multitude of ways beyond autophosphorylation. 
w By extension, this increases receptor activity by removing inhibitory proximal C-term interactions (161) and 
providing additional sites for adaptor binding. 
x Alternatively, phosphatidylinositol-4,5-bisphosphate (PI4,5-P2), phosphatidylinositol-3,4, 5-triphosphate 
(PI3,4,5-P3). 
y Robust readouts of MAPK and/or PI3K/AKT activation are used as a readout of EGFR downstream signaling 
throughout this work. 
z EGFR is mutated in ≤ 2 % of these cancers, and few of these mutations are recurrent (179). 
aa Besides erlotinib and gefitinib, most other FDA-approved reversible TKIs bind to the inactive confirmation of 
their targets (182,213). 
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Abstract 
Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-
terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer. We 
describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were 
treated with EGFR tyrosine kinase inhibitors (TKIs) with documented anti-tumor responses. In vitro, EGFR-
RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR-TKIs and therapeutic 
antibodies. These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling 
and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration. 
Statement of Significance 
We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in 
patients with lung cancer and document responses to the EGFR inhibitor, erlotinib, in 4 patients whose tumors 
harbored EGFR fusions. Findings from these studies will be immediately translatable to the clinic as there are 
already several approved EGFR inhibitors. 
Introduction 
Oncogenic mutations in the epidermal growth factor receptor (EGFR) are found in a subset of patients 
with non-small cell lung cancer (NSCLC) and serve as important predictive biomarkers in this disease (1-3). 
These mutations, which most commonly occur as either small in frame deletions in exon 19 or point mutations 
in exon 21 (L858R) within the EGFR tyrosine kinase domain, confer constitutive activity and sensitivity to 
EGFR tyrosine kinase inhibitors (TKIs). Several large phase III clinical trials have shown that patients with 
EGFR-mutant lung cancer derive superior clinical responses when treated with EGFR-TKIs as compared with 
standard chemotherapy (4-6), and several EGFR inhibitors are already FDA-approved. These trials used PCR-
based ‘hotspot’ testing, which typically interrogate for EGFR point mutations and small indels in exons 18-21. 
More recently, next-generation sequencing (NGS) of tumor samples has allowed for the identification of 
additional mechanisms whereby the EGF receptor may become aberrantly activated (7,8), further documenting 
the importance of EGFR signaling in the pathogenesis of lung cancer. Here, we report, for the first time in lung 
cancer, the presence of oncogenic EGFR fusions, most commonly EGFR-RAD51, which contain the entire 
EGFR tyrosine kinase domain fused to RAD51, a protein involved in DNA damage responses. We 
demonstrate that these fusions are oncogenic in pre-clinical studies and show that patients whose tumors 
harbor EGFR fusions derive significant clinical benefit from treatment with EGFR-TKI therapy. 
Frequency of EGFR Alterations in Lung Cancer 
To determine the frequency of EGFR fusions in lung cancer, we analyzed data from ~10,000 clinical 
cases (Table S2.1). Fusion events, defined by a genomic breakpoint in EGFR exons 23 through intron 25, 
were detected in 5 patients, each of which is described below. 
Case Reports 
Patient 1, a 35-year-old female, was diagnosed with metastatic lung adenocarcinoma after presenting 
with generalized weakness and worsening vision. Imaging studies revealed widespread disease in the bone, 
liver, lymph nodes, adrenal glands, and hard palate (Table 2.1). MRI showed innumerable metastases in the 
brain, dura, and left globe, resulting in retinal detachment. She was initially treated with radiotherapy to the 
brain and spine. Due to significant debility in the setting of tumor-induced disseminated intravascular 
coagulation (DIC), she was a poor candidate for cytotoxic chemotherapy. A lymph node biopsy was sent for 
genomic profiling using an extensively validated hybrid capture- based NGS diagnostic platform 
(FoundationOne) (9) and found to harbor a novel EGFR rearrangement at exon 25, resulting in the formation of 
an EGFR-RAD51 fusion gene (Figures 2.1A–B and Table S2.2). The patient was treated with the EGFR-TKI, 
Patient 
No. Age Gender Ethnicity Diagnosis 
Smoking 
Status 
Sites of 
disease Prior Treatment 
EGFR 
fusion 
EGFR 
TKI 
Best 
response 
Duration of 
EGFR TKI 
therapy 
1 35 Female SouthAsian 
Stage IV lung
adenocarcinoma Never
• Lung
• Lymph
nodes
• Bone
• Brain
• Adrenal
gland
• Breast
• Peritoneum
• Eye
• RT to the whole
brain and T8
vertebra
EGFR- 
RAD51 erlotinib PR 8 months 
2 21 Female Caucasian Stage IV lung adenocarcinoma 3 pack years
• Lung
• Lymph
nodes
• Bone
• Brain
• RT to the thoracic
spine
• Radiosurgery to
brain mets
• RT to the right hip
EGFR- 
RAD51 erlotinib PR 5 months 
3 43 Female Caucasian Stage IV lungadenocarcinoma 
10 pack years, 
quit > 10 
years ago 
• Lung
• Bone
• Brain
• WBI
• Carboplatin,
pemetrexed,
bevacizumab,
• 6 cycles
EGFR- 
PURB erlotinib PR
20 months, 
on-going 
4 38 Male Caucasian Stage IV lungadenocarcinoma 
Former light 
smoker (3 
pack years) 
• Lung
• Lymph
nodes
• Pleura
• Bone
• Cisplatin/
Pemetrexed,
• 6 cycles
• Maintenance
pemetrexed,
• 11 cycles
EGFR- 
RAD51 erlotinib PR
6 months, on- 
going 
5 60 Female Caucasian Stage IV lung adenocarcinoma Never
• Lung
• Lymph
nodes
• Brain
• Craniotomy
• RT to surgical bed
• Carboplatin/
pemetrexed,
• 4 cycles
• Maintenance
pemetrexed,
• 6 cycles
EGFR- 
RAD51 N/A N/A N/A 
Table 2.1: Clinical characteristics of patients with NSCLC harboring EGFR kinase fusions 
Abbreviations: RT, radiation therapy; WBI, whole-brain irradiation; PR, partial response, N/A, not applicable; mets, metastases. This table corresponds to Table 1 
from Konduri, Gallant et al., Cancer Discovery, 2016 (10). 
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erlotinib. Within two weeks of erlotinib initiation, DIC had resolved (Figure S2.1A) and the patient experienced 
clinical improvement with a noticeable decrease in supraclavicular lymphadenopathy and a hard palate 
metastatic lesion. After six months of treatment, the primary left lung mass and largest two liver lesions had 
decreased by 69% per RECIST (11) (Figure 2.1C and Figure S2.1B), and the patient experienced an 
improvement in her functional status. She remained on erlotinib for 8 months, after which she experienced 
disease progression. 
Patient 2, a 21-year-old female, was diagnosed with metastatic lung adenocarcinoma after presenting 
with right shoulder pain and unintentional weight loss. MRI revealed extensive metastatic disease in the spine 
and a right paraspinal mass extending into neuroforamina. Additional imaging studies showed metastatic 
disease in the brain, innumerable lung nodules, lymph nodes, and right acetabulum. Biopsy of an axillary 
lymph node showed metastatic adenocarcinoma consistent with lung primary. NGS testing revealed an EGFR-
RAD51 fusion. The patient received palliative radiotherapy to the spine and brain metastases. Subsequently, 
the patient reported hemoptysis and dyspnea with exertion. Complete blood count showed a marked drop in 
platelet number and elevated lactate dehydrogenase, consistent with DIC. She was not a candidate for 
systemic chemotherapy. She was started on erlotinib approximately 6 weeks after initial presentation. 
Thrombocytopenia resolved within 10 days (Figure S2.2A), and the patient experienced symptomatic 
improvement. CT scans obtained 3 months after the initiation of erlotinib showed a significant regression of 
bilateral miliary nodules as well as a 43% decrease in the index lesions of the left lower lobe (LLL), subcarinal 
lymph node, and right apical soft tissue mass compared to baseline (Figure 2.1C and Figure S2.2B). The 
patient remained on erlotinib for 5 months with response, but she is no longer taking this medication due to 
nonmedical issues. 
Patient 3, a 42-year-old female, was diagnosed with metastatic lung adenocarcinoma after presenting 
with right hip pain. Imaging studies revealed widespread disease including the primary left lower lobe (LLL) 
lesion, lytic lesions in the right pelvis and acetabulum, and brain metastases. Biopsy of a lung mass was 
positive for adenocarcinoma. She was initially treated with whole brain radiotherapy and platinum based 
chemotherapy with a partial response. While receiving chemotherapy, her tumor biopsy sample was sent for 
NGS testing and found to harbor an EGFR rearrangement at exon 25, resulting in the formation of a fusion 
gene between EGFR and PURB (Table S2.2 and Figures S2.3A–B). At the time of disease progression on 
chemotherapy, the patient was treated with erlotinib, resulting in a 48% decrease in the LLL index lesion on-
going for 20 months (Figure 2.1C and Figure S2.3C). 
Patient 4, a 38-year-old male, was diagnosed with metastatic lung adenocarcinoma after presenting 
with dyspnea and progressive weakness. Imaging studies showed metastatic disease to the lungs, lymph 
nodes, pleura, and bone. A pleural biopsy was performed, and NGS testing identified an EGFR-RAD51 fusion. 
He was initially treated with cisplatin/pemetrexed followed by maintenance pemetrexed. At the time of disease 
progression, the patient was started on erlotinib, with partial response after 2 cycles of therapy (Figure 2.1C 
and Figure S2.4). The patient has now received erlotinib for 6 months with continued response. 
Patient 5, a 60-year-old female, initially presented with headache, slurred speech, and left foot drag. 
MRI revealed three enhancing cerebral masses with midline shift. Further imaging studies showed a 4 cm 
mass in the lingula and lymphadenopathy. Biopsy of the lung mass revealed adenocarcinoma. The patient 
underwent resection of a right frontal tumor followed by radiotherapy. She was treated with four cycles of 
carboplatin/pemetrexed with partial response followed by pemetrexed maintenance therapy. During this 
treatment, NGS testing was completed and revealed an EGFR-RAD51 fusion. The patient continues to receive 
benefit from pemetrexed therapy; she has not yet been treated with an EGFR-TKI. 
EGFR-RAD51 is Oncogenic 
We stably expressed EGFR variants in Ba/F3 cells and detected expression of EGFR-RAD51 at the 
expected molecular weight as compared to EGFR wild-type (WT) and the known oncogenic EGFR- L858R 
mutation (Figure 2.2A). We observed that, analogous to EGFR-L858R, EGFR-RAD51 was able to activate 
downstream signaling through the MAPK and PI3K/AKT pathways. EGFR-RAD51 was also able to sustain IL-
3-independent proliferation of Ba/F3 cells, an activity phenotype associated with the transforming function of 
other oncogenic tyrosine kinases (Figure 2.2B) (12). In parallel, we expressed the same EGFR variants in 
NR6 cells (which lack endogenous EGFR (13)) (Figure S2.5A–B). EGFR-RAD51 significantly increased 
colony formation of NR6 cells in soft agar—a hallmark of tumor cells—as compared to control cells and those 
expressing EGFR-WT (Figure S2.5C–D).
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Figure 2.1: EGFR fusions are clinically actionable. 
A, scaled representation of EGFR-RAD51 depicting the genomic structure of the fusion. ATG, translational start site; blue, 
EGFR; orange, RAD51. B, schematic representation of the EGFR-RAD51 fusion protein domain structure. Numbers 
correspond to amino acid residues. Y, tyrosine residue; ECD, extracellular domain; TM, transmembrane helix; TKD, 
tyrosine kinase domain; C-term, carboxyl terminus region; N-term, amino terminus; OD, oligomerization domain/section; 
ATPase, adenylpyrophosphatase; blue, EGFR; orange, RAD51. C, serial CT scans from index patients with lung 
adenocarcinoma harboring EGFR fusions, documenting response to the EGFR-TKI erlotinib. Left images, scans obtained 
prior to initiation of erlotinib. Right images, scans obtained during erlotinib therapy. This figure corresponds to Figure 1 
from Konduri, Gallant et al., Cancer Discovery, 2016 (10).
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 EGFR contains several autophosphorylation sites in the C-terminal tail of the receptor (including 
tyrosines 1016, 1092, and 1197) that positively regulate the transforming activity of EGFR by mediating 
downstream proliferative signaling (14). These autophosphorylation sites, which serve as docking sites for 
signaling adaptor proteins, are lacking in the EGFR-RAD51 fusion (Figure 2.1B and Figure 2.2C). Notably, 
however, EGFR-RAD51 contains tyrosine 869, a phosphorylation site within the kinase domain which is critical 
for complete EGFR function and transformation in NSCLC (15). The presence of tyrosine 869 may explain why 
EGFR-RAD51 is still able to activate downstream oncogenic signaling via the PI3K/AKT and MAPK pathways 
(Figure 2.2A and C). Notably, these EGFR fusions also lack tyrosine 1069, the CBL binding site which targets 
EGFR for degradation. Indeed, EGFR-RAD51 is more stable (has a slower turnover rate) compared with the 
WT EGF receptor (Figure S2.6A–B), suggesting that EGFR-RAD51 receptor stability might also play a role in 
its oncogenic properties. Taken together, these data support that EGFR-RAD51 is able to activate tumorigenic 
signaling and confer an oncogenic phenotype. 
 
Computational Modeling of EGFR-RAD51 
 The EGFR tyrosine kinase is activated through ligand-mediated formation of asymmetric (N-lobe to C- 
lobe) dimers (16). Kinase fusions, on the other hand, commonly share a mechanism of activation whereby the 
fusion partner drives dimerization of the kinase and leads to ligand-independent activation (17). Given the 
presence of RAD51, a self-assembling filamentous protein (18), we hypothesized that the EGFR-RAD51 fusion 
protein can form such partner-driven dimers. To validate this hypothesis, we modeled EGFR-RAD51 based on 
available experimental structures of RAD51 and the active asymmetric EGFR dimer. Conformational loop 
sampling with Rosetta demonstrates that it is geometrically feasible for EGFR kinase subunits to adopt the 
asymmetric (active) dimeric conformation when fused to RAD51 (Figure 2.2D). Further, the concatenation of 
RAD51 subunits could bring tethered EGFR kinase domains close together, increasing their local 
concentration, and leading to further EGFR activation (Figure S2.7). Although this structural modeling 
demonstrates that the EGFR-RAD51 is geometrically capable of forming active dimers, further experimental 
data are needed to confirm this mechanism. 
 
EGFR-RAD51 can be Therapeutically Targeted with Existing EGFR Inhibitors 
 The finding of recurrent EGFR fusions in lung cancer is of particular interest because EGFR-TKIs have 
proven an effective therapeutic strategy for tumors harboring certain EGFR mutations. Therefore, we sought to 
determine the effectiveness of EGFR-TKIs against EGFR-RAD51. We treated Ba/F3 cells expressing EGFR-
RAD51 with erlotinib (1st-generation reversible EGFR-TKI), afatinib (2nd- generation irreversible EGFR/HER2-
TKI), and osimertinib (3rd-generation irreversible EGFR-TKI) to assess the effects of these inhibitors on 
cellular proliferation. EGFR-L858R served as a positive control in this experiment. Each TKI effectively 
inhibited the growth of Ba/F3 cells expressing EGFR-RAD51 to varying degrees (Figure 2.3A and Table 
S2.3). Downstream MAPK and PI3K/AKT signaling was also inhibited with TKI treatment (Figure 2.3B). The 
on-target effect of EGFR-TKIs could be observed when blotting for phospho-tyrosine from immunoprecipitated 
EGFR-RAD51 protein (Figure 2.3C) and when observing the phosphorylation status of tyrosine 869, which is 
included in the fusion protein (Figure S2.8). Finally, we tested the effects of the FDA-approved EGFR 
antibody, cetuximab, in our cell culture models. Cetuximab binds to the EGFR extracellular domain and blocks 
the binding of growth factors, such as EGF (19). In contrast to EGFR-L858R, proliferation of Ba/F3 cells 
expressing EGFR-RAD51 was potently inhibited by cetuximab (Figure 2.3D and Figure S2.9). Together, 
these results show that the EGFR-RAD51 can be potently inhibited by a variety of EGFR-targeted agents, 
suggesting several intriguing clinical avenues. 
 
Discussion 
 Just over ten years ago, ‘canonical’ EGFR point mutations and short indels in the kinase domain were 
detected retrospectively by PCR-based ‘hotspot’ testing in patients with lung cancer who responded to EGFR-
TKI therapy (1-3). Assessing for these ‘canonical’ EGFR mutations is now the accepted standard of care 
worldwide for patients with lung cancer. Here, by utilizing a comprehensive NGS assay that interrogates the 
entire coding region of EGFR (as well as introns 7, 15, 24, 25, and 26), we identified novel EGFR fusions in 
lung cancer patients—EGFR-RAD51 and EGFR-PURB—that would otherwise have gone undetected by the 
standard of care. 
 While distinct EGFR fusions have previously been observed in glioma (20), this is the first 
documentation of patients with EGFR fusion positive tumors that derived significant and sustained anti-tumor 
responses from treatment with the EGFR-TKI, erlotinib. Our in vitro work also hints at afatinib being potent  
36 
Figure 2.2: EGFR-RAD51 is an oncogenic EGFR alteration. 
A, Ba/F3 lines stably expressing pMSCV (vector only), EGFR-WT, EGFR-L858R or EGFR-RAD51 were subjected to 
Western blot analysis with indicated antibodies. The three distinct EGFR variants were detected at the anticipated 
molecular weight (MW) of 150 kD. EGFR-RAD51 fusion is detected with both the N-terminal EGFR antibody [EGFR(N)] 
and with the RAD51 antibody. B, Ba/F3 cells transduced with indicated constructs (pMSCV, vector only) were grown in 
the absence of IL3 and counted every 24 hours. ***, P < 0.0001. C, Ba/F3-expressing EGFR variants were serum starved 
for 16 hours, treated with 50 ng/mL EGF for 5 minutes, and subjected to Western blot analysis with indicated antibodies. 
D, ribbon diagram and space-filling model of the EGFR-RAD51 kinase domains illustrating the proposed mechanism of 
activation. Purple, first EGFR kinase domain; green, second EGFR kinase domain; red, first RAD51 partner; blue, second 
RAD51 partner; yellow asterisks, active sites. This figure corresponds to Figure 2 from Konduri, Gallant et al., Cancer 
Discovery, 2016 (10). 
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Figure 2.3: EGFR-RAD51 is therapeutically targetable with EGFR inhibitors.  
A, Ba/F3 lines stably expressing EGFR-L858R or EGFR-RAD51 were treated with increasing doses of erlotinib, afatinib, 
or osimertinib for 72 hours. Each point represents six replicates. Data are presented as the mean percentage of viable 
cells compared with vehicle control ± SD. B, Ba/F3 lines stably expressing EGFR-L858R or EGFR-RAD51 were treated 
with increasing doses of erlotinib or afatinib for 2 hours and subjected to Western blot analysis with indicated antibodies. 
C, Ba/F3 cells stably expressing EGFR-RAD51 were serum starved for 16 hours and then treated with 100 nmol/L afatinib 
for 1 hour followed by 50 ng/mL EGF for 5 minutes. EGFR was immunoprecipitated from cellular lysates with an antibody 
targeting the EGFR N-terminus and then subjected to Western blot analysis with indicated antibodies. D, Ba/F3 cells 
stably expressing EGFR-L858R or EGFR-RAD51 were treated with increasing doses of cetuximab for 72 hours. Each 
point represents six replicates. Data are presented as the mean percentage of viable cells compared with vehicle control ± 
SD. ***, P < 0.0001. E, Ba/F3 cells stably expressing EGFR-L858R or EGFR-RAD51 were treated with 5 μg/mL 
cetuximab and counted every 24 hours. Each point represents the average of three replicates ± SD. ***, P < 0.0001. This 
figure corresponds to Figure 3 from Konduri, Gallant et al., Cancer Discovery, 2016 (10).
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against EGFR-RAD51—highlighting that the structural effects of the EGFR mutation, the resultant 
conformation of the EGFR kinase domain, and the type of EGFR inhibitor are all important factors in 
determining the efficacy of a specific EGFR-TKI against a particular EGFR mutation (21). 
Interestingly, EGFR-RAD51 fusions were markedly sensitive to both EGFR-TKIs and the EGFR 
antibody, cetuximab. While some unselected NSCLC patients respond to cetuximab, the monoclonal anti-
EGFR antibody adds minimal benefit for most patients—even when combined with chemotherapy (22,23). 
Previous work has shown that cetuximab sensitivity is correlated with asymmetric dimerization (24). As our 
modeling suggests that the EGFR-RAD51 fusion is activated by virtue of constitutive dimerization, these 
findings suggest a unique molecular cohort that may benefit from cetuximab. Further, these findings provide a 
rationale for therapeutically targeting this subset of lung cancers with a wide array of anti-EGFR therapies, 
many of which are already FDA-approved. On-going work will elucidate whether the deregulated RAD51 
component of the EGFR-RAD51 fusion protein may also be a therapeutic vulnerability for treatment with 
platinum-based and PARP-inhibitor therapies. 
Our experimental work also demonstrates that EGFR-RAD51 fusions are oncogenic and able to 
mediate downstream signaling through the MAPK and PI3K/AKT pathways. While this may seem surprising, 
given that EGFR-RAD51 fusions lack the C-terminal tail known to be important for EGFR signal transduction, 
analyses of several cancer types have identified EGFR C-terminal deletions as recurrent and transforming 
events (25-27). The exact mechanism whereby these EGFR C-terminal deletions activate the EGFR kinase 
domain and confer transforming properties remains unclear. In the case of EGFR-RAD51 fusions, we believe 
there is a unique role for RAD51 given the specific fusion event’s recurrence. A common characteristic of 
tyrosine kinase fusions is that the fusion partner (here, RAD51) contributes an oligomerization domain, which 
promotes activation of the kinase (28). As demonstrated by our structural modeling, EGFR-RAD51 fusion 
proteins could be activated by virtue of RAD51 oligomerization. Similarly, structural modeling has shown that 
PURB proteins can self-associate in the absence of nucleic acids . Additional experimental work will be 
required to determine whether activation of EGFR fusion proteins is driven by asymmetric dimerization of the 
EGFR tyrosine kinase domain, dimerization through the known partner oligomerization interface, or both. 
The cases presented here highlight that adjusting our strategy and using newly available tools, such as 
comprehensive NGS tests, could prove useful in detecting alternative ways in which the EGFR pathway is 
altered (and can be targeted) in tumors. Based on the observation that the EGFR-RAD51 fusions detected in 
the first two patients occurred with breakpoints in EGFR intron 24, we defined further fusion events by the 
presence of a genomic breakpoint in EGFR exons 23 through intron 25. While we limited our investigation to 
these parameters, we cannot exclude that other EGFR rearrangements may exist in lung cancer outside of 
these parameters. Refinements in the assay may help discover more clinically relevant EGFR fusions or 
alterations in the future. 
Methods 
EGFR plasmid construction 
A cDNA encoding the EGFR-RAD51 fusion was synthesized by Life Technologies based on the 
combined Refseq sequences of EGFR (NM_ 005228) and RAD51 (NM_002875) (Figure S2.10). The pMSCV-
puro vector backbone (Clontech) was used to construct all retroviruses. Assembly of pMSCV-puro-EGFR-WT 
and pMSCV-puro-EGFR-L858R was previously described (29). EGFR-RAD51 was subcloned from the pMA 
synthesis vector (Life Technologies) into the HpaI site of pMSCV-puro using blunt end ligation. All plasmids 
were sequence verified in the forward and reverse directions (10). 
Cell Culture 
Ba/F3 cells were purchased from DSMZ. Plat-GP cells were purchased from CellBioLabs. NR6 cells 
have been previously described (13). Ba/F3 cells were maintained in RPMI 1640 medium (Mediatech, Inc.). 
NR6 and Plat-GP cells were maintained in DMEM (Gibco). Media was supplemented with 10% heat inactivated 
fetal bovine serum (Atlanta Biologicals) and penicillin-streptomycin (Mediatech, Inc.) to final concentrations of 
100 U/ml and 100 µg/ml, respectively. The Ba/F3 cell line was supplemented with 1 ng/mL murine IL-3 (Gibco). 
The Plat-GP cell line was cultured in the presence of 10 µg/mL blasticidin (Gibco). All cell lines were 
maintained in a humidified incubator with 5% CO2 at 37°C and routinely evaluated for mycoplasma 
contamination.  
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Ba/F3 and NR6 Cell Line Generation 
The empty pMSCV-puro retroviral vector or pMSCV-puro vectors encoding EGFR (either EGFR-WT, 
EGFR-L858R, or EGFR-RAD51) were transfected, along with the envelope plasmid pCMV-VSV-G (Addgene), 
into cells Plat-GP packaging cells (CellBioLabs). Viral media was harvested 48 hours after transfection, spun 
down to remove debris, and supplemented with 2 µg/mL polybrene (Santa Cruz). 2.5×106 Ba/F3 cells (or 1×106 
NR6 cells) were re-suspended in 10 mL viral media. Transduced cells were selected for 1 week in 2 µg/mL 
puromycin (Invivogen), and Ba/F3 cells were selected for an additional week in the absence of IL-3. Stable 
polyclonal populations were used for experiments and routinely tested for expression of EGFR constructs. 
 
Compounds 
Erlotinib, afatinib, and osimertinib (AZD9291) were purchased from Selleck Chemicals. Cetuximab was 
purchased from ImClone. 
 
Antibodies, Immunoprecipitation, and Immunoblotting 
The following antibodies were obtained from Cell Signaling Technology: phospho-EGFR tyrosine 845 
(#2231, 1:1000 dilution), phospho-EGFR tyrosine 992 (#2235, 1:500 dilution), phospho-EGFR tyrosine 1068 
(#2234, 1:1000 dilution), phospho-EGFR tyrosine 1173 (#4407, 1:1000 dilution), C-term EGFR clone D38 
(#4267, 1:2000 dilution), phospho-AKT serine 473 (#9271, 1:500 dilution), AKT (#9272, 1:1000 dilution), 
phospho-ERK threonine 202/tyrosine 204 (#9101, 1:2000 dilution), ERK (#9102, 1:2000 dilution), HRP-
conjugated anti-mouse (#7076, 1:5000 dilution), and HRP-conjugated anti-rabbit (#7074, 1:5000 dilution). β-
actin antibody (#A2066, 1:5000 dilution) was purchased from Sigma-Aldrich. N-term EGFR clone H11 (MA-
13070, 1:500 dilution) and HRP-conjugated anti-goat (PA-129617, 1:5000 dilution) were purchased from 
Thermo Fisher. N-term EGFR clone 528 (#120, 1:500 dilution) and C-term RAD51 clone C20 (#6862, 1:1000 
dilution) were purchased from Santa-Cruz Biotechnologies. Anti-phosphotyrosine clone 4G10 (#05-321; 1:2000 
dilution) was purchased from Millipore. 
For immunoprecipitation, cells were harvested, washed in PBS, and lysed in NDLB buffer (1% Triton-X-
100, 137 mM NaCl, 10% Glycerol, 20 mM Tris·HCl, pH 8.0) with freshly added 40 mM NaF, 1 mM Na-
orthovanadate, and protease inhibitor mini tablets (Thermo Scientific). Protein was quantified using protein 
assay reagent and a SmartSpec plus spectrophotometer (Bio-Rad) per the manufacturer’s protocol. 300–500 
µg of lysates were subjected to overnight immunoprecipitation with 2 µg N-term EGFR clone 528 (Santa 
Cruz#120; 10 µL). Antibody was precipitated with Protein A Dynabeads (Invitrogen). Immunoblotting was then 
performed as described below. 
  For immunoblotting, cells were harvested, washed in PBS, and lysed in RIPA buffer (150 mM NaCl, 1% 
Triton-X-100, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM Tris·HCl, pH 8.0) with freshly added 40 mM NaF, 1 
mM Na-orthovanadate, and protease inhibitor mini tablets (Thermo Scientific). Protein was quantified (as 
detailed above) and 20µg of lysates were subjected to SDS-PAGE. Protein was transferred to PVDF 
membranes (Millipore) at 1000 mA·hr, blocked in 5% BSA, and incubated with antibodies as detailed above. 
Detection was performed using Western Lightning ECL reagent (Perkin Elmer) and autoradiography film paper 
(Denville). Samples analyzed with N-term EGFR clone 528 were prepared under non-reducing and non-boiled 
conditions. 
 
Cell Viability, Counting, and Clonogenic Assays 
For viability experiments, cells were seeded at 5,000 cells/well in 96-well plates and exposed to 
treatment the following day. At 72 hours post drug addition, Cell Titer Blue reagent (Promega) was added, and 
fluorescence at 570 nm was measured on a Synergy MX microplate reader (Biotek) according to the 
manufacturer’s instructions.  
For cell counting experiments, cells were seeded at 10,000 cells/well in 24-well plates in the absence of 
1 ng/mL IL-3. Every 24 hours, cells were diluted 20 fold and counted using a Z1 Coulter Counter (Danaher).  
For cell counting experiments with drug, cells were seeded at 20,000 cells/well in 12-well plates in the 
absence of 1 ng/mL IL-3. Drugs were added at the following concentrations: erlotinib 500 nM, afatinib 50 nM, 
osimertinib 500 nM, cetuximab 5 µg/mL. Every 24 hours, cells were diluted 20 fold and counted using a Z1 
Coulter Counter (Danaher).  
 
Soft Agar Assays 
1.5 mL of 0.5% agar/DMEM was layered in each well of a 6-well dish. A total of 5,000 NR6 cells in 1.5 
mL of 0.33% agar/DMEM were seeded on top of the initial agar and allowed to grow for three weeks. Each cell 
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line was plated in triplicate. Colonies were counted using GelCount (Oxford Optronix) with identical acquisition 
and analysis settings. 
Structural Modeling of the EGFR-RAD51 Fusion 
The sequence of the EGFR-RAD51 fusion protein was used to generate a structural model based on 
the crystal structure templates 1SZP.PDB (S. cerevisiae Rad51) (18) and 2GS6.PDB (human EGFR) (16). 
PyMOL version 1.5.0.3 (Schrödinger) was used to combine two monomers of yeast RAD51 and two kinase 
domains of EGFR into a single template structure for input to modeling. The N-termini of the RAD51 domains 
were positioned close to the C-termini of the EGFR domains to represent the fusion result. Modeller version 
9.14 (30) was then used to generate the dimeric model of the fusion protein structure. The conformational 
space for the dimer was then sampled using Rosetta version 2015.05 (31). A total of 20,000 independent 
modeling runs were performed using kinematic loop closure. To illustrate the arrangement of the filament, the 
crystallographic symmetry records from 1SZP. PDB were then used to construct eight additional copies of the 
complex in PyMOL. 
Clinical Data and Tumor Genotyping 
Protected health information was reviewed according to the Health Insurance Portability and 
Accountability Act (HIPAA) guidelines. Genomic profiling of tumor samples was performed using a hybrid 
capture-based NGS diagnostic platform (FoundationOne) (9). The database of >56,000 Foundation Medicine 
clinical cases (Primary_150929_114735, November 2nd, 2015) was interrogated for rearrangement class 
events to identify those cases likely to harbor a EGFR fusion event using the FoundationOne Molecular 
Information Browser v0.8 (9). Cases involving an event with a genomic breakpoint in EGFR exons 23 through 
intron 25 were manually investigated to evaluate the potential of each individual rearrangement. Exon 
boundaries were chosen on the basis of the index cases (EGFR-RAD51 harboring a genomic breakpoint in 
EGFR intron 24).  
Statistics and Data Presentation 
All experiments were performed using at least three technical replicates and at least two independent 
times (biological replicates). For statistical analyses, all biological and technical replicates were pooled to 
perform an integrated assessment on the differences among groups. To determine the IC50s, a logistic 
regression was applied after data was transformed using log transformation. To determine the differences in 
cell counts, IC50s, time, and dose trends, and in order to account for the dependence of technical replications 
and repeated measurements, the linear mixed model was used to perform the analysis. The assumption of 
normality for mixed model was investigated. If necessary, data was transformed using log transformation for 
the linear mixed model. R3.2.2 (www.R-project.org) was used to perform all statistical analyses. 
Each figure or panel shows a single representative experiment with the statistical significance derived 
from integrated experimental analyses—as described above. Unless indicated otherwise, data is presented as 
mean ± standard deviation. Western blot autoradiography films were scanned in full color at 600 dpi, 
desaturated in Adobe Photoshop CC, and cropped in Powerpoint. Genomic and proteomic diagrams were 
created in Adobe Illustrator CC. Patient images were cropped to highlight the region of interest. No other image 
alterations were made.
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CHAPTER III: EGFR-KDD 
 
Adapted from: Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Brewer MR, York 
SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, and Lovly CM. EGFR Kinase Domain 
Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. 
Cancer Discovery. 2015 Nov 1;5(11):1155–63. 
 
Abstract  
 Oncogenic EGFR mutations are found in 10-35% of lung adenocarcinomas. Such mutations, which 
present most commonly as small in-frame deletions in exon 19 or point mutations in exon 21 (L858R), confer 
sensitivity to EGFR tyrosine kinase inhibitors (TKIs). In analyzing the tumor from a 33-year-old male never 
smoker, we identified a novel EGFR alteration in lung cancer: EGFR exon 18-25 kinase domain duplication 
(EGFR-KDD). Through analysis of a larger cohort of tumor samples, we detected additional cases of EGFR-
KDD in lung, brain, and other cancers. In vitro, EGFR-KDD is constitutively active, and computational modeling 
provides potential mechanistic support for its auto-activation. EGFR-KDD-transformed cells are sensitive to 
EGFR-TKIs and, consistent with these in vitro findings, the index patient had a partial response to the EGFR-
TKI, afatinib. The patient eventually progressed, at which time, re-sequencing revealed an EGFR-dependent 
mechanism of acquired resistance to afatinib, thereby validating EGFR-KDD as a driver alteration and 
therapeutic target. 
 
Statement of Significance  
 We identified oncogenic and drug sensitive EGFR exon 18-25 kinase domain duplications (EGFR-KDD) 
that are recurrent in lung, brain, and soft tissue cancers and documented that a patient with metastatic lung 
adenocarcinoma harboring the EGFR-KDD derived significant anti-tumor response from treatment with the 
EGFR inhibitor, afatinib. Findings from these studies will be immediately translatable as there are already 
several approved EGFR inhibitors in clinical use. 
 
Introduction  
 The prospective identification and rational therapeutic targeting of tumor genomic alterations have 
revolutionized the care of patients with lung cancer and other malignancies. Oncogenic mutations in the 
epidermal growth factor receptor (EGFR) tyrosine kinase domain are found in an important subset of non-small 
cell lung cancer (NSCLC), and several large phase III clinical trials have shown that patients with EGFR-
mutant lung cancer derive superior clinical responses when treated with EGFR tyrosine kinase inhibitors (TKIs) 
as compared with standard chemotherapy (1-3). Such mutations, which most commonly occur as either small 
in-frame deletions in exon 19 or point mutations in exon 21 (L858R), confer constitutive activity to the EGFR 
tyrosine kinase and sensitivity to EGFR-TKIs (4). Other oncogenic alterations, including ALK and ROS1 gene 
rearrangements, have similarly allowed for the rational treatment of molecular cohorts of NSCLC (5,6). 
Unfortunately, despite these significant advances in defining clinically relevant molecular cohorts of lung 
cancer, the currently identified genomic alterations account for only 50-60% of all tumors (7). Additional 
analyses are necessary to identify therapeutically actionable molecular alterations in these tumors.  
 Here, we describe the case of a 33-year-old male never smoker with metastatic lung adenocarcinoma 
whose tumor lacked all previously described actionable genomic alterations in this disease. Targeted next 
generation sequencing (NGS) based genomic profiling identified a novel in-frame tandem duplication of EGFR 
exons 18-25, the exons that encode the EGFR tyrosine kinase domain. This EGFR kinase domain duplication 
(EGFR-KDD) had not previously been reported in lung cancer, and there were no pre-clinical data or clinical 
evidence to support the use of EGFR inhibitors in patients whose tumors harbor the EGFR-KDD. However, the 
index patient was treated with the EGFR-TKI, afatinib, with rapid symptomatic improvement and significant 
decrease in tumor burden. Notably, upon disease progression, the patient’s tumor harbored an increase in the 
copy number of the EGFR-KDD, solidifying the role of this EGFR alteration as a novel driver in this disease. 
Through analysis of a large set of annotated tumors, we demonstrate that the EGFR-KDD is recurrent in lung, 
brain, and soft tissue tumors. Overall, our data show, for the first time, that EGFR-KDD is an oncogenic and 
therapeutically actionable alteration.  
 
Case Report 
A 33-year-old male never smoker was diagnosed with stage IV lung adenocarcinoma after presenting 
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with cough and fatigue. His tumor biopsy was sent for genomic profiling using an extensively validated hybrid-
capture-based NGS diagnostic assay (FoundationOne) (8). The patient’s tumor was found to be negative for 
any previously described actionable alterations in lung cancer, including negative for the presence of 
previously described EGFR alterations such as L858R, G719A/C/S, and L861Q point mutations, exon 19 
deletion/insertion, and exon 20 insertion (9). Interestingly, however, the patient’s tumor was found to harbor an 
intragenic alteration in EGFR resulting in the tandem duplication of exons 18-25 (Figure S3.1A). The presence 
of this alteration was confirmed by direct sequencing (data not shown) and by an independent clinical NGS 
assay (MSK-IMPACT™)(10)(Figure S3.1B). Since exons 18-25 of EGFR encode the entire tyrosine kinase 
domain, this alteration results in an EGFR protein that has an in-frame kinase domain duplication (Figure 3.1A 
and Figure S3.2). Notably, this EGFR alteration had not previously been reported in lung cancer; the EGFR-
KDD (as duplication of exons 18-25 or 18-26) had only been reported in isolated cases of glioma to date (11-
15). There were no data regarding the frequency of this alteration in tumor samples, nor were there data 
regarding the efficacy of EGFR-targeted agents against the EGFR-KDD.  
Frequency of EGFR-KDD in Lung and Other Cancers 
To determine the frequency of the EGFR-KDD in lung cancer and other tumors, we analyzed data from 
>38,000 clinical cases, each of which had results from FoundationOne targeted sequencing, analogous to the 
index patient. The EGFR-KDD was detected in 5 tumors from ~7,200 total lung cancers tested. In addition, 
EGFR-KDD was identified in 3 gliomas, 1 sarcoma, 1 peritoneal carcinoma, and 1 Wilms’ Tumor (Table 3.1). 
Among samples in The Cancer Genome Atlas (TCGA), we found previously unreported cases of the EGFR-
KDD in lung adenocarcinoma (16) and glioblastoma multiforme (17,18) (Table 3.1 and Figures S3.3A–D). 
Two additional cases were found by MSK-IMPACT™ sequencing (Table 3.1). Together, these data show that 
the EGFR-KDD is a recurrent mutation in lung cancer, glioma, and other human malignancies. It is important to 
note, however, that since most conventional (exomic) sequencing platforms would not routinely detect this 
particular EGFR alteration (due to its intronic breakpoints), these numbers are likely an underestimate, and the 
true prevalence of the EGFR-KDD remains unknown. 
The EGFR-KDD is Oncogenic 
We expressed EGFR-KDD in NR6 and Ba/F3 cells (Figures 3.1B–E). We observed expression of 
EGFR-KDD at the expected molecular weight as compared to EGFR wild-type (WT) and the well-characterized 
EGFR-L858R mutation (Figures 3.1B and D). In contrast to EGFR-WT, both EGFR-L858R and EGFR-KDD 
displayed high levels of autophosphorylation. Consistent with these data, EGFR-KDD protein is constitutively 
autophosphorylated in the absence of serum in A1235 cells, a glioma cell line which harbors endogenous 
EGFR-KDD (11) (Figure S3.4). To address whether EGFR-KDD is an oncogenic alteration, we tested its ability 
to confer anchorage-independent growth to NR6 cells. EGFR-KDD significantly increased colony formation in 
soft agar as compared to both EGFR-WT and the known oncogenic EGFR-L858R mutation (Figure 3.1C and 
Figures S3.5A–D). Expression of a kinase dead version of the EGFR-KDD (called EGFR-KDD-dead) 
abrogated the growth of NR6 cells in soft agar, consistent with the requirement of kinase activity for 
anchorage-independent growth. In parallel, we expressed the same EGFR variants in Ba/F3 cells (Figure 
3.1D). EGFR-KDD, but not its kinase dead counterpart, induced IL-3-independent proliferation of Ba/F3 cells, 
an activity phenotype associated with the transforming function of other oncogenic tyrosine kinases (19) 
(Figure 3.1E). As previously reported, EGFR-L858R, but not EGFR-WT, was able to support IL-3 independent 
growth of Ba/F3 cells (19).  
Computational Modeling Demonstrates that EGFR-KDD can form Intra-Molecular Dimers 
To provide insight into the mechanism of activation of EGFR-KDD, we examined the structure of the 
EGF receptor. The EGFR tyrosine kinase is known to be activated either due to increased local concentration 
of EGFR (e.g., as a result of ligand binding or overexpression), mutations in the activation loop (e.g., L858R) 
(20), or through formation of asymmetric (N-lobe to C-lobe) inter-molecular dimers between two EGFR proteins 
(21). Given the presence of two tandem in-frame kinase domains within the EGFR-KDD structure, we 
hypothesized that EGFR-KDD could form an intra-molecular dimer. To test this hypothesis, we modeled the 
EGFR-KDD based on the available experimental structure of the active asymmetric EGFR dimer (21). 
Conformational loop sampling with Rosetta demonstrates that the linker between the tandem tyrosine kinase 
domains allows for the proper positioning of the two domains necessary for asymmetric dimerization and intra-
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Figure 3.1: The EGFR-KDD is an oncogenic EGFR alteration.  
A, schematic representation of EGFR-KDD depicting the genetic and protein domain structures. ECD, extracellular 
domain; TM, transmembrane helix; TKD1, first tyrosine kinase domain; TKD2, second tyrosine kinase domain; C-term, 
carboxyl terminus region. Blue, EGFR exons 18–25 #1; green, EGFR exons 18–25 #2. B, representative Western blot of 
NR6 cells stably expressing indicated EGFR constructs. EGFR-KDD-dead is a kinase-dead version of EGFR-KDD. C, 
NR6 cells stably expressing the indicated constructs (pMSCV = vector only) were plated in triplicate in soft agar, grown for 
15 days, and quantified for colony formation. D, representative Western blot of BA/F3 cells expressing indicated EGFR 
constructs. E, BA/F3 cells transfected with indicated constructs (pMSCV = vector only) were grown in the absence of IL3 
and counted every 24 hours. F, ribbon diagram and space-filling model of the EGFR-KDD kinase domains (GLY 696—
PRO 1370) illustrating the proposed mechanism of autoactivation. This figure corresponds to Figure 1 from Gallant et al. 
Cancer Discovery, 2015 (22).
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Table 3.1: The EGFR-KDD is a recurrent alteration.  
Characteristics of EGFR-KDD exons 18–25 patients from Foundation Medicine, TCGA, and Memorial Sloan Kettering 
Cancer Center datasets. NOS = not otherwise specified. * = index patient. † = this patient’s tumor also contained high level 
amplification of wild-type EGFR and an EGFR G719C mutation. The EGFR-KDD and EGFR G719C alterations were 
below the level of wild-type EGFR amplification, and presumably reflect sub-clonal populations. This table corresponds to 
Table 1 from Gallant et al. Cancer Discovery, 2015 (22).
Dataset Identification # Age Gender Reported diagnosis 
Foundation 
Medicine
FM-1 52 Female Lung adenocarcinoma 
FM-2* 33 Male Lung adenocarcinoma 
FM-3 53 Female Lung adenocarcinoma 
FM-4 57 Female Lung adenocarcinoma 
FM-5 29 Female Lung NSCLC (NOS) 
FM-6 53 Female Brain astrocytoma 
FM-7 49 Male Brain glioblastoma 
FM-8 54 Male Brain glioblastoma 
FM-9 2 Female Kidney Wilms’ tumor 
FM-10 63 Female Peritoneal serous carcinoma 
FM-11 27 Female Soft tissue sarcoma (NOS) 
TCGA TCGA-49-4512 69 Male Lung adenocarcinoma 
TCGA-12-0821 62 Female Brain glioblastoma 
MSKCC MSKCC-1* 33 Male Lung adenocarcinoma 
MSKCC-2 67 Female Lung adenocarcinoma 
MSKCC-3
† 53 Male Brain glioblastoma 
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molecular EGFR activation (Figure 3.1F). Therefore, our model suggests that EGFR-KDD is an oncogenic 
variant of the EGF receptor likely by virtue of its ability to form intramolecular asymmetric (activated) dimers. 
Although modeling demonstrates that the EGFR-KDD is geometrically capable of forming intra-molecular 
asymmetric dimers, further experimental data would be needed to confirm this mechanism 
The EGFR-KDD can be Therapeutically Targeted with Existing EGFR-TKIs 
We sought to determine whether EGFR-TKIs are an effective therapeutic strategy for tumors harboring 
the EGFR-KDD. We treated Ba/F3 cells expressing EGFR-WT, EGFR-L858R, and EGFR-KDD with erlotinib 
(1st generation reversible EGFR-TKI) (23), afatinib (2nd generation irreversible inhibitor of EGFR/HER2) (24), 
and AZD9291 (3rd generation mutant specific EGFR-TKI) (25) to assess the effects of these inhibitors on the 
autophosphorylation (and by extension, the kinase activity) and downstream signaling properties of the EGFR 
kinase. All three EGFR-TKIs were able to inhibit EGFR-KDD tyrosine phosphorylation in a dose-dependent 
manner, albeit to different levels (Figure 3.2A). Afatinib was the most potent inhibitor of EGFR-KDD 
autophosphorylation, at doses similar to those required for EGFR-L858R inhibition. Activation of downstream 
MAPK signaling was also inhibited in Ba/F3 cells expressing EGFR-KDD, as shown by decreased ERK 
phosphorylation after drug treatment. Similar results were observed in 293T cells transfected with EGFR 
variants (Figure S3.6A) and in A1235 cells which harbor endogenous EGFR-KDD (Figure S3.6B). To 
determine whether inhibition of EGFR autophosphorylation translated to inhibition of cellular proliferation, we 
treated Ba/F3 cells expressing various EGFR constructs with erlotinib, afatinib, and AZD9291. All three distinct 
EGFR-TKIs effectively inhibited the growth of EGFR-KDD Ba/F3 cells (Figure 3.2B and Table S3.1). 
Consistent with our signaling data, the growth inhibition observed was most pronounced with afatinib. 
Analogous results were seen in A1235 cells (Figure S3.6C). Together, these results show that the EGFR-KDD 
can be potently inhibited by afatinib, leading to decreased cell viability. 
Treatment of the Index Patient with Afatinib 
Since there were no data regarding the use of EGFR-TKIs or monoclonal antibodies in the setting of a 
tumor harboring the EGFR-KDD, the index patient was initially treated with standard first line chemotherapy for 
stage IV lung adenocarcinoma (cisplatin/pemetrexed/bevacizumab) (26). However, at the time of disease 
progression on this treatment regimen, the patient was treated with afatinib. Immediately after beginning 
afatinib, the patient reported feeling markedly better with improvements in his symptoms of cough and fatigue. 
After two cycles of afatinib, the patient showed a partial radiographic response (~50% tumor shrinkage) per 
RECIST criteria (27) (Figure 3.3A). This clinical activity is consistent with our in vitro studies and provides 
rationale for further clinical investigation. 
Acquired Resistance to Afatinib 
The index patient developed acquired resistance to afatinib after 7 cycles of therapy (Figure 3.3A). 
This duration of response is in line with the typical responses observed in other EGFR-mutant lung cancers 
treated with EGFR-TKIs (1-3). Molecular profiling was performed on the afatinib resistant tumor biopsy sample, 
and this testing uncovered significant amplification of the EGFR-KDD allele as the only genomic alteration that 
differed from his pre-treatment tumor sample (Figure 3.3B). This sequencing result was confirmed via EGFR 
fluorescence in situ hybridization (FISH) (Figure 3.3C). Amplification of the mutant EGFR allele has been 
reported as a mechanism of acquired resistance in the context of canonical EGFR mutations (e.g. exon 19 
deletion, L858R) in lung cancer (28). Therefore, amplification of the EGFR-KDD in this post-treatment sample 
suggests an EGFR-dependent mechanism of resistance, thereby further validating this EGFR alteration as a 
driver and therapeutic target in patients. 
Discussion 
Although much progress has been made over the past several decades, lung cancer remains the 
leading cause of cancer deaths worldwide (29). The discovery of oncogenic EGFR mutations that sensitize 
lung cancers to EGFR-TKIs heralded the dawn of molecularly-targeted therapy in this disease (30-32). Indeed, 
numerous phase III studies have now documented that patients with EGFR-mutant tumors derive significant 
clinical and radiographic benefit from treatment with EGFR-TKIs, such as gefitinib, erlotinib, and afatinib (1-3). 
The majority of previously described activating mutations in EGFR are a series of small deletions in exon 19 or 
leucine to arginine substitutions at position 858 (L858R) in exon 21 (33). However, because mutations 
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Figure 3.2: The EGFR-KDD can be therapeutically targeted with existing EGFR TKIs.  
A, Ba/F3 lines stably expressing EGFRWT, EGFRL858R, or EGFR-KDD were treated with increasing doses of erlotinib, 
afatinib, or AZD9291 for 2 hours and lysed for Western blot analysis with the indicated antibodies. B, Ba/F3 lines stably 
expressing EGFRL858R or EGFR-KDD were treated with increasing doses of erlotinib, afatinib, or AZD9291 for 72 hours. 
Cell titer blue assays were performed to assess cell viability. Each point represents quadruplicate replicates. Data are 
presented as the mean percentage of viable cells com- pared with vehicle control ± SD. This figure corresponds to Figure 
2 from Gallant et al. Cancer Discovery, 2015 (22).
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Figure 3.3: Serial chest CT scans of 33-year- old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and 
subsequent acquired resistance.  
A, left image, patient images after six cycles of cisplatin/pemetrexed/bevacizumab (largest mass diameter = 6.62 cm). Middle image, patient images after two 
cycles of afatinib (largest mass diameter = 2.72 cm). Right image, patient images after seven cycles of afatinib (largest mass diameter = 6.20 cm). The red 
arrowheads are pointing to the largest mass used for RECIST evaluation. B, copy-number data from FoundationOne NGS targets along chromosome 7 
demonstrating amplification of the EGFR-KDD allele at the time of acquired resistance to afatinib (maroon squares) compared with the pre-afatinib tumor biopsy 
sample (blue squares). The x-axis represents chromosome 7. C, EGFR FISH of pre-afatinib (left image) and post-afatinib (right image) tumor biopsy samples used 
for the NGS analysis shown in B. Pre-afatinib, 1.6 copies of EGFR per chromosome 7 centromere (1.6 EGFR/CEP7); post-afatinib, 4.2 EGFR/CEP7. Green 
puncta, CEP7; red puncta, EGFR. This figure corresponds to Figure 3 from Gallant et al. Cancer Discovery, 2015 (22).
after 7 cycles of afatinib pre-afatinib after 2 cycles of afatinib 
0
1
2
3
R
el
at
iv
e 
co
py
 n
um
be
r a
lte
ra
tio
n
Pre-afatinib
Post-afatinib (acquired resistance)
x-axis = chromosome 7 
ex   ex 
18   25 
EGFR 
pre-afatinib post-afatinib 
A
B  C
49 
50 
historically have been interrogated by ‘hot-spot’ PCR-based methods, most EGFR mutations are biased to fall 
between exons 18 and 21. 
Here, we report the EGFR kinase domain duplication (EGFR-KDD) for the first time in lung cancer. This 
EGFR alteration contains an in-tandem and in-frame duplication of exons 18-25, which encode the entire 
EGFR kinase domain. We demonstrate that the EGFR-KDD is an oncogenic and constitutively activated form 
of the EGF receptor. We provide a structural model whereby the EGFR-KDD can be activated by virtue of 
asymmetric intra-molecular dimerization, as opposed to the typical asymmetric inter-molecular dimerization 
between adjacent EGFR molecules. Furthermore, we demonstrate that the EGFR-KDD can be therapeutically 
targeted with EGFR-TKIs, many of which are already FDA-approved. Additionally, we establish that the EGFR-
KDD alteration is not only recurrent in lung cancer but also in gliomas and other tumor types.  
Most importantly, we provide the first documentation of a clinical response to EGFR inhibitor therapy in 
a lung cancer patient whose tumor harbored the EGFR-KDD alteration. In contrast to lung cancer patients with 
more common EGFR mutations (e.g., exon 19 deletion and L858R), prior to our study, there was no precedent 
to support the use of EGFR inhibitors in patients whose lung tumors harbor the EGFR-KDD alteration. 
Therefore, our patient was not eligible for first-line EGFR-TKI therapy and was instead treated with platinum 
based chemotherapy, the standard of care for metastatic lung adenocarcinoma (34). The index patient was 
treated with afatinib for second-line therapy because this agent is FDA approved for the treatment of EGFR-
mutant NSCLC and because, interestingly, afatinib was consistently the most potent EGFR-TKI against the 
EGFR-KDD across several different assays. This was not unexpected as it has been shown that various EGFR 
mutations or truncations have differential sensitivity to EGFR-TKIs due to nuanced structural differences (35). 
The marked tumor regression and improved functional status seen with afatinib therapy provides important 
clinical validation for the EGFR-KDD as an actionable alteration in lung cancer. Overall, the index patient 
derived a partial response to afatinib for 7 cycles, after which there was progression of disease. His tumor was 
re-biopsied and found to contain amplification of the EGFR-KDD in this post-treatment sample—suggesting an 
EGFR-dependent mechanism of resistance and validating this EGFR alteration as a driver and therapeutic 
target in patients. 
This case also reinforces the need to functionally validate and discern the therapeutic ‘actionability’ of 
genomic alterations as increasingly sophisticated methods of NGS-based assays are being brought to the 
forefront of clinical diagnostics. Notably, the EGFR-KDD would not have been recognized by the ‘hot-spot’ 
PCR-based methods for EGFR mutational analysis described above. Therefore, it is not surprising that this 
EGFR alteration had not previously been detected. In fact, the EGFR-KDD in the index patient’s tumor was 
identified because of a fortuitous intronic breakpoint that lay close to the exonic probes of the NGS diagnostic 
assay. Therefore, we hypothesize that the EGFR-KDD may have gone and may continue to go undetected in 
other tumors because standard (exomic) sequencing platforms do not target this particular alteration due to its 
large intragenic repeat and intronic breakpoint. Thus, while our data show that the EGFR-KDD is recurrent in 
multiple tumor types, this alteration would not be detected with currently approved PCR-based methods and is 
difficult to detect using standard exomic sequencing, consequently making our reported frequency a likely 
underestimate. Future design of tumor sequencing platforms should incorporate intronic probes for EGFR in 
order to more reliably detect the EGFR-KDD. 
In summary, we have identified a recurrent, oncogenic, and drug sensitive EGFR-KDD in a subset of 
patients with lung cancer, glioma, and other cancer types. Our findings provide a rationale for therapeutically 
targeting this unique subset of EGFR-KDD driven tumors with EGFR tyrosine kinase inhibitors, many of which 
are already FDA-approved. Therefore, findings from our studies are expected to be rapidly translated into the 
clinic as they provide a new avenue for precision medicine in these difficult-to-treat malignancies. 
Methods 
Cell culture 
The human lung adenocarcinoma cell line, II-18, has been previously described and was verified to 
harbor the EGFR-L858R mutation direct by cDNA sequencing (36). A1235 cells were a kind gift from Drs. 
Fenstermaker and Ciesielski (Roswell Park Cancer Institute, Buffalo, NY) (11). 293T cells were purchased 
from ATCC. BA/F3 cells were purchased from DSMZ. Plat-GP cells were purchased from CellBioLabs. NR6 
cells were a kind gift from Dr. William Pao (37). II-18 and BA/F3 cells were maintained in RPMI 1640 medium 
(Mediatech, Inc.). A1235, 293T, and NR6 cells were maintained in DMEM (Gibco). Media was supplemented 
with 10% heat inactivated fetal bovine serum (Atlanta Biologicals) and penicillin-streptomycin (Mediatech, Inc.) 
to final concentrations of 100 U/ml and 100 µg/ml, respectively. The BA/F3 cell line was supplemented with 1 
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ng/mL murine IL-3 (Gibco). The Plat-GP cell line was cultured in the presence of 1 µg/mL blasticidin (Gibco). 
All cell lines were maintained in a humidified incubator with 5% CO2 at 37°C and routinely evaluated for 
mycoplasma contamination. Besides verifying the status of EGFR mutations in cell lines, no additional cell line 
identification was performed. 
 
Compounds 
 Erlotinib, afatinib, and osimertinib were purchased from Selleck Chemicals. 
 
EGFR Plasmid Construction 
 A cDNA encoding the EGFR-KDD (exon 18-25 tandem duplication) was synthesized by Life 
Technologies based on the consensus coding sequence. The pMSCV-puro vector backbone (Clontech) was 
used to construct all retroviruses. Assembly of pMSCV-puro-EGFR-WT and pMSCV-puro-EGFR-L858R was 
previously described (38). The EGFR-KDD was subcloned from the pMA synthesis vector (Life Technologies) 
into the HpaI site of pMSCV-puro using blunt end ligation. The pcDNA3.1 vector was used for transient 
expression experiments in 293T cells. Assembly of pcDNA-EGFR-WT and pcDNA-EGFR-L858R was 
previously described (32). EGFR-KDD was subcloned from the pMA synthesis vector (Life Technologies) into 
the pcDNA3.1/V5 vector (Life Technologies) using Gateway cloning (Life Technologies). All plasmids were 
sequence verified in the forward and reverse directions. EGFR-KDD-dead was constructed using multi-site-
directed mutagenesis (Agilent) of the catalytic lysines (K745 and K1096) to methionines using the following 
primer:  
KM-F: 5’–AAAGTTAAAATTCCCGTCGCTATCATGGAATTAAGAGAAGCAAC–3’. 
The plasmids were fully re-sequenced in each case to ensure that no additional mutations were introduced. 
 
BA/F3 and NR6 Cell Line Generation 
 The empty pMSCV-puro retroviral vector or pMSCV-puro vectors encoding EGFR (either EGFR-WT, 
EGFR-L858R, EGFR-KDD, or EGFR-KDD-dead) were transfected, along with the envelope plasmid pCMV-
VSV-G (CellBioLabs), into cells Plat-GP packaging cells (CellBioLabs). Viral media was harvested 48 hours 
after transfection, spun down to remove debris, and supplemented with 2 µg/mL polybrene (Santa Cruz). 
2.5×106 BA/F3 cells (or 1×106 NR6 cells) were re-suspended in 10 mL viral media. Transduced cells were 
selected for 1 week in 2 µg/mL puromycin (Invitrogen) and BA/F3 cells were selected for an additional week in 
the absence of IL-3. Stable polyclonal populations were used for experiments and routinely tested for 
expression of EGFR constructs. 
 
Antibodies and Immunoblotting 
 The following antibodies were obtained from Cell Signaling Technology: phospho-EGFR tyrosine 1068 
(#2234, 1:1000 dilution), EGFR (#4267, 1:1250 dilution), phospho-ERK threonine 202/tyrosine 204 (#9101, 
1:2000 dilution), ERK (#9102, 1:2000 dilution), HRP-conjugated anti-mouse (#7076, 1:5000 dilution), and HRP-
conjugated anti-rabbit (#7074, 1:5000 dilution). The actin antibody (#A2066, 1:5000 dilution) was purchased 
from Sigma-Aldrich. The EGFR antibody (#610017, 1:2000 dilution) was purchased from BD Pharmingen. For 
immunoblotting, cells were harvested, washed in PBS, and lysed in RIPA buffer (150 mM NaCl, 1% Triton-X-
100, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM Tris·HCl, pH 8.0) with freshly added 40 mM NaF, 1 mM Na-
orthovanadate, and protease inhibitor mini tablets (Thermo Scientific). Protein was quantified using protein 
assay reagent and a SmartSpec plus spectrophotometer (Bio-Rad) per the manufacturer’s protocol. Lysates 
were subjected to SDS-PAGE followed by blotting with the indicated antibodies and detection by Western 
Lightning ECL reagent (Perkin Elmer). 
 
Cell Viability, Counting, and Clonogenic assays 
 For viability experiments, cells were seeded at 5,000 cells/well in 96-well plates and exposed to 
treatment the following day. At 72 hours post drug addition, Cell Titer Blue reagent (Promega) was added, and 
fluorescence at 570 nm was measured on a Synergy MX microplate reader (Biotek) according to the 
manufacturer’s instructions. For cell counting experiments, cells were seeded at 20,000 cells/well in 24-well 
plates in the presence or absence of 1 ng/mL IL-3. Every 24 hours, cells were diluted 20 fold and counted 
using a Z1 Coulter Counter (Danaher). For clonogenic assays, cells were seeded at 5,000 cells/well in 24-well 
plates and exposed to treatment the following day. Media and inhibitors were refreshed every 72 hours, and 
cells were grown for 1 week or until confluence in control wells. Cells were fixed with 4% v/v formalin and 
stained with 0.025% crystal violet. Dye intensity was quantified using an infrared imaging system (LI-COR). 
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Viability assays were set up in quadruplicate, clonogenic assays were set up in triplicate, and cell-counting 
assays in duplicate. All experiments were performed at least three independent times. Data are presented as 
the percentage of viable cells compared to control (vehicle only treated) cells. Regressions were generated as 
sigmoidal dose-response curves using Prism 6 (GraphPad) by normalizing data and constraining the top to 
100. 
Soft Agar Assays 
1.5 mL of 0.5% agar/DMEM was layered in each well of a 6-well dish. A total of 10,000 NR6 cells in 1.5 
mL of 0.33% soft agar/DMEM were seeded on top of the initial agar and allowed to grow for 15 days. Each cell 
line was plated in triplicate. Colonies were counted using GelCount (Oxford Optronix) with identical acquisition 
and analysis settings. 
Transient Transfections 
293T cells were transfected using Lipofectamine 2000 (Life Technologies) per the manufacturer’s 
recommendations. 24 hours post-transfection, cells were treated for two hours, gathered for western blot 
analysis, and prepared as described above.  
Structural Modeling of the EGFR-KDD 
The linker residues in the EGFR-KDD protein sequence, FFSSPSTSRTPLLSSLLVEPLTPS, were 
defined as those between the two kinase domains and not present in the X-ray crystal structure of EGFR in its 
allosterically activated dimeric form, 2GS6.pdb (21).This linker was manually built and placed into the EGFR 
crystal structure using PyMOL 1.5.0.3. The conformational space for the linker was then sampled using the 
loop modeling functionality of Rosetta version 2015.05 (39). 20,000 independent loop modeling runs were 
performed using kinematic closure. The best model from these runs was still lacking residues 748-750, 992-
1004, 1099-1101, and 1343-1355 because these surface-exposed loops were not resolved in the experimental 
structure. These four loops were reconstructed using Modeller 9.14, and the model with the lowest DOPE 
score was selected (40). Those loops were then sampled for an additional 20,000 runs using Rosetta to 
generate the complete energy-minimized model of EGFR-KDD residues GLY 696 - PRO 1370. 
Tumor Biopsy Samples 
All patient tumor biopsy samples were obtained under Institutional Review Board (IRB) approved 
protocols (Vanderbilt University IRB# 050644). Written informed consent was obtained from the index patient. 
All samples were de-identified, protected health information reviewed according to the Health Insurance 
Portability and Accountability Act (HIPAA) guidelines, and studies conducted in accordance with the 
Declaration of Helsinki. 
Validation of EGFR-KDD 
Nucleic acids were isolated from formalin-fixed, paraffin-embedded tissue sections using the AllPrep DNA/RNA 
FFPE Kit (Qiagen). Nucleic acids were isolated from A1235 cell pellets using RNAeasy and DNAeasy kits 
(Qiagen). RT-/PCR were used to amplify the ‘breakpoint’ region following exon 25 and preceding exon 18 of 
EGFR-KDD. RT-PCR was performed with the SuperScript III one-step RT-PCR system (Life Technologies) 
using 100 ng RNA and the following primers: 
Ex24-25F: 5’–GTTTTCCCAGTCACGACCTTGTCATTCAGGGGGATG–3’ 
Ex18-19R: 5’–CAGGAAACAGCTATGACGGGATCCAGAGTCCCTTATACA–3’ 
PCR was performed with HotStarTaq master mix (Qiagen) using 100 ng DNA and the following primers: 
Ex25F: 5’–GTTTTCCCAGTCACGACAGAACCAAGGGGGATTTCAT–3’ 
Ex18R: 5’–CAGGAAACAGCTATGACTTGGTCTCACAGGACCACTG–3’ 
RT-/PCR products, which included the EGFR-KDD ‘breakpoint’, were sequenced in both directions using M13 
primers, BigDye Terminator chemistry, and 3730 DNA Analyzers (Applied Biosystems). Aside from the 
EGFRKDD, 
no mutations or alterations were found in either the sequenced regions of the A1235 cell line or the 
patient sample (as compared to the EGFR CCDS). 
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Identifying EGFR-KDD in The Cancer Genome Atlas 
Copy number data from the Broad Institute TCGA Genome Data Analysis Center 2015-04-02 run were visually 
inspected to identify samples with focal amplification of the EGFR-KDD region (exons 18-25). RNA-seq 
(e714b8a4-dd57-4b01-83fd-d3a9fb2d4ad1120 and c552b1e3-9158-4c4d-b02b-b16ff7903552) and whole-
genome sequencing (27c2031a-39f1-473c-88a6-9e7a03cedf04) files were inspected to confirm the presence 
of tandem duplication reads. Raw data available at: doi:10.7908/C1K64H04 and doi:10.7908/C1MP525H. 
 
EGFR Fluorescence in situ Hybridization (FISH) 
EGFR FISH was performed by Integrated Oncology, a LabCorp specialty testing group, using the EGFR-CEP7 
Dual Color DNA Probe (Vysis). A trained pathologist quantified the copies of CEP7 and EGFR in 60 nuclei per 
sample. 
 
Statistics and Data Presentation 
All experiments were performed using at least two technical replicates and at least three independent times 
(biological replicates). Each figure or panel shows a single representative experiment. Unless indicated 
otherwise, data is presented as mean ± standard deviation. Western blot autoradiography films were scanned 
in full color at 600 dpi, desaturated in Adobe Photoshop CC, and cropped in Powerpoint. EGFR-FISH images 
were normalized using ‘Match Color’ in Adobe Photoshop CC. No other image alterations were made.
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CHAPTER IV: FUTURE DIRECTIONS 
Overview 
This chapter is divided into two sections with the first focusing on EGFR-RAD51 and the second 
focusing on EGFR-KDD. Both sections describe ongoing work and future directions with an eye towards 
understanding the oncogenic proteins’ mechanism of action. Specifically, each section details efforts aimed at 
creating cell line models of the EGFR re-arrangement, systems being developed to test for their mechanisms 
of activation, and hypotheses about how the molecules may be propagating downstream mitogenic signaling. 
EGFR-RAD51: Ongoing Work and Future Directions 
Creating a Cell Line Model of EGFR-RAD51 
The main limitation in our current work on EGFR-RAD51 has to do with the cell lines used to model the 
oncogenic fusion. Firstly, both Ba/F3 and NR6 cell lines are murine cell lines that may not be representative of 
the human milieu in which EGFR-RAD51 leads to tumor formation. While the Ba/F3 model is a well validated 
predictor of oncogenic properties of a gene (1-3), and though growth in soft agar is correlated with the 
transformed phenotype (4), murine cells are more amenable to transformation than human cells (5,6). Our 
current models cannot identify potential differences that EGFR-RAD51 expression may have in human cells. 
Secondly, our pMSCV retroviral system (7) uses MMLV-based overexpression of EGFR-RAD51. Although the 
relative activity of promoters depends on the cell type and on the particular cDNA sequence, the long terminal 
repeats (LTRs) that drive MMLV gene expression are generally strong promoters (8). Therefore, it is 
conceivable that a relatively high amount of expressed protein is the factor responsible for cellular 
transformation. This presumed high expression is problematic because oncogenic fusions have been found to 
express at relatively low levels as compared to endogenous proteins (9). Lastly, it is possible that breakage of 
the RAD51 gene (which would occur in cells with EGFR-RAD51 fusions) is the key oncogenic property of 
EGFR-RAD51. Because loss or mutation of a single RAD51 allele is genotoxic, it could be that the gene fusion 
is oncogenic by virtue of its ability to cause RAD51-mediated loss of homologous recombination (HR) and 
increased amounts of chromosomal instability (10). Together, these factors point towards the need for a more 
nuanced approach toward the cellular study of EGFR-RAD51. 
To circumvent cell line limitations, we are taking the following approaches (in increasing likelihood of 
success):  
1. Searching for human lung cancer cell lines that harbor endogenous EGFR-RAD51;
2. Using the CRISPR/Cas9 system to create an in situ chromosomal rearrangement in AALE cells (normal
lung epithelial cells); 
3. Attempting to create cell lines from EGFR-RAD51 index patients; and
4. Reconstructing our stable EGFR-RAD51 cells using human bronchial epithelial cells (HBEC).
To find an available human cell line harboring an EGFR fusion, we will use a set of converging 
electronic database searches. First, we will search the Cancer Cell Line Encyclopedia (CCLE) (11) for cells 
that are sensitive to EGFR-targeted therapies and/or harbor predicted truncation mutations in EGFR. Cells with 
intronic mutations will have their sequences examined manually because fusions often occur in non-coding 
regions (12). The Genomics of Drug Sensitivity in Cancer (GDSC) (13,14) will also be queried for an alternative 
source of cell line sensitivity to EGFR-targeted therapies. Because the CCLE (174 lung cancer cell lines) and 
GDSC (217 cell lines) databases only have an overlapping fraction of the ≥ 300 available lung cancer cell lines 
(15), a manual search will need to be performed on the remaining cell lines. Because the N-term of EGFR is a 
recurrent feature in EGFR fusions and because functional protein expression is critical for driver oncogenes, 
we will perform a selective search for EGFR protein expression. First pass searches will be performed with the 
image searching capabilities of the most common search engines. Databases will be searched with the cell line 
names, and the terms EGFR, western blot, mutation, and/or lung cancer. Experiments and papers will be 
retrieved, experimental details checked, and cell lines expressing EGFR, as determined by known C-term 
antibodies, will be eliminated from the search. As the majority of antibodies used for western blotting bind the 
C-term of EGFR, and because EGFR is critical to lung epithelial cells and is usually expressed in all NSCLCs 
(16), any cell line that does not express C-term EGFR in a western blot image will be re-queried using 
MEDLINE and EMBASE. Finally, in parallel, GEO, and other databases, will be searched for any available 
genetic data on lung cancer cell lines not analyzed by the CCLE and GDSC. Sequencing data will be manually 
analyzed using validated fusion detection tools (17). Any potential hits will be acquired and tested for the 
presence of the expected EGFR fusion. While this search method has a low chance of success (based on our 
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published frequency of EGFR fusions in NSCLC (18)), finding an endogenous model of an EGFR fusion would 
be a boon to our research efforts. 
As there currently exists no known lung cancer cell line harboring the endogenous EGFR-RAD51 
fusion, we are utilizing CRISPR/Cas9 technology to create the fusion in normal human lung epithelial cells. 
This method has successfully been used to create endogenous lung cancer related fusions including the 
EML4-ALK and KI5B-RET inversions and the CD74-ROS1 translocation (19). Using standard methods (20), 
we created, synthesized, and tested 4 different Cas9 gRNAs: 2 targeting intron 24 of EGFR and 2 targeting 
intron 3 of RAD51 (Figure 4.1A and Table S4.1). These gRNAs were subcloned into pX458 vectors and their 
efficacy tested in 293FT cells. After transient transfection into 293FT cells, all 4 gRNAs were able to induce 
double stranded DNA (dsDNA) breaks in their target locations as determined by SURVEYOR assay (Figure 
4.1B). As the transfection of a single plasmid containing multiple gRNAs is more efficient than transfecting two 
plasmids (21), multiplexed constructs, each containing one EGFR and one RAD51 gRNA, were created. These 
multiplexed constructs retained their ability to induce dsDNA breaks in 293FT cells, albeit, less efficiently 
(Figure 4.1C). Using both multiplexed EGFR-RAD51 sgRNA constructs, we attempted to generate the 
translocation between chromosomes 15 (RAD51) and 7 (EGFR) in normal human lung cells (using the AALE 
cell line; hTERT and SV40 immortalized normal human bronchial epithelial cells (22)). To date, 140 putative 
EGFR-RAD51 AALE clones have been isolated and frozena. While some clones tested positive for the fusion 
by breakpoint RT-PCR, none of the positive RT-PCR hits tested positive for expression of the protein by 
western blotting (Figures 4.1D–E). In total, 48 putative clones have tested negative for the EGFR-RAD51 
fusion; the other half remains untested and frozen as pellets or cells in DMSO. However, as the frequency of in 
vitro CRISPR/Cas9 induced translocations is rather lowb, current efforts should be maintained. 
Because we already know of 5 patients with EGFR fusions, the most straightforward approach to 
creating a cell line would be to obtain tumor tissue from these patients. However, there are several logistical 
hurdles including patient privacy laws, IRB approval, and long distance shipping of tumor tissues. The ideal 
way to generate a cell line is from a large amount of fresh tumor tissue. Such tissue can be mechanically 
dissociated and grown into cell lines over time. Our lab has some success with this approach (23), and it has 
proven to be a generally reliable method to model human tumors in vitro (24). However, acquiring such tissue 
from our index patients is unlikely given the logistical hurdles mentioned above. Alternatively, a small piece of 
fresh tissue (such as a repeat biopsy) could be used with a feeder layer of cells and specialized media to grow 
indefinitely as conditionally reprogrammed cells (25-27). Unfortunately, this latter method introduces several 
artifacts into the cell culture system, such as the feeder cells. A potential solution could be to acquire freshly 
snap frozen and/or slowly frozen (in DMSO supplemented media) tumor biopsies; recent research has shown 
that tumor cells can be revived from such frozen tissue (28). As reviving frozen biopsies has been 
accomplished, and because we have documented the existence of several EGFR fusion patients, this 
approach may prove to be the most feasible and least artificial option. 
The least sophisticated option (but still more nuanced than our original Ba/F3 and NR6 cells) would be 
to create a human model of EGFR-RAD51 using our retroviruses and established normal human lung cell 
lines. Using reagents in lab, we could re-create pMSCV based EGFR-RAD51 retrovirus and infect HBEC (29) 
or AALE cell lines at various MOI. Using varying doses of puromycin, we could then select human lung cells 
harboring EGFR-RAD51. Alternatively, we could subclone our construct into our lab’s doxyxycline-inducible 
pRetroX-TRE3G system to create differently-expressing clones. Regardless of approach, selecting a variety of 
stable clones could allow us to see what happens at varying levels of EGFR-RAD51 expression; but, we would 
still be left with an overexpression system. 
Testing Homologous Recombination in Cells Harboring EGFR-RAD51 
Because RAD51 functions as a critical component of HR (30), we hypothesize that cancers driven by 
EGFR-RAD51 will be sensitive to therapies aimed at the DNA damage response. Being able to target an 
oncogenic fusion with targeted therapy (EGFR-TKIs) and synthetic lethality (DNA damaging agents) would be 
an exciting finding and would have implications in cases of acquired resistance. We hypothesize that EGFR-
RAD51 antagonizes normal HR processes through RAD51 haploinsufficiency and/or through RAD51 
mislocalization. To test whether EGFR-RAD51 could cause RAD51 haploinsufficiency, we would need a cell 
line of endogenous EGFR-RAD51, as outlined in the section above. However, testing sensitivity to therapies 
aimed at the DNA damage response and whether EGFR-RAD51 causes RAD51 mislocalization can be 
accomplished with our available reagents. 
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Figure 4.1: Utilizing the CRISPR/Cas9 system to promote EGFR-RAD51 formation in cells 
A, schematic depicting the strategy for generating chromosomal rearrangements using Cas9 from S. pyogenes (SpCas9) 
that directs DNA cleavage at each targeted genomic site. The EGFR-RAD51 rearrangement results from a translocation 
between chromosomes 15 and 7. Shown are the intronic sites where Cas9 was targeted. Adapted from (19). B, 
SURVEYOR assay for single EGFR and RAD51 gRNAs. 293FT cells were transfected with constructs expressing Cas9 
alone (PX458, vector) or with a targeting sgRNA (EGFR#1, #1, or RAD51#1, #2). For each sgRNA target site, the 
surrounding ~800 bp SURVEYOR assay to assess the formation of indels. C, SURVEYOR assay for multiplexed EGFR-
RAD51 (#1, #2) PX458 constructs. Throughout: red triangles indicate predicted T7EI cleavage sites (31). D, RT-PCR of 
putative EGFR-RAD51 AALE clones. + = positive control = Ba/F3 EGFR-RAD51. D, western blot of putative EGFR-
RAD51 AALE clones. + = positive control = Ba/F3 EGFR-RAD51; – = negative control = AALE. RAD51 blot is taken 
between 100 and 200 kD.
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To test whether cancers driven by EGFR-RAD51 are sensitive to therapies aimed at the DNA damage 
response, we will treat our published IL-3 independent Ba/F3 cells with a variety of agents. Specifically, we will 
test whether the Ba/F3 cells harboring EGFR-RAD51 are hyper-sensitive to PARP inhibitors and relevant 
platinum based chemotherapy agents (cisplatin and carboplatin) compared to similar (Ba/F3) cells expressing 
pMSCV vector, EGFR-WT, or EGFR-L858R. We will also test commercially available inhibitors aimed at 
RAD51-mediated strand exchange, such as RI-1 and B02 (32). Hypersensitivity to these agents (which target 
the DNA damage response and/or RAD51 specifically) as opposed to EGFR inhibitors would point towards the 
RAD51 portion of EGFR-RAD51 impacting normal DNA repair.  
Since endogenous RAD51 is known to traffic between the cytoplasm and the nucleus (33,34), we 
hypothesize that EGFR-RAD51 fusions could inhibit normal RAD51 function by trapping endogenous RAD51 in 
the cytoplasm, at the cell membranec. Therefore, if Ba/F3 cells harboring EGFR-RAD51 are hyper-sensitive to 
DNA-damaging agents, then we will test to see whether this is due to RAD51 localization. We will test this 
hypothesis by immunofluorescently evaluating the subcellular localization of co-expressed RFP-tagged RAD51 
and/or GFP-tagged EGFR-RAD51 upon treatment with DNA damaging agents. If cells harboring EGFR-RAD51 
are hypersensitive to HR-targeted agents, then we would expect to see increased amounts of RAD51 in the 
cytoplasm (as opposed to the nucleus). 
Determination of EGFR-RAD51 Mode ofActivation and Signaling 
Our published computational modeling suggests that EGFR-RAD51 can form the asymmetric dimers 
required for EGFR kinase activation and that RAD51, a filamentous protein (36), could help induce EGFR-
RAD51 multimerization (18). However, dimerization of EGFR-RAD51, as we modeled, could be driven by 
asymmetric dimerization of the EGFR tyrosine kinase domain, dimerization through the known RAD51 
dimerization interface, or both (Figure 4.2).  
To test this hypothesis, we are repeating our experiments in Ba/F3 and NR6 cells, but with constructs 
deficient in EGFR-RAD51 dimerization. Specifically, we created EGFR asymmetric dimerization interface 
mutants (I706Q and V948R (37)), EGFR kinase dead mutants (K745M and D837N), RAD51 oligomerization 
interface mutants (F993E, A996W, A1097W, and A1099W (38-42)d); and combinations thereof (Figure 4.2). 
We have created stable cell lines (Ba/F3 and NR6) with some of these various dimerization-impaired forms of 
EGFR-RAD51 and will test whether they still are able to transform cells. Regardless of their transforming 
potential, cells harboring these constructs will all be tested for downstream signaling, including signaling via the 
PI3K/AKT and MAPK pathways, in the absence or presence of EGF and EGFR-TKIs. If ablating the EGFR 
asymmetric dimer interface and/or RAD51 oligomerization prohibits transformation, we will confirm the 
interaction with immunoprecipitation (IP) experiments. Specifically, we will determine whether EGFR-RAD51 
can co-IP with itself in the presence or absence of EGF. To accomplish this, we have created a series of dual 
tagged EGFR-RAD51 plasmids—pcDNA-EGFR-RAD51-V5/His and pTracer-EGFR-RAD51-FLAG/MYC—both 
of which are similar sized and driven by CMV promoters. We will add the same point mutations as indicated 
above, co/express these plasmids in EGFR-null CHO cells, and perform reciprocal IP experiments with or 
without EGF. Running the IP product out on a denaturing gel will allow us to determine what drives EGFR-
RAD51 dimerization, and, by proxy, activation. 
While these experiments could shed light on the nature of EGFR-RAD51 dimerization and activation, it 
still remains unclear as to how the fusion propagates downstream signaling. EGFR contains several 
(auto)phosphorylable tyrosines in the C-term tail of the receptor that positively regulate the transforming activity 
of EGFR by mediating downstream proliferative signaling. However, half of these tyrosine residues are absent 
in EGFR-RAD51 due to the fusion protein’s lack of a C-term. Of the residues present in EGFR-RAD51, only 
tyrosines 869, 915, 944, and 978 have been experimentally verified as being able to bind adapters at 
physiologically relevant concentrations (43-45) (Figure 4.3A). We will systematically transform these sites from 
tyrosines to phenylalanines (Y to F mutants) in order to test whether these residues are necessary for 
transformation. We plan to then generated Ba/F3 cells stably expressing these constructs to determine 
whether the mutants are able to support IL-3 independent growth. To support these results, we will similarly 
test anchorage independent growth in NR6 cells. As tyrosine 869 is the SRC phosphorylation site, in parallel, 
we will treat cells expressing EGFR-RAD51 ‘wild-type’ (not containing any YF mutations) with SRC inhibitors, 
such as saracatinib (46), to determine if SRC
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Figure 4.2: Proposed key residues for EGFR-RAD51 dimer and oligomer formation. 
Left: ribbon diagram and space-filling model of the EGFR–RAD51 kinase domains illustrating the proposed mechanism of 
activation from (18). Purple, first EGFR kinase domain; green, second EGFR kinase domain; red, first RAD51 partner; 
blue, second RAD51 partner. Top insert: zoom of the EGFR asymmetric dimerization interface with key contact residues 
highlighted. Yellow, valine 948 (V948); red, isoleucine 706 (I706). Bottom insert: zoom of the RAD51 oligomerization 
interface with key contact residues highlighted. Orange, phenylalanine 993 (F993) and alanine 996 (A996); green, alanine 
1097 (A1097) and alanine 1099 (A1099). Interaction between neighboring RAD51 molecules follows a ‘key-lock’ principle 
where F993 is intercalated between A1097 and A1099. A996 helps stabilize this key-lock and is evolutionarily conserved 
back to bacteria (38).
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Figure 4.3: Determining how EGFR-RAD51 propagates downstream mitogenic signaling. 
A, schematic representation of EGFR-RAD51 with physiologically relevant (auto)phosphorylable tyrosines marked. 
Numbers correspond to amino acid residues. Y, tyrosine residue. B, schematic representation of EGFR-RAD51 Δint24+ 
with physiologically relevant (auto)phosphorylable tyrosines marked. C, NR6 cells stably expressing EGFR-RAD51 or 
EGFR-RAD51 Δint24+ were subjected to western blot analysis with indicated antibodies. The two distinct EGFR variants 
were detected at the anticipated molecular weight of 150 and 110 kD. Both constructs can be detected with the N-terminal 
EGFR antibody, but only the fusion can be detected with the RAD51 antibody. D, Alignment of EGFR-RAD51 with high 
scoring effectors, adaptors, and/or kinases (47-50). Residues surrounding EGFR-RAD51 Y1222 are indicated in the table 
relative to Y1222 at position 0. The consensus binding sequence of NCK1 (51) and consensus phosphorylation site of 
several kinases are indicated below (52,53). In the case of multiple amino acids being selected as substrate at a particular 
position, they are listed in order of relative selectivity (54).
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inhibition interrupts signaling and proliferation of cells expressing EGFR-RAD51. Of note, SRC and Y869 have 
been deemed critical for EGFR-mediated transformation (55). 
Still, because EGFR C-term deletions have been reported in lung (56) and other cancers (57) it could 
be that EGFR-RAD51 is able to transduce signal independent of any phosphotyrosines or other C-term 
adapter moities. To test this hypothesis, we have created an EGFR construct that spans EGFR exons 1-24, 
which we call EGFR Δint24+ (Figures 4.3A–B).  We have created stable Ba/F3 and NR6 cells using this 
construct and will test the ability of this EGFR-RAD51 variant to support downstream mitogenic signaling 
(Figure 4.3C). We are also planning on creating combinations of Δint24+ with tyrosines 869, 915, 955, and 
998 substituted with phenylalanines (singly, and in combination). If the variants are unable to support 
oncogenic signaling and transformation, the data would point towards a key role for the RAD51 portion of 
EGFR-RAD51 and would bring into question previous findings claiming EGFR Δint24+ is oncogenic (56,57). 
As such, an alternative and intriguing hypothesis has to do with the RAD51 portion of the fusion serving 
as the docking site for downstream adaptors. Although tyrosine phosphorylation of RAD51 is a contentious 
topice, there is mounting evidence that RAD51 is regulated by tyrosine phosphorylation in humans (62). One of 
RAD51’s phosphorylation sites (Y315) is present in EGFR-RAD51 as Y1222 (Figure 4.3A). Stringent 
computational prediction of cell signaling motif interactions using a variety of approaches (47,48) predicts that 
NCK1, a known oncogenic adaptor protein (63), can bind to pY1222. Indeed, NCK1’s SH2 binding motif 
YDx(V/p) (51) is found as YDSP in EGFR-RAD51. Similar computational prediction using a variety of 
approaches (49,50) predicts that Y1222 could be phosphorylated by ABL (which has been experimentally 
confirmed (62)), SRC family kinases, and/or EGFR—each with decreasing likelihood (Figure 4.3D). Therefore, 
we hypothesize that EGFR-RAD51 is phosphorylated at Y1222, perhaps as a result of autophosphorylation. To 
test this hypothesis, we have created a series of mutants: EGFR-RAD51 D837N (which ablates the EGFR 
kinase activity); Y1222F (which removes RAD51’s tyrosine phosphorylation site); and combinations of the two. 
We will create stable cell lines (Ba/F3 and NR6) with EGFR-RAD51 Y1222F to see whether the mutant is still 
able to transform cells. If ablating the RAD51 tyrosine phosphorylation site prevents cellular transformation, 
then we will perform co-expression experiments in CHO cells to test for autophosphorylation. Additionally, 
since NCK1 is the most likely adaptor, we will perform co-IP experiments with/out Y1222F. Together these 
studies will should reveal the mechanism by which EGFR-RAD51 is activated and propagates downstream 
signal. 
EGFR-KDD: Ongoing Work and Future Directions 
Creating a Cell Line Model of EGFR-KDD 
As discussed above with regards to our EGFR-RAD51 work, the main limitation with our current EGFR-
KDD work has to do with the cell lines (Ba/F3 and NR6) that we use as our models. To circumvent the 
limitations of an overexpression/murine model, we attempted to develop a cell line from the index patient 
whose tumor harbored EGFR-KDD. At the time of acquired resistance to afatinib, the patient underwent a 
series of endobronchial ultrasound biopsies. After routine pathological assessment, remaining tumor sample 
was sent to Foundation Medicine (a company which performs targeted NGS on tumor samples (64)) and to our 
laboratory. In the lab, the ~0.5 mm3 biopsy was minced with a sterile scalpel. Then, the biopsy was placed in 
media with feeder cells for conditional cell re-programming (25,27) (Figure 4.4A). Under these conditions, the 
biopsy expanded and maintained its original glandular architecture for 8 passages. (Figure 4.4B) However, the 
conditionally reprogrammed cells (CRCs) are difficult to use for cellular-based assays (such as the MTT cell 
viability assay) because of the feeder cells. Therefore, we tried several different methods to wean the CRCs off 
the feeder cells, including culture on different sized vessels, on different surfaces (plastic, collagen, agar), with 
different media (such as the lung epithelial cell specific LHC9 (65)), and at different densities. No matter what 
method we used (including a variety of media and culture surfaces [see Methods]), it appeared (via light 
microscopy) that the cells changed morphology with each of these conditions, never retaining the glandular 
morphology of the initial biopsy (Figure 4.4C). Moreover, while the cells tested positive for EGFR-KDD during 
the first passage as CRCs, they seemed to lose expression of the EGFR-KDD with repeated passage and in 
different conditions (Figures 4.4D–E). While we have retained several pieces of the original biopsy, early 
passage CRCs, and differentiated cells for further optimization and testing, the index patient has unfortunately 
passed away, preventing further tissue collection.
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Figure 4.4: Development of a conditionally reprogrammed cell line from the index EGFR-KDD patient.  
A, overview of the development of conditionally reprogrammed cells (CRCs) from an endobronchial biopsy of the index 
patient with a lung adenocarcinoma harboring EGFR-KDD. For details, see methods (27). B, 4 x microphotographs of 
CRCs showing the development from day 1 at 12 hours, day 3 at 48 hours, 2 weeks, and over the course of 8 passages. 
P, passage. C, 4 x microphotographs of parental CRCs and derivatives cultured in various media, at confluence. D, PCR 
amplification of the EGFR-KDD exon 25-18 breakpoint in A1235 cells (glioma cell line harboring EGFR-KDD), at various 
passages of the CRCs, from the cells in varying media (at P1), and from the cells grown as CRCs on collagen-coated 
plates. E, PCR amplification of the EGFR-KDD exon 25-18 breakpoint in A1235 cells (glioma cell line harboring EGFR-
KDD) and in the index patient’s primary tumor biopsy.
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Maximizing Inhibition of EGFR-KDD 
As shown in our published data, erlotinib, afatinib, and/or osimertinib can inhibit the proliferation of cells 
harboring EGFR-KDD; however, whether these agents are the best way to inhibit the proliferation of cells 
driven by EGFR-KDD remains an open question. This is an important question, with regards to the clinical 
treatment of tumors harboring EGFR-KDD and the biology of EGFR-KDD: various activation states of EGFR 
can best be treated by structurally different EGFR-TKIs (66). Therefore, we ran MTT assays against Ba/F3 
cells harboring EGFR-KDD and tested the ability of all available EGFR-TKIs (erlotinib, gefitinib, afatinib, 
dacomitinib, neratinib, lapatinib, osimertinib, and rociletinib) to inhibit EGFR-KDD proliferation over a 4-log, 20-
dose range (Figure 4.5A). The irreversible TKIs afatinib and dacomitinib proved to be the most potent TKIs 
against EGFR-KDD, even when adjusting for clinically attainable plasma concentrations (67-74) (Figure 4.5B). 
The anti-EGFR antibody cetuximab was also tested against EGFR-KDD and EGFR-L858R using MTT assays 
and proved to have little to no effect (data not shown)f. The clinically useful combination of cetuximab and 
afatinib (77,78) was also tested in soft agar assays and proved to be no more potent than either agent alone 
against the EGFR-KDD (Figures 4.5C–D).  
Several therapeutic avenues remain to be explored and could prove effective against the EGFR-KDD. 
Agents targeting MAPK (such as the MEK inhibitors trametinib and selumetinib) and agents targeting the 
PI3K/AKT pathway (such as MK-2206, dactolisib, and/or pictilisib) alone and in combination (dual vertical 
inhibition) with EGFR-TKIs have yet to be tested against the EGFR-KDD. We also plan on treating our cell line 
models with other agents that target EGFR signaling: anti-EGFR therapeutic antibodies with different targeting 
epitopes (panitumumab, Sym004, and necitumumab), EGFR-TKIs that may sample different activation states 
of the kinase (canertinib, icotinib, and vandetanib), and, because mutant EGFR is reliant upon the chaperone 
protein HSP90 for proper folding (79), HSP90 inhibitors (17AAG, ganetespib, and luminespib).  
Acquired Resistance to EGFR-TKIs in the Setting of EGFR-KDD 
Acquired resistance to afatinib in a patient whose tumor harbored the EGFR-KDD was described in our 
initial publication (80). For this patient, the putative mechanism of resistance involved genomic amplification of 
the whole EGFR-KDD allele, without any additional mutations (such as T790M). Since our initial publication, a 
report of acquired resistance in another patient with EGFR-KDD has been published (81). This patient was 
treated with EGFR-TKIs (erlotinib and gefitinib) on and off for 10 years before developing EGFR-KDD ‘T790M’. 
However, this publication did not differentiate which of the EGFR-KDD gatekeeper residues was mutated 
(T790M or T1141M)g. It is important to understand where the TM mutation is located as it will information 
EGFR biology and, potentially, future treatment.  
In order to model resistance is the setting of EGFR-KDD we initially planned on developing isogenic 
pairs of EGFR-TKI sensitive and resistant A1235 cell lines (which harbor endogenous EGFR-KDD). However, 
because these cell lines are glioblastoma lines, and because of the biological differences between brain and 
lung epithelia, this approach was abandoned. Instead, we focused on performing an ENU mutagenesis screen 
on Ba/F3 cell lines, which is a validated means of modeling resistance to TKIs (82,83). BA/F3 cells (EGFR-
L858R and -KDD) were exposed to 50 µg/mL N-ENU for 48 hours, expanded, and grown in the presence of 
drug. EGFR-L858R served as a positive control in this experiment. The drugs used (based on clinically 
achievable doses (67,70,74)) were erlotinib (at 500, 1000, 2000 nM), afatinib (at 10, 100, 1000 nM), and 
osimertinib (at 200, 500, 1000 nM). The experiment was repeated twice (N=2), and, each time ≥ 72 resistant 
clones of EGFR-L858R were identified—at all drug / dose ranges. However, both times, EGFR-KDD failed to 
develop any resistant clones—even after 1 month of culture. We hypothesize that the lack of emergent 
resistance, in this assay, in EGFR-KDD cells may have to do with the fact that ENU works by creating points 
mutations / indels and not large genomic rearrangements; it is unlikely that ENU can induce amplification of the 
whole EGFR-KDD allele as was seen in the initial patient resistant to afatinib. To test whether the clinically 
observed T790M mutation can mediate resistance when located in EGFR-KDD, we have created Ba/F3 cells 
harboring EGFR-KDD-T790M and EGFR-KDD-T1141M. While we hypothesize that T1141M would mediate 
resistance (in the acceptor positon of the asymmetric dimmer (84)), both will be tested against EGFR-TKIs and 
compared to EGFR-KDD. In parallel, EGFR-T790M will be compared with EGFR-L858R. These findings 
should hint at the mechanism of activation of EGFR-KDD, especially if EGFR-KDD-T1141M mediates EGFR-
TKI resistance.
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Figure 4.5: Maximizing inhibition of the EGFR-KDD 
A, Ba/F3 cell lines stably expressing EGFR-L858R (black) or EGFR-KDD (blue) were treated with increasing doses of 
erlotinib, gefitinib, afatinib, dacomitinib, neratinib, lapatinib, osimertinib, and rociletinib for 72 hours. CellTiter Blue assays 
were performed to assess viability at endpoint, and an EC50 derived from curve fitting in Prism. Each bar represents the 
average result from triplicate experiments ± SD. B, EC50 results from Figure 4.5A adjusted for clinically attainable plasma 
concentrations (67-74). C, NR6 cells stably expressing EGFR-L858R or EGFR-KDD were grown in soft agar for three 
weeks in presence of the indicated drugs and quantified for colony formation . C5 = 5 µg/mL cetuximab; A100 = 100 nM 
afatinib; C5+A100 = 5 µg/mL cetuximab + 100 nM afatinib. D, A1235 cells (glioma cell line harboring EGFR-KDD) were 
treated with cetuximab, afatinib, or the combination, lysed, and analyzes for western blot analysis with the indicated 
antibodies. C = 5 µg/mL cetuximab; A = 100 nM afatinib; A+C = 5 µg/mL cetuximab + 100 nM afatinib.
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Adding Experimental Support to the Intra-Molecular Asymmetric Dimer Model 
As discussed in the introductory chapter, the activation of EGFR involves the formation of an 
asymmetric dimer between two EGFR TKDs, in which one TKD serves as an allosteric activator of the other 
(37). This mechanism of activation for EGFR does not require activation loop phosphorylation by a kinase (85); 
instead, this allosteric activation involves the C-lobe of one EGFR TKD (the first kinase of ‘activator’) forming a 
tight interface with the N-lobe of another (the second kinase or ‘receiver’), which stabilizes the second kinase / 
receiver in the active conformation (Figure 1.4B and Figure 4.6A). Given the presence of two tandem kinase 
domains within the EGFR-KDD, we hypothesized that EGFR-KDD could form an intra-molecular asymmetric 
dimer. To test this hypothesis, we modeled the EGFR-KDD based on the available experimental structure of 
the active asymmetric EGFR dimer. Conformational loop sampling with Rosetta demonstrated that the linker 
between the tandem tyrosine kinase domains allows for the proper positioning of the two domains necessary 
for asymmetric dimerization and intra-molecular activation (Figure 3.1F and Figure 4.6B) (80). Although this 
structural modeling demonstrates that the EGFR-KDD is geometrically capable of forming active intra-
molecular dimers, further experimental data are needed to confirm this mechanism. 
To provide experimental support for our structural model of EGFR-KDD, we created mutant variants of 
the protein which would be unable to propagate downstream signal if the EGFR-KDD was forming an intra-
molecular dimer (Figures 4.7A–B). Based on our model and on the documented existence of higher ordered 
EGFR oligomers (86,87), we hypothesize that EGFR-KDD can form intra- and inter- molecular dimers (Figure 
4.8A). Consistent with this hypothesis, mutating the contact residues at the C-lobe within the first kinase 
(V948R) or at the N-lobe within the second kinase (I1057Q) should ablate EGFR-KDD intra-molecular 
dimerization and auto-activation (Figure 4.8B). Similarly, since the second (receiver) kinase is active in an 
intra-molecular dimer, mutating the catalytic aspartate of the second TKD (D1188N) should impair EGFR-KDD 
enzymatic activity (Figure 4.8B). Mutations that do not interfere with the intra-molecular dimerization 
interface—I706Q (N-lobe interface disruption of the first kinase) and V1299R (C-lobe interface disruption of the 
second kinase)—should allow for constitute activation of the EGFR-KDD (Figure 4.8C). Moreover, ablating the 
activity of the first kinase (D837N) should have no effect on EGFR-KDD auto-activation and intra-molecular 
activation as this first kinase only serves to activate the second by physical contact and not phosphorylation 
(Figure 4.8C). Finally, any mutation that ablates intra-molecular dimerization or auto-activation should be 
rescued by the addition of EGF—which should allow for inter-molecular dimerization by creating chains of 
active kinase domains. These mutations and hypotheses are summarized in Figures 4.8. 
In order to create these EGFR-KDD mutants, we first constructed a new EGFR-KDD cDNA in which we 
used the degeneracy of the genetic code to create two distinct kinase domains, at the nucleotide level, that 
encoded for the same amino acid sequence (Figure S4.1). With two differently-coded kinase domains, we 
were able to use site-directed mutagenesis to insert the previously mentioned amino acid mutations at the N-
lobe, C-lobe, and catalytic interfaces. Had we used our previously published EGFR-KDD cDNA, any attempt to 
insert a single amino acid mutation with site-directed mutagenesis would have forcibly inserted two such 
mutations (because of the identically-coded tandem kinase domains). We successfully created all the 
aforementioned EGFR-KDD mutants and confirmed all variants by bi-directional Sanger sequencing.  
Unfortunately, despite repeated attempts, we could not reproducibly re-create the western blot from Figure 4.8 
or create reliable EGFR-KDD cell line models. In fact, we could barely produce any EGFR-KDD (and variant) 
protein—in any system we tested (Figures S4.2A–C). 
A series of troubleshooting experiments led us to conclude that the low level of EGFR-KDD expression 
had to do with the new, degenerate, EGFR-KDD constructs (with degenerate kinase domains). Specifically, in 
creating the two degenerate kinase domains, we produced an EGFR-KDD cDNA that could not express at 
levels suitable for cellular transformation likely due to several translation-related factors (88). For one, because 
the degenerate kinase domain was encoded using rarer codons, we had a transcript that had a poor codon 
adaptation index (88,89) (Figure S4.2D). Simultaneously, these rare codons were, at times, in tandem, which 
can predispose to ribosomal frameshift and improper translation (88,90) (Figure S4.2E). We therefore devised 
a new cloning and mutational scheme to insert mutations in the EGFR-KDD constructs (two wild-type EGFR 
kinase domains) that we had previously published (80). Using multi-site directed mutagenesis, a repeating 
restriction site, and a series of sub-cloning reactions, we were able to generate all EGFR-KDD constructs in a 
non-degenerate construct (see methods and Figure S4.3A). We proceeded to create new retroviral EGFR-
KDD plasmids and stable Ba/F3 cells harboring the variants (Figure S4.3B).
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Figure 4.6: Comparison of WT-EGFR activation and putative EGFR-KDD auto-activation. 
A, also Figure 1.4B. Ribbon diagram and space filling model of the asymmetric dimer of the EGFR TKD (PDB 2GS6 (37)) 
generated using Chimera (91). The activator kinase is colored navy, and the receiver (enzymatically active) kinase is 
colored dark green. Key contact residues at the asymmetric interface are highlighted in orange (valine 948) and magenta 
(isoleucine 706). B, ribbon diagram and space-filling model of the EGFR-KDD kinase domains illustrating the proposed 
mechanism of autoactivation (80), generated using Chimera (91). The first kinase, or activator kinase, is colored navy, 
and the second kinase, or receiver (enzymatically active) kinase, is colored dark green. The linker is colored red. Key 
contact residues at the asymmetric (intra-molecular) interface are highlighted in orange (valine 948) and magenta 
(isoleucine 1057). 
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Figure 4.7: Key residues for EGFR-KDD intra- and inter- molecular dimerization and function 
A, ribbon diagram and space-filling model of the EGFR-KDD kinase domains illustrating the proposed mechanism of 
autoactivation (80), generated using Chimera (91). The first kinase, or activator kinase, is colored navy, and the second 
kinase, or receiver (enzymatically active) kinase, is colored dark green. The linker is colored red. Key residues are 
displayed, colored, and highlighted: I706 (isoleucine 706, black); D837 (aspartate 837, yellow); V948 (valine 948, orange); 
I1057 (isoleucine 1057, magenta); D1188 (aspartate 1188, dark red); V1299 (valine 1299, white). B, model of EGFR-KDD 
auto-activation; adapted from (92). The first kinase, or activator kinase, is colored navy, and the second kinase, or 
receiver (enzymatically active) kinase, is colored dark green. The linker is colored red. Key residues are pictured as 
circles: I706 (isoleucine 706, black); D837 (aspartate 837, yellow); V948 (valine 948, orange); I1057 (isoleucine 1057, 
magenta); D1188 (aspartate 1188, dark red); V1299 (valine 1299, white).
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Figure 4.8: Expected effects of EGFR-KDD dimerization-inhibiting point mutations 
A, expected effect of EGF withdrawal (top) and addition (bottom) on EGFR-KDD. Removing EGF should have no effect on EGFR-KDD kinase activity; adding EGF 
promotes EGFR-KDD multimerization and mass activation. B, expected effect of intra-molecular dimerization inhibiting (V948R or I1057Q) and receiver kinase 
dead (D1188N) mutations. Any of these mutations, alone or in combination, would ablate intra-molecular auto-activation in the absence of EGF (top), but this 
would be rescued with addition of EGF (bottom). C, expected effect of inter-molecular dimerization inhibiting (I706Q or V1299R) and activator kinase dead 
(D837N) mutations. Any of these mutations, alone or in combination, would ablate inter-molecular activation. The molecule could still auto-activate in the absence 
of EGF (top), but this would activity would not be greater with the addition of EGF (bottom). D, expected western blot if individual EGFR-KDD mutants were to be 
expressed in EGFR-null cells ± EGF and probed with the indicated antibodies. Brackets indicate the scenarios from the mutants in the panels of this figure.
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We will now use these cell line models (and others) in a series of experiments to determine how the 
variants effect activation of the EGFR-KDD protein. Specifically, we will test whether the EGFR-KDD variants 
can overcome IL-3 dependence of Ba/F3 cells and anchorage-dependence of NR6 cells and YAMC EGFR-/- 
cells—EGFR null cells that contain a heat labile large T antigen (93). Additionally, we will repeat transient 
transfection westerns and perform drug sensitivity experiments to gain insight into the structural mechanism of 
activation of the EGFR-KDD. We are confident that the degenerate KDD construct could not express well due 
to several contextual translation issues (Figure S4.2) and believe that our new system will allow us to tease 
out the mechanism of activation of the EGFR-KDD—providing experimental support for the structural model we 
proposed and a new way to study EGFR biology.  
Methods 
Cell Culture 
A1235 cells were a kind gift from Drs. Fenstermaker and Ciesielski (Roswell Park Cancer Institute, 
Buffalo, NY) (94). 293F/T cells were purchased from ATCC. Ba/F3 cells were purchased from DSMZ. Plat-GP 
cells were purchased from CellBioLabs. NR6 cells were a kind gift from Dr. William Pao (Roche, CH) (77). 
Ba/F3 cells were maintained in RPMI 1640 medium (Mediatech). YAMC EGFR-/- cells were a kind gift from Dr. 
Robert Whitehead (Vanderbilt University, TN) (95). A1235, 293F/T, and NR6 cells were maintained in DMEM 
(Gibco). Media was supplemented with 10% heat inactivated fetal bovine serum (Atlanta Biologicals) and 
penicillin-streptomycin (Mediatech) to final concentrations of 100 U/ml and 100 µg/ml, respectively. The Ba/F3 
cell line was supplemented with 1 ng/mL murine IL-3 (Gibco). The Plat-GP cell line was cultured in the 
presence of 1 µg/mL blasticidin (Gibco). YAMC EGFR-/- cells were cultured in DMEM containing 5 % FBS, 1 
µg/mL insulin (Sigma), 10 µM ɑ-thioglycerol Sigma), 1 µM (or ~0.5 µg/mL) hydrocortisone (Sigma), and 5 U/mL 
murine γ-interferon (Peprotech). Due to their heat-labile large T antigen, YAMC EGFR-/- cells were cultured at 
33 ºC. All other cell lines were maintained in a humidified incubator with 5% CO2 at 37°C and routinely 
evaluated for mycoplasma contamination. 
gRNA Target Selection and Cloning 
Suitable gRNAs were created using the online CRISPR Design Tool (96) with Streptococcus pyogenes 
Cas9 (SpCas9) as the chosen nuclease and with the most recent human genome reference sequence 
(GRCh37/hg19). Oligos were synthesized (Eurofins MWG Operon), annealed, and ligated into the BbsI sites of 
pSpCas9(BB)-2A-GFP (PX458, Addgene) (20). gRNA sequences are listed in Table S4.1. EGFR and RAD51 
gRNAs were multiplexed into PX458 using the PrecisionX Multiplex gRNA Cloning Kit (SBI), an H1 promoter 
amplicon (97), and overlapping PCR primers (Table S4.1). The resulting PX458 constructs (EGFR-RAD51#1 
and #2 [each having the corresponding EGFR and RAD51 gRNAs]) have an EGFR gRNA driven by a H1 
promoter and a RAD51 gRNA driven by a U6 promoter. The multiplexed gRNAs were also subcloned from 
PX458 into the BsmBI sites of plentiCRISPRv2 (98). 
gRNA Testing in 293FT Cells 
293FT cells (Thermo) were plated the day before transfection at 1×106 cells per well of a six-well plate. 
On the day of transfection, the medium was replaced with 2 mL of antibiotic-free DMEM (Gibco) with 10% heat 
inactivated fetal bovine serum (FBS, Atlanta Biologicals). Cells were transfected with 3 µg of PX458 and a 2:1 
ratio (µL L2K: µg DNA) of Lipofectamine 2000 (Life Technologies) via 500 mL of OPTI-MEM (Life). 48 hours 
later, transfection efficiencies were estimated by detection of the green fluorescent protein (GFP) reporter; 
transfection efficiencies averaged > 90% (data not shown). After visualization of GFP, cells were manually 
detached from plates, washed with PBS, snap frozen, and their DNA extracted with the DNEasy kit (Qiagen). 
sgRNA functional testing was then performed with the SURVEYOR nuclease assay (99) per the 
manufacturer’s instructions (IDT). 200 ng of DNA was amplified by HotStarTaq Mastermix PCR (Qiagen) using 
primers that created 800 bp amplicons surrounding the sgRNA-targeted sites (Table S4.1). SURVEYOR 
products were the run on 2% TBE-agarose gels and visually inspected for banding (Figures 4.1B–C). 
Transfecting and Testing AALE Cells with Multiplexed EGFR-RAD51 Constructs 
5×106 AALE cells (a kind gift of Dr. Meyerson, DFCI) were plated in a 100 mm dish the day before 
transfection. On the day of transfection, the medium was replaced with 6 mL of antibiotic-free DMEM with 10% 
heat inactivated fetal bovine serum. Cells were transfected with 10 µg of PX458 and a 2:1 ratio (µL L2K: µg 
DNA) of Lipofectamine 2000 via 500 mL of OPTI-MEM. Media was replaced after 24 hours and cells split into 
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4×96-well plates by limiting dilution 72 hours after transfection. Single clones were marked after 24 hours, 
transferred to 12-well plates after two weeks, and then expanded into 100 mm dishes. After reaching 
confluence, cells were trypsinized and split 1:1 into pellets for DNA extraction or into supplemented DMSO 
media for long term storage. 
To test for the presence of EGFR-RAD51 fusions, DNA was extracted from ½ of the cell pellets with the 
DNEasy kit and RT-PCR performed with SuperScript III One-Step RT-PCR System with Platinum Taq (Life). 
RT-PCR primers are listed in Table S4.1. Ba/F3 cells stably expressing EGFR-RAD51 were used as a positive 
control (18). Samples that had signal nearly equivalent signal as compared to the positive control subsequently 
had protein extracted from the other ½ of the cell pellets and were subjected to western blot analysis. Cells 
were lysed in RIPA buffer (150 mM NaCl, 1% Triton-X-100, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM 
Tris·HCl, pH 8.0) with freshly added 40 mM NaF, 1 mM Na-orthovanadate, and protease inhibitor mini tablets 
(Thermo). Protein was quantified using protein assay reagent and a SmartSpec plus spectrophotometer (Bio-
Rad) per the manufacturer’s protocol. Lysates were subjected to SDS-PAGE followed by blotting with the 
indicated antibodies (C-term RAD51 clone C20 #6862, 1:1000 dilution from Santa-Cruz and actin #A2066 
1:5000 dilution from Sigma) and detection by Western Lightning ECL reagent (Perkin Elmer). 
Creation of EGFR-RAD51 Dimerization-Impaired Mutants 
Mutations were introduced into pMa-EGFR-RAD51 (18) with the QuickChange II kit (Stratagene). Site-
directed mutagenesis was carried out per the manufacturer’s recommendations with the exception of extension 
time being set at 1.5 mins / kb. Mutagenesis primers are listed in Table S4.2. After bi-directional dideoxy 
sequencing, EGFR-RAD51 mutants were subcloned into the BglII/EcoRI sites of pMSCV-puro (Clontech) or 
into the BamHI/EcoRI sites of pcDNA3.1 (Life). Plasmids were then re-sequenced to ensure proper insertion 
and that no additional mutations were introduced. 
Creation of Tagged EGFR-RAD51 Constructs 
New stop codons with restriction sites were introduced into pMa-EGFR-RAD51 (18) with the 
QuickChange II kit (Stratagene). Site-directed mutagenesis was carried out per the manufacturer’s 
recommendations with the exception of extension time being set at 1.5 mins / kb. Mutagenesis primers are 
listed in Table S4.2. After bi-directional dideoxy sequencing, EGFR-RAD51 mutants were subcloned into the 
HindIII/EcoRI sites of pTracer-CMV2ΔGFP-3xFLAG (Clontech) or into the HindIII/EcoRI sites of 
pcDNA6/V5His-B. Plasmids— pTracer-EGFRRAD51-3XFLAG and pcDNA-EGFRRAD51-V5/His—were then 
re-sequenced to ensure proper insertion and that no additional mutations were introduced. 
Derivation of the VP-34 Cell Line 
VP34 was derived from the index patient with a lung adenocarcinoma harboring EGFR-KDD as a 
conditionally reprogrammed cell line, per protocol (27). Briefly, fresh endobronchial biopsy tissue was taken 
from the patient to the lab and mechanically diced/separated. This tissue was laid scrapped into a 100 mm dish 
containing F-medium and 5×104 lethally irradiated (3000 rad via Cesium irradiation) 3T3 cells. Cells were 
thereafter maintain like normal cell with the difference being that every passage was onto a new 100 mm dish 
with freshly irradiated 3T3 cells. 
F-medium: 370 mL of DMEM, 125 mL of F12 nutrient mix, 0.5 mL of hydrocortisone/EGF mix (25 μg/ml 
hydrocortisone in EtOH; 0.125 μg/ml EGF), 0.5 mL of 10 µg/mL insulin, 0.5 mL of amphotericin B (Gibco), 5 
mL pf P/S, and 4.3 μL of cholera toxin (Sigma). After adding the ROCK inhibitor Y-27632 (Enzo) to a final 
concentration of 10 μM, the medium was kept at 4 °C for up to 2 months. 
Creation of Stable Cell Lines Harboring EGFR-RAD51 and EGFR-KDD Mutants 
Empty pMSCV-puro retroviral vector or pMSCV-puro vectors encoding EGFR-KDD or RAD51 variants 
were transfected, along with the envelope plasmid pCMV-VSV-G (CellBioLabs), into cells Plat-GP packaging 
cells (CellBioLabs). Viral media was harvested 48 hours after transfection, spun down to remove debris, and 
supplemented with 2 µg/mL polybrene (Santa Cruz). 2.5×106 Ba/F3 cells, 1×106 NR6 cells, or 1×106  YAMC 
EGFR-/- cells were re-suspended in 10 mL viral media. Transduced cells were selected for 1 week in 2 µg/mL 
puromycin (Invitrogen) and Ba/F3 cells were selected for an additional week in the absence of IL-3. Stable 
polyclonal populations were used for experiments and routinely tested for expression of EGFR constructs. 
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Soft Agar and MTT Assays 
Cell viability assays, including soft agar and CellTiter Blue assays were performed as previously 
described (18,80). 
ENU Mutagenesis Resistance Screen 
ENU mutagenesis was performed per established protocols (82,83). Briefly, ENU (Sigma) was 
dissolved in DMSO at 50 mg/mL and stored in aliquots at 80°C. ENU was added to Ba/F3 EGFR-L858R or 
EGFR-KDD cells (5×106 cells) to a concentration of 50 µg/mL, followed by culture for 12 to 24 hours. This dose 
of ENU has been established as minimally cytotoxic (82). The cells were then washed 3 times, re-plated in 
complete medium, and allowed to expand over 1 week under exponential growth conditions. 
ENU-exposed Ba/F3 cells were the plated and cultured in 96-well plates at 1×105 cells/well in 200 µL 
complete media supplemented with graded concentrations of the respective inhibitors. Inhibitor concentrations 
were as follows: erlotinib (at 500, 1000, 2000 nM), afatinib (at 10, 100, 1000 nM), and osimertinib (at 200, 500, 
1000 nM). Non-mutagenized Ba/F3 EGFR-L858R cells, incubated with the maximum concentration of each 
drug, were included as controls. Wells were observed for cell growth by visual inspection under an inverted 
microscope and media color change every 2 to 3 days for at least 4 weeks. When growth in a well occurred, 
cells were transferred to 24-well plates and expanded in the presence of the corresponding inhibitor 
concentration used in the screen. If growth was simultaneously observed in all 96 wells of a given condition, 
only 24 wells were expanded for further analysis. Cells were enventually expanded to 100 mm dishes and 
frozen down. 
Creation of EGFR-KDD Sequences, Mutations, and Constructs 
The degenerate EGFR-KDD sequence was designed by replacing the first repeat of exons 18–25 with 
a degenerate sequence. This degenerate sequence was created by copying exons 18–25 of EGFR 
(CCDS5514.1) into GeneDesign (100) and using the most different RCSU codon juggling algorithm. The 
complete cDNA (Figure S4.1) was synthesized by Life Technologies. 
Mutations were introduced into pMa-EGFR-KDD (degenerate) with the QuickChange II kit (Stratagene). 
Site-directed mutagenesis was carried out per the manufacturer’s recommendations with the exception of 
extension time being set at 1.5 mins / kb. Mutagenesis primers are listed in Table S4.3. After bi-directional 
dideoxy sequencing, EGFR-KDD (degenerate) mutants were subcloned into the BglII/EcoRI sites of pMSCV-
puro (Clontech) or into the BamHI/EcoRI sites of pcDNA3.1 (Life). Plasmids were then re-sequenced to ensure 
proper insertion and that no additional mutations were introduced. 
Mutations were introduced into pMa-EGFR-KDD (tandem identical sequences) (80)with the Multi-Side 
Direction Mutagenesis kit (Stratagene). Site-directed mutagenesis was carried out per the manufacturer’s 
recommendations with the exception of extension time being set at 1.5 mins / kb. Mutagenesis primers are 
listed in Table S4.3. After bi-directional dideoxy sequencing, pMa-EGFR-KDD (tandem) mutants were digested 
with ClaI and re-combined per Figure S4.3 to create all 10 mutants. Plasmids were then re-sequenced to 
ensure proper insertion and that no additional mutations were introduced. pMA-EGFR-KDD (tandem) single 
mutants were then blunt ligated into the HpaI site of pMSCV-puro (Clontech). Plasmids were finally re-
sequenced to ensure proper insertion and that no additional mutations were introduced.
74 
References 
1. Palacios, R. & Steinmetz, M. Il-3-dependent mouse clones that express B-220 surface antigen, contain
Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727–734 (1985).
2. Daley, G. Q. & Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic cell line by
the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 85,
9312–9316 (1988).
3. Warmuth, M., Kim, S., Gu, X.-J., Xia, G. & Adrián, F. Ba/F3 cells and their use in kinase drug
discovery. Curr Opin Oncol 19, 55–60 (2007).
4. Cifone, M. A. & Fidler, I. J. Correlation of patterns of anchorage-independent growth with in vivo
behavior of cells from a murine fibrosarcoma. Proc. Natl. Acad. Sci. U.S.A. 77, 1039–1043 (1980).
5. Holliday, R. Neoplastic transformation: the contrasting stability of human and mouse cells. Cancer
Surv. 28, 103–115 (1996).
6. Weinberg, R. A. The biology of cancer. (2014).
7. Hawley, R. G., Lieu, F. H., Fong, A. Z. & Hawley, T. S. Versatile retroviral vectors for potential use in
gene therapy. Gene Ther. 1, 136–138 (1994).
8. Miller, A. D. & Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotech. 7,
980–2– 984–6– 989–90 (1989).
9. Frenkel-Morgenstern, M. et al. Chimeras taking shape: potential functions of proteins encoded by
chimeric RNA transcripts. Genome Research 22, 1231–1242 (2012).
10. Kim, T. M. et al. RAD51 Mutants Cause Replication Defects and Chromosomal Instability. Mol. Cell.
Biol. 32, 3663–3680 (2012).
11. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug
sensitivity. Nature 483, 603–307 (2013).
12. Shaver, T. M. et al. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-
Negative Breast Cancer and Other Malignancies. Cancer Research 76, 4850–4860 (2016).
13. Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker
discovery in cancer cells. Nucleic Acids Research 41, D955–61 (2013).
14. Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 1–44 (2016).
15. Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L. & Minna, J. D. Lung Cancer Cell Lines as
Tools for Biomedical Discovery and Research. JNCI Journal of the National Cancer Institute 102,
1310–1321 (2010).
16. Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung
development, renewal and cancer. Nature 507, 190–194 (2014).
17. Latysheva, N. S. & Babu, M. M. Discovering and understanding oncogenic gene fusions through data
intensive computational approaches. Nucleic Acids Research 44, 4487–4503 (2016).
18. Konduri, K. et al. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discovery 6,
601–611 (2016).
75 
19. Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using CRISPR/Cas technology. Nature
Communications 5, 3728 (2014).
20. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281–
2308 (2013).
21. Maddalo, D. et al. In vivo engineering of oncogenic chromosomal rearrangements with the
CRISPR/Cas9 system. Nature 516, 423–427 (2015).
22. Lundberg, A. S. et al. Immortalization and transformation of primary human airway epithelial cells by
gene transfer. Oncogene 21, 4577–4586 (2002).
23. Lovly, C. M. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat
Med 20, 1027–1034 (2014).
24. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl.
Acad. Sci. U.S.A. 105, 4283–4288 (2008).
25. Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.
Am. J. Pathol. 180, 599–607 (2012).
26. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug
combinations for cancer. Science 346, 1480–1486 (2014).
27. Liu, X. et al. Conditional reprogramming and long-term expansion of normal and tumor cells from
human biospecimens. Nature Protocols 12, 439–451 (2017).
28. Walsh, A. J., Cook, R. S., Sanders, M. E., Arteaga, C. L. & Skala, M. C. Drug response in organoids
generated from frozen primary tumor tissues. Sci. Rep. 1–11 (2015).
29. Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral
oncoproteins. Cancer Research 64, 9027–9034 (2004).
30. Krejci, L., Altmannova, V., Spirek, M. & Zhao, X. Homologous recombination and its regulation.
Nucleic Acids Research 40, 5795–5818 (2012).
31. Vouillot, L., Thélie, A. & Pollet, N. Comparison of T7E1 and surveyor mismatch cleavage assays to
detect mutations triggered by engineered nucleases. G3: Genes| Genomes| Genetics (2015).
32. Carvalho, J. O. F. & Kanaar, R. Targeting homologous recombination-mediated DNA repair in cancer.
Expert Opin. Ther. Targets 18, 000–000 (2014).
33. Davies, A. A. et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein.
Molecular Cell 7, 273–282 (2001).
34. Jeyasekharan, A. D. et al. A cancer-associated BRCA2 mutation reveals masked nuclear export
signals controlling localization. Nature Publishing Group 20, 1191–1198 (2013).
35. Rajendram, M. et al. Anionic Phospholipids Stabilize RecA Filament Bundles in Escherichia coli.
Molecular Cell 60, 374–384 (2015).
36. Bell, J. C. & Kowalczykowski, S. C. RecA: Regulation and Mechanism of a Molecular Search Engine.
Trends Biochem. Sci. 41, 491–507 (2016).
37. Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of
the kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006).
76 
38. Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex.
Nature 420, 287–293 (2002).
39. Shin, D. S. et al. Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly
and control by BRCA2. EMBO J. 22, 4566–4576 (2003).
40. Conway, A. B. et al. Crystal structure of a Rad51 filament. Nat. Struct. Mol. Biol. 11, 791–796 (2004).
41. Davies, O. R. & Pellegrini, L. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments
from disassembly by BRC repeats. Nat. Struct. Mol. Biol. 14, 475–483 (2007).
42. Reymer, A., Frykholm, K., Morimatsu, K., Takahashi, M. & Nordén, B. Structure of human Rad51
protein filament from molecular modeling and site-specific linear dichroism spectroscopy. Proceedings
of the National Academy of Sciences 106, 13248–13253 (2009).
43. Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family.
Mol. Syst. Biol. 1, E1–E13 (2005).
44. Jones, R. B., Gordus, A., Krall, J. A. & MacBeath, G. A quantitative protein interaction network for the
ErbB receptors using protein microarrays. Nature 439, 168–174 (2006).
45. Kaushansky, A., Gordus, A., Chang, B., Rush, J. & MacBeath, G. A quantitative study of the
recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Mol. BioSyst.
4, 643–12 (2008).
46. Laurent F Hennequin et al. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-
(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-
Specific c-Src/Abl Kinase Inhibitor†. J. Med. Chem. 49, 6465–6488 (2006).
47. Obenauer, J. C., Cantley, L. C. & Yaffe, M. B. Scansite 2.0: Proteome-wide prediction of cell signaling
interactions using short sequence motifs. Nucleic Acids Research 31, 3635–3641 (2003).
48. Kundu, K., Mann, M., Costa, F. & Backofen, R. MoDPepInt: an interactive web server for prediction of
modular domain-peptide interactions. Bioinformatics 30, 2668–2669 (2014).
49. Xue, Y. et al. GPS: a comprehensive www server for phosphorylation sites prediction. Nucleic Acids
Research 33, W184–W187 (2005).
50. Wong, Y. H. et al. KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation
sites based on sequences and coupling patterns. Nucleic Acids Research 35, W588–W594 (2007).
51. Frese, S. et al. The phosphotyrosine peptide binding specificity of Nck1 and Nck2 Src homology 2
domains. J. Biol. Chem. 281, 18236–18245 (2006).
52. Pinna, L. A. & Ruzzene, M. How do protein kinases recognize their substrates? Biochim. Biophys.
Acta 1314, 191–225 (1996).
53. Ubersax, J. A. & Ferrell, J. E., Jr. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol.
Cell Biol. 8, 530–541 (2007).
54. Songyang, Z. et al. Catalytic Specificity of Protein-Tyrosine Kinases Is Critical for Selective Signaling.
Nature 373, 536–539 (1995).
55. Chung, B. M. et al. The role of cooperativity with Src in oncogenic transformation mediated by non-
small cell lung cancer-associated EGF receptor mutants. Oncogene 28, 1821–1832 (2009).
56. Cho, J. et al. Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion
77 
Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies. Cancer Research 71, 
7587–7596 (2011). 
57. Park, A. K. J., Francis, J. M., Park, W.-Y., Park, J.-O. & Cho, J. Constitutive asymmetric dimerization
drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Oncotarget 6, 8839–8850 (2015).
58. Hunter, T. The Genesis of Tyrosine Phosphorylation. Cold Spring Harbor Perspectives in Biology 6,
a020644–a020644 (2014).
59. Chi, A. et al. Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron
transfer dissociation (ETD) mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 104, 2193–2198 (2007).
60. Gould, K. L. & Nurse, P. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates
entry into mitosis. Nature 342, 39–45 (1989).
61. Parker, L. L., Atherton-Fessler, S. & Piwnica-Worms, H. p107wee1 is a dual-specificity kinase that
phosphorylates p34cdc2 on tyrosine 15. Proc. Natl. Acad. Sci. U.S.A. 89, 2917–2921 (1992).
62. Subramanyam, S., Ismail, M., Bhattacharya, I. & Spies, M. Tyrosine phosphorylation stimulates activity
of human RAD51 recombinase through altered nucleoprotein filament dynamics. Proc. Natl. Acad. Sci.
U.S.A. 113, E6045–E6054 (2016).
63. Li, W., Hu, P., Skolnik, E. Y., Ullrich, A. & Schlessinger, J. The SH2 and SH3 domain-containing Nck
protein is oncogenic and a common target for phosphorylation by different surface receptors. Mol. Cell.
Biol. 12, 5824–5833 (1992).
64. Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on
massively parallel DNA sequencing. Nature Biotechnology 31, 1023–1031 (2013).
65. Lechner, J. F. & LaVeck, M. A. A serum-free method for culturing normal human bronchial epithelial
cells at clonal density. Journal of tissue culture methods 9, 43–48 (1985).
66. Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to
EGFR kinase inhibitors. Cancer Discovery 2, 458–471 (2012).
67. Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor
tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267–3279
(2001).
68. Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective
oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor
types. J. Clin. Oncol. 20, 4292–4302 (2002).
69. Burris, H. A. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a
Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily
Pretreated Patients With Metastatic Carcinomas. Journal of Clinical Oncology 23, 5305–5313 (2005).
70. Eskens, F. A. L. M. et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor
of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off
schedule in patients with advanced solid tumours. Br. J. Cancer 98, 80–85 (2008).
71. Wong, K. K. et al. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor
Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. Clinical Cancer Research 15, 2552–2558
(2009).
78 
72. Janne, P. A. et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with
advanced malignant solid tumors. Clin. Cancer Res. 17, 1131–1139 (2011).
73. Sequist, L. V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372, 1700–
1709 (2015).
74. Jänne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372,
1689–1699 (2015).
75. Li, S. et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer
Cell 7, 301–311 (2005).
76. Meador, C. B. et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung
cancer. Molecular Cancer Therapeutics 14, 542–552 (2015).
77. Regales, L. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse
models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000–3010 (2009).
78. Janjigian, Y. Y. et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant
EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery 4, 1036–1045 (2014).
79. Ahsan, A. et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and
tumors. Neoplasia 14, 670–677 (2012).
80. Gallant, J. N. et al. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in
Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery 5, 1155–1163 (2015).
81. Baik, C. S., Wu, D., Smith, C., Martins, R. G. & Pritchard, C. C. Durable Response to Tyrosine Kinase
Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem
Kinase Domain Duplication. Journal of Thoracic Oncology 10, e97–e99 (2015).
82. Bradeen, H. A. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in
an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood
108, 2332–2338 (2006).
83. Ercan, D. et al. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Clin. Cancer Res. 21, 3913–3923 (2015).
84. Red Brewer, M. et al. Mechanism for activation of mutated epidermal growth factor receptors in lung
cancer. Proceedings of the National Academy of Sciences 110, E3595–604 (2013).
85. Lemmon, M. A. & Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell 141, 1117–1134
(2010).
86. Huang, Y. et al. Molecular basis for multimerization in the activation of the epidermal growth factor
receptor. Elife 5, 18756 (2016).
87. Needham, S. R. et al. EGFR oligomerization organizes kinase-active dimers into competent signalling
platforms. Nature Communications 7, 13307 (2016).
88. Brar, G. A. Beyond the Triplet Code: Context Cues Transform Translation. Cell 167, 1681–1692
(2016).
89. Sharp, P. M. & Li, W. H. The codon Adaptation Index--a measure of directional synonymous codon
usage bias, and its potential applications. Nucleic Acids Research 15, 1281–1295 (1987).
79 
90. Jacks, T., Madhani, H. D., Masiarz, F. R. & Varmus, H. E. Signals for ribosomal frameshifting in the
Rous sarcoma virus gag-pol region. Cell 55, 447–458 (1988).
91. Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J
Comput Chem 25, 1605–1612 (2004).
92. Kovacs, E., Zorn, J. A., Huang, Y., Barros, T. & Kuriyan, J. A Structural Perspective on the Regulation
of the Epidermal Growth Factor Receptor. Annu. Rev. Biochem. 84, 739–764 (2015).
93. Dise, R. S., Frey, M. R., Whitehead, R. H. & Polk, D. B. Epidermal growth factor stimulates Rac
activation through Src and phosphatidylinositol 3-kinase to promote colonic epithelial cell migration.
AJP: Gastrointestinal and Liver Physiology 294, G276–G285 (2007).
94. Fenstermaker, R. A., Ciesielski, M. J. & Castiglia, G. J. Tandem duplication of the epidermal growth
factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene
16, 3435–3443 (1998).
95. Whitehead, R. H., VanEeden, P. E., Noble, M. D., Ataliotis, P. & Jat, P. S. Establishment of
conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58
transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 90, 587–591 (1993).
96. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnology 31,
827–832 (2013).
97. Ranganathan, V., Wahlin, K., Maruotti, J. & Zack, D. J. Expansion of the CRISPR-Cas9 genome
targeting space through the use of H1 promoter-expressed guide RNAs. Nature Communications 5,
4516 (2014).
98. Sanjana, N. E., Shalem, O. & Zhang, F. correspondence. Nat Meth 11, 783–784 (2014).
99. Guschin, D. Y. et al. in Engineered Zinc Finger Proteins (eds. Mackay, J. P. & Segal, D. J.) 649, 247–
256 (Humana Press, 2010).
100. Richardson, S. M., Nunley, P. W., Yarrington, R. M., Boeke, J. D. & Bader, J. S. GeneDesign 3.0 is an 
updated synthetic biology toolkit. Nucleic Acids Research 38, 2603–2606 (2010). 
Notes 
a Interestingly, while the majority of these clones (92) were derived from AALE cells transfected with the 
PX458-EGFR-RAD51#2 construct (which appears to be more efficient at inducing indels in EGFR and RAD51 
(Figure 4.1C), only clones from PX458-EGFR-RAD51#1 construct were tested for presence of the fusion.  
b Peter S. Choi, PhD, Meyerson lab, personal communication: “for creating the fusions, I had a very tough time 
generating clones with anything beyond intrachromosomal inversions/deletions. Even for those events, it was 
usually in the single-digit percentages… I think the efficiency is still too low to make it practical (although 
screening by PCR from genomic DNA is not too bad).” 
c Adding weight to this hypothesis is the observation that, in yeast, RECA (the RAD51 homolog) polymerizes at 
and is stabilized by the cell membrane (35). 
d EGFR-RAD51 residues corresponding to the oligomerization residues of RAD51 were determined by aligning 
the RAD51 CCDS (10062.1) with the EGFR-RAD51 ORF translation. 
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e This is argued because RAD51 homologs, such as RECA in yeast (36), could be said to predate the 
evolution of tyrosine phosphorylation (58). While there exist no know protein tyrosine kinases in yeast (59), 
tyrosine phosphorylation appears to play a key part in yeast signaling (60)—even if such phosphorylation is 
performed by dual specificity kinases, such as WEE1 (61). 
f Cetuximab binds to the extracellular domain of EGFR and inhibits ligand binding (75). However, MTT assays 
are not the best method of testing for cetuximab efficacy; soft-agar assays are better for reasons that aren’t 
quite clear (76). 
g Based on the sequencing platform and alignments, the authors could not differentiate between the two 
mutations. Personal communication with Christina Baik, MD, MPH and Colin Pritchard, MD, PhD: “We didn’t 
specifically investigate if the T790M mutation was in only one or both kinase domains, so we can’t say for 
sure.” NB: it could also be the case that the patient’s other EGFR was mutated to T790M. 
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CHAPTER V: DISCUSSION 
Summary of Findings 
These studies have established two EGFR rearrangements, EGFR-KDD and EGFR-RAD51, as bona 
fide oncogenes and therapeutic targets in lung adenocarcinoma. Prior to these studies, EGFR-KDD (1-5) and 
EGFR fusions (6,7) had only been detected in glioma. Now, we have data that these alterations are recurrent 
in lung cancer and targetable with available anti-EGFR therapiesa. Our work is already proving clinically 
relevant as these alterations have been identified in additional lung cancer patients—who may now have more 
targeted treatment options. Still, further translational studies are needed to understand how best to detect 
these alterations, treat them with available anti-EGFR (and other) agents, and manage the acquired resistance 
that companies treatment with anti-EGFR agents (8). In terms of basic science, these alterations offer 
interesting models to study EGFR biology because of the unique ways in which they may be activating the 
receptor, recruiting adaptors, and signaling downstream. 
EGFR Rearrangements in Lung Adenocarcinoma 
Current knowledge about EGFR-mutant lung adenocarcinoma is largely derived from the initial and 
most prevalent mutations detected in patients: EGFR-L858R and EGFR-ex19del (9-11). As both these 
mutations activate the EGFR TKD and sensitize cancers harboring these mutations to EGFR-TKIs, they have 
come to define EGFR-mutant lung adenocarcinoma. Indeed, most phase III trials investigating first-line 
treatment of patients with EGFR-TKIs defined EGFR-mutant lung adenocarcinoma as those cancers harboring 
these ‘common’ mutations (EGFR-L858R or EGFR-ex19del)b. As a result, all first and second generation 
EGFR-TKIs are FDA approved to treat these specific common EGFR mutations. This is problematic because 
there is significantly less evidence to support the treatment of tumors harboring uncommon EGFR mutations 
(defined as anything but EGFR-L858R or EGFR-ex19del) and because it presumes that EGFR-L858R and 
EGFR-ex19del are equivalent mutations. However, a wealth of pre-clinical and clinical data has shown that not 
all EGFR mutations are created equal. For one, the kinase activity of common EGFR mutants, their sensitivity 
to EGFR TKIs, and structures are all slightly, but significantly, different (20,21). Clinically, this translates to 
patients with EGFR-L858R and EGFR-ex19del tumors having significantly different progression free and 
overall survivals (22)c. Together, these data point towards a need for better understanding of individual and 
less common EGFR mutations present in lung adenocarcinoma. 
While L858R and ex19del do account for the majority of EGFR-mutant lung adenocarcinoma, their 
reported prevalence (up to 90% of EGFR-mutant lung adenocarcinoma (24)) is deceivingly high due to clinical 
laboratory detection methods. Because the first-identified TKI-sensitizing EGFR mutations in lung 
adenocarcinoma (G719X, ex19del, L858R, and L861Q (9-11)) were all single nucleotide variants (SNVs) or 
small insertions/deletions (indels), PCR followed by dideoxynucleotide sequencing was initially used for 
detection of variants. While these techniques have evolved, leading to more sensitive multiplexed assays that 
query mutations in several genes at once (25-27), PCR-based methods remain the standard for detection of 
EGFR mutations in lung adenocarcinoma (28)d. Because they rely on panels of pre-determined primers, PCR-
based tests are biased towards known mutations in exon 18–21 of EGFR, which encode the majority of the 
EGFR TKD. As a result of this bias, some currently available clinical diagnostic tests are specific—for EGFR 
L858R, ex19del, and a few other mutations—and not very sensitive for EGFR alterations; it is possible that 
they over-report EGFR SNVs and indels (L858R or ex19del) while under-reporting larger scale rearrangements 
that maintain the wild type sequence of EGFR (such the KDD and fusion events). 
To overcome sensitivity limits in PCR-based methods, next generation sequencing (NGS) has recently 
made its way into the clinical realm for tumor mutational testinge. While NGS allows for comprehensive whole 
genome sequencing (WGS), throughput and turnaround time have prevented this method from becoming part 
of routine clinical testing. Instead, hybrid-capture-based methods, somewhat of a middle ground between WGS 
and PCR-based methods, are becoming the standard for identifying actionable targets in lung 
adenocarcinoma. These methods pair capture of transcripts using biotinylated primers, NGS, and large scale 
bioinformatics to enable detection of known mutations and discovery of new alterations. While this approach 
(specifically, the FoundationOne® test (31))f allowed us to detect EGFR-KDD and EGFR fusions in several 
patients, it does have it’s drawbacks: namely, the panels of probes used in these assays interrogate only 
specific regions of cancer-related genes and may therefore miss detection of certain novel mutations in other 
locations of the genome.  
As a result of these diagnostic limitations, we believe that our reported prevalence of EGFR-KDD and 
EGFR fusions is smaller than the true proportion of these rearrangements in lung adenocarcinoma. PCR-
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based methods would have missed (and in some patients did) these alterations because they maintain an 
intact EGFR TKD sequence. At the same time, NGS methods may have missed EGFR-KDD and EGFR 
fusions because genomic breakpoints for these rearrangements occur in introns. While available NGS 
diagnostics usually sequence the entirety of known cancer driver coding sequences, they only sequence 
specific introns in select genes known to commonly undergo rearrangementsg. It is our understanding that 
EGFR-KDD and EGFR fusions were identified as a result of exonic EGFR sequencing reads extending into 
introns and serendipitously identifying the rearrangements’ breakpoints. Clearly, the identification of EGFR-
KDD and EGFR fusions point towards a need for hybrid-capture-based probes located in the introns of EGFR 
and RAD51. Such probes would be more likely to identify these rearrangements, provide patients with the 
opportunity to receive targeted therapy, and increase the relative prevalence of EGFR-KDD and RAD51. 
Further refinements of these assays, combined with the ever-increasing speed and ever-decreasing cost of 
WGS, may help discover more clinically relevant EGFR fusions or alterations in the future. 
The ability to detect an increasing number of EGFR (and other) alterations led to the discovery of 
EGFR-KDD and EGFR fusions; but, as with other uncommon EGFR alterations, led to questions with regards 
to how best to treat these alterations. While evidence from our laboratory models and from the treated index 
patients suggested that these alterations are actionable with EGFR-TKIs, it isn’t clear which EGFR-TKI is most 
potent against these alterations—due to likely subtle structural differences amongst agents and 
rearrangements (32)—and/or whether combinations of agents may be better suited for therapy. Even if 
optimally treated with EGFR-TKIs, tumors harboring uncommon EGFR mutations acquire resistance (33). It is 
also notable that patients whose tumors harbored EGFR re-arrangements developed the T790M resistance 
mutations after treatment with EGFR-TKIs. It is unclear whether these patients could benefit from treatment 
with the T790M-selective EGFR-TKI osimertinib (34), from dual EGFR blockade with afatinib (an EGFR-TKI) 
and cetuximab (the anti-EGFR antibody) (35,36), or from combination treatment with a MEK inhibitor (37). 
More work is needed to determine the optimal EGFR-TKIs used to treat EGFR rearrangements, the approach 
in the setting of acquired resistance, and, potentially, the sequence of therapies (38).  
EGFR Rearrangements and the Biology of EGFR 
Because our data suggests that the EGFR-KDD is activated via intramolecular dimerization, the 
alteration could be used to test the current model of physiological / WT- EGFR activation: ligand-induced, 
receptor-mediated dimerization of the ECD (39-41) that is propagated across the plasma membrane via 
interactions within the TM (42,43) and JM domains (44-46) and results in allosteric activation of the TKD via 
asymmetric dimerization (47,48). These various moving pieces contribute both activating and inhibiting forces 
to maintain EGFR mitogenic signaling strength (tone) and prevent inappropriate ligand-independent activation. 
However, it is currently unclear which of these counterbalancing regulatory forces/movements dominate when 
the receptor is activated. As our data point towards the EGFR-KDD being constitutively active in the absence 
of ligand but further activated in the presence of ligand (by virtue of asymmetric dimerization), they also 
indicate that EGFR activation may be less reliant on the ECD and membrane interactions than on asymmetric 
dimerization (and the JM latch). A crystal structure of the EGFR-KDD ICDh could support our data and reveal 
the most critical pieces for EGFR activation. 
EGFR-RAD51, on the other hand, could be used to test models of RTK signaling. It is commonly held 
that the first response to autophosphorylation of RTKs is the recruitment and activation of a host of 
downstream signaling adaptors (49). However, EGFR-RAD51 does not contain a C-term beyond the kinase 
domain. As a result, this fusion lacks signaling adaptor binding sites. Interestingly, EGFR-RAD51 is able to 
activate downstream signaling via the MAPK and PI3K/AKT pathways. Because it has been demonstrated that 
EGFR can multimerize (50), and because a higher local density of phospho-tyrosines is able to recruit different 
adaptor molecules (51), we hypothesize that EGFR-RAD51 is able to signal downstream by formation of large 
concatemers. These large active signaling EGFR complexes could contain such a high density of phospho-
tyrosine 869 that these residues could recruit MAPK and PI3K/AKT pathway molecules such as GRB2 and 
SHC in addition to SRC. Thus EGFR-RAD51 could help validate that promiscuity changes with local protein 
concentration may contribute to the oncogenic potential of RTKS and other signaling proteins (52). 
Conclusion 
Over the past decade, NSCLC, specifically, EGFR-mutant lung adenocarcinoma, has served as a 
model for personalized medicine. The field has taken a complex disease (NSCLC), traced the problem to one 
of its genetic origins (EGFR), and rationally treated the root cause (with EGFR-TKIs). Data in these studies 
demonstrate the diversity of modes through which EGFR protein is activated in lung adenocarcinoma. The 
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cancer is able to maintain EGFR tone through a variety of radical genomic alterations, including gene 
duplication and fusioni. The resultant gene products, the EGFR-KDD and EGFR-RAD51, are recurrent 
oncogenic alterations and therapeutically actionable targets, highlighting the importance of EGFR in lung 
adenocarcinoma. Similar to the field as a whole, these studies have taken a complex disease (index cases of 
patients with driver-negative lung adenocarcinoma), traced the problem to one of its genetic origins (EGFR re-
arrangements), demonstrated the oncogenicity of these proteins, highlighted the actionability of EGFR-
rearrangements, and yielded valuable models for future study of biology. There is still much to learn, including 
how EGFR re-arrangements are activated and how they propagate signal. Fortunately, in an age of precision 
medicine, there exist the knowledge, technologies, and systems to address these problems and readily study 
all aspects of EGFR—in the laboratory and in the clinic.
84 
References 
1. Steck, P. A. et al. Expression of epidermal growth factor receptor and associated glycoprotein on
cultured human brain tumor cells. J. Cell. Biochem. 32, 1–10 (1986).
2. Steck, P. A., Lee, P., Hung, M. C. & Yung, W. K. Expression of an altered epidermal growth factor
receptor by human glioblastoma cells. Cancer Research 48, 5433–5439 (1988).
3. Panneerselvam, K., Kanakaraj, P., Raj, S., Das, M. & Bishayee, S. Characterization of a novel
epidermal-growth-factor-receptor-related 200-kDa tyrosine kinase in tumor cells. Eur. J. Biochem. 230,
951–957 (1995).
4. Fenstermaker, R. A., Ciesielski, M. J. & Castiglia, G. J. Tandem duplication of the epidermal growth
factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene 16,
3435–3443 (1998).
5. Ciesielski, M. J. & Fenstermaker, R. A. Oncogenic epidermal growth factor receptor mutants with
tandem duplication: gene structure and effects on receptor function. Oncogene 19, 810–820 (2000).
6. Frattini, V. et al. Frattubu.V_2013_Nature Genetics_Genomic landscape of GBM - EGFR fusions.
Nature Publishing Group 45, 1141–1149 (2013).
7. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
8. Camidge, D. R., Pao, W. & Sequist, L. V. Acquired resistance to TKIs in solid tumours: learning from
lung cancer. Nature Publishing Group 1–9 (2014).
9. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are
associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306–
13311 (2004).
10. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science 304, 1497–1500 (2004).
11. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139 (2004).
12. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361,
947–957 (2009).
13. Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic
lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology 31, 3327–3334 (2013).
14. Wu, Y.-L. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label,
randomised phase 3 trial. Lancet Oncol. 15, 213–222 (2014).
15. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N
Engl J Med 362, 2380–2388 (2010).
16. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer
harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised
phase 3 trial. Lancet Oncol. 11, 121–128 (2010).
17. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients
with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
85 
18. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,
randomised, phase 3 study. Lancet Oncol. 12, 735–742 (2011).
19. Wu, Y.-L. et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label,
ENSURE study. Annals of Oncology 26, 1883–1889 (2015).
20. Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows
increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer
Research 66, 8163–8171 (2006).
21. Yun, C.-H. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism
of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217–227 (2007).
22. Kuan, F.-C. et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated
non-small-cell lung cancers: a systematic review and meta-analysis. Br. J. Cancer 113, 1519–1528
(2015).
23. Sebastian, M., Schmittel, A. & Reck, M. First-line treatment of EGFR-mutated nonsmall cell lung cancer:
critical review on study methodology. Eur Respir Rev 23, 92–105 (2014).
24. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in
lung cancer. Nat. Rev. Cancer 7, 169–181 (2007).
25. Pan, Q., Pao, W. & Ladanyi, M. Rapid polymerase chain reaction-based detection of epidermal growth
factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7, 396–403 (2005).
26. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to
guide personalized cancer medicine. EMBO Mol Med 2, 146–158 (2010).
27. Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted
therapy in non-small-cell lung cancer. J Mol Diagn 13, 74–84 (2011).
28. Tan, D. S. W. et al. The International Association for the Study of Lung Cancer Consensus Statement
on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.
Journal of Thoracic Oncology 11, 946–963 (2016).
29. Weiss, G. J. et al. Evaluation and comparison of two commercially available targeted next-generation
sequencing platforms to assist oncology decision making. Onco Targets Ther 8, 959–967 (2015).
30. Kuderer, N. M. et al. Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in
Oncology. JAMA Oncol (2016).
31. Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on
massively parallel DNA sequencing. Nature Biotechnology 31, 1023–1031 (2013).
32. Vivanco, I. et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR
kinase inhibitors. Cancer Discovery 2, 458–471 (2012).
33. Lohinai, Z. et al. Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR
Mutations in Lung Adenocarcinoma. J Thorac Oncol 10, 738–746 (2015).
34. Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to
EGFR inhibitors in lung cancer. Cancer Discovery 4, 1046–1061 (2014).
86 
35. Regales, L. et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse
models of EGFR mutant lung cancer. J. Clin. Invest. 119, 3000–3010 (2009).
36. Janjigian, Y. Y. et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant
EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery 4, 1036–1045 (2014).
37. Tricker, E. M. et al. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-
Mutant Lung Cancer. Cancer Discovery 5, 960–971 (2015).
38. Meador, C. B. et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung
cancer. Molecular Cancer Therapeutics 14, 542–552 (2015).
39. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor
extracellular domains. Cell 110, 775–787 (2002).
40. Garrett, T. P. J. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular
domain bound to transforming growth factor alpha. Cell 110, 763–773 (2002).
41. Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell
110, 669–672 (2002).
42. Arkhipov, A. et al. Architecture and membrane interactions of the EGF receptor. Cell 152, 557–569
(2013).
43. Endres, N. F. et al. Conformational Coupling across the Plasma Membrane in Activation of the EGF
Receptor. Cell 152, 543–556 (2013).
44. Thiel, K. W. & Carpenter, G. Epidermal growth factor receptor juxtamembrane region regulates allosteric
tyrosine kinase activation. Proceedings of the National Academy of Sciences 104, 19238–19243 (2007).
45. Jura, N. et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane
segment. Cell 137, 1293–1307 (2009).
46. Red Brewer, M. et al. The juxtamembrane region of the EGF receptor functions as an activation domain.
Molecular Cell 34, 641–651 (2009).
47. Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the
kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006).
48. Valley, C. C. et al. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth
factor receptor in lung cancer. Molecular Biology of the Cell 26, 4087–4099 (2015).
49. Lemmon, M. A. & Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell 141, 1117–1134
(2010).
50. Huang, Y. et al. Molecular basis for multimerization in the activation of the epidermal growth factor
receptor. Elife 5, 18756 (2016).
51. Jones, R. B., Gordus, A., Krall, J. A. & MacBeath, G. A quantitative protein interaction network for the
ErbB receptors using protein microarrays. Nature 439, 168–174 (2006).
52. Fan, Q.-W. et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in
glioblastoma. Cancer Cell 24, 438–449 (2013).
53. Stein, R. A. & Staros, J. V. Insights into the evolution of the ErbB receptor family and their ligands from
sequence analysis. BMC Evol. Biol. 6, 79 (2006).
87 
54. Kovacs, E., Zorn, J. A., Huang, Y., Barros, T. & Kuriyan, J. A Structural Perspective on the Regulation of
the Epidermal Growth Factor Receptor. Annu. Rev. Biochem. 84, 739–764 (2015).
55. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127–
137 (2001).
56. Yoshihara, K. et al. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Oncogene 34, 4845–4854 (2015).
88 
Notes 
a EGFR-KDD was also found in other cancers but additional data is needed to determine if EGFR-KDD is 
therapeutically actionable in non-lung cancers. 
b The only phase III trials that tested tumors for EGFR mutations other than EGFR-L858R and EGFR-ex19del 
were the IPASS (12) and LUX-Lung trials (13,14). Both of these trials tested for EGFR-T790M, L861Q, G719X, 
S768I, and ex20ins in addition to the common mutations. The NEJ002 (15), WJTOG3405 (16), EURTRAC 
(17), OPTIMAL (18), and ENSURE (19) trials only tested for EGFR-L858R and EGFR-ex19del. 
c Regardless of trial/treatment, patients with EGFR-ex19del tumors have significantly better PFS and OS than 
those with EGFR-L858R (22,23). 
d In fact, the only FDA-approved diagnostic test, the cobas® EGFR Mutation Test, is a PCR-based test that 
only probes for 42 different SNVs and indels in exons 18-21. 
e While these tests are increasingly becoming standard of care, they must be approached with care. Not every 
NGS assay is equal (often yielding differing results on the same samples (29,30)), and none are FDA 
approved. 
f The test simultaneously sequences the coding region of 315 cancer-related genes plus introns from 28 genes 
often rearranged or altered in cancer. 
g These tests do sequence regions where known fusion events do occur, such as the introns of EML4, ALK, 
CD74, and ROS1. 
h As of this writing, the Lovly lab is working with the Kuriyan lab to obtain this structure. 
i That being said, gene duplication and fusion events are not so rare—especially, and intriguingly so, with 
EGFR. In fact, three duplication events led to the four HER family members that are present in vertebrates (53-
55). Moreover, oncogenic fusions can commonly be found in normal cells and tissues (56). 
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APPENDIX 
Diagnosis and genotype # cases 
Total # of clinical samples genotyped 56,240 
Total # of non-small cell lung cancer cases 10,097 
# of cases harboring EGFR L858R mutation 472 
# of cases harboring EGFR exon 19 deletion 668 
# of cases harboring EGFR G719X mutation 92 
# of cases harboring EGFR L861Q mutation 36 
# of cases harboring EGFR S768I mutation 36 
# of cases harboring EGFR exon 20 insertion 193 
# of cases harboring EGFR exon 19 insertion 4 
# of cases harboring EGFR exon 18-25 kinase domain duplication 4 
# of cases harboring EGFR fusions 5 
Table S2.1: Summary of EGFR alterations in NSCLC identified by FoundationOne.  
The Foundation Medicine database of annotated clinical cases was interrogated for the presence of various EGFR 
genomic alterations known to recur in lung cancer. The ‘X’ in G719X denotes any of several amino acids which may be 
substituted for glycine in this variant. EGFR fusions events were defined by a genomic breakpoint in EGFR exons 23 
through intron 25. This table corresponds to Supplementary Table 1 from Konduri, Gallant et al., Cancer Discovery, 2016 
(1).
	 
Table S2.2: Summary of genomic coordinates for the kinase fusions identified in this study.  
The sample number is depicted in the far left column. For tumor samples in which a kinase fusion was identified, the genomic coordinates for each of the fusion 
genes is indicated. Additional alterations are noted. N/A = Not Applicable, * = breakpoint not clear. This table corresponds to Supplementary Table 2 from Konduri, 
Gallant et al., Cancer Discovery, 2016 (1).
Patient 
No. Gender Age 
Fusion 
Detected 
Event 
Coverage 
5’gene 
breakpoint 
3’gene 
breakpoint Exons 
Other EGFR 
alterations Other alterations 
1  Female 35 EGFR-RAD51 345 
EGFR intron 24 
(chr7:55268583) 
RAD51 intron 3 
(chr15:40995548) 
EGFR exons 1-24 
RAD51 exons 4-9 None 
• CDKN2A loss 
• CDKN2B loss 
• MYC amplification 
2 Female 21 EGFR-RAD51 304 
EGFR intron 24 
(chr7:55268151) 
RAD51 intron 3 
(chr15:40995888) 
EGFR exons 1-24 
RAD51 exons 4-9 None 
• CTNNB1 T41A 
• RANBP2 T951M 
• CDKN2B loss 
• TP53 loss 
• CDKN2A loss 
3 Female 42 EGFR-PURB 21 
EGFR exon 25 
(chr7:55269019) 
PURB 3’ UTR 
(chr7:44919491) 
EGFR exons 1-25 
PURB 3’ UTR  None 
• CREBBP S893L 
• ARID1A Q1095* 
4 Male 38 EGFR-RAD51 197 
EGFR intron 24 
(chr7:55268641) 
RAD51 intron 3 
(chr15:40993432) 
EGFR exons 1-24 
RAD51 exons 4-9 None 
• RBM10 S570fs*133 
• CHD4 D316H 
• MYC amplification 
• MCL1 amplification 
• IKBKE amplification 
• PIK3C2B amplification 
• MDM4 amplification 
5 Female 60 EGFR-RAD51 223 
EGFR intron 24 
(chr7:55268412) 
RAD51 intron 3 
(chr15:40995404) 
EGFR exons 1-24 
RAD51 exons 4-9 
EGFR 
amplification 
• GRIN2A R1318W 
• ATR Q2408* 
• ARID1A P1484fs*10 
• FGF3 amplification 
• FGF4 amplification 
• CDKN2A loss 
• PDCD1LG2 amplification 
• CCND1 amplification 
• CD274 amplification 
• FGF19 amplification 
• EMSY amplification 
• HGF amplification 
• JAK2 amplification 
• CDKN2B loss 
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Figure S2.1: Additional information for Patient 1. 
A, platelet counts in peripheral blood samples from patient 1 before and after the initiation of erlotinib therapy. ULN= 
upper limit of normal for platelet count. LLN= lower limit of normal for platelet count. B, Serial CT scans from patient 1 
documenting response to the EGFR TKI, erlotinib. This figure includes the images from Figure 2.1C (as denoted on the 
left side of the image) and as well as additional images showing response to erlotinib at other disease sites. This figure 
corresponds to Supplementary Figure 1 from Konduri, Gallant et al., Cancer Discovery, 2016 (1).
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Figure S2.2: Additional information for Patient 2. 
A, platelet counts in peripheral blood samples from patient 2 before and after the initiation of erlotinib therapy. ULN= 
upper limit of normal for platelet count. LLN= lower limit of normal for platelet count. B, Serial CT scans from patient 2 
documenting response to the EGFR TKI, erlotinib. This figure includes the images from Figure 2.1C (as denoted on the 
left side of the image) and as well as additional images showing response to erlotinib at other disease sites. This figure 
corresponds to Supplementary Figure 2 from Konduri, Gallant et al., Cancer Discovery, 2016 (1).
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Figure S2.3: Additional information for Patient 3. 
A, scaled representation of EGFR-PURB depicting the genomic structure of the fusion. ATG = translational start site. Blue 
= EGFR. Orange = PURB. B, putative representations of EGFR-PURB protein structures. Numbers correspond to amino 
acid residues. Y = tyrosine residue. ECD = extracellular domain. TM = transmembrane helix. TKD = tyrosine kinase 
domain. The three different EGFR-PURB protein variants (v1, v2, v3) are based on the different potential reading frames 
of the fusion sequence. C, Serial CT scans from patient 3 documenting response to the EGFR TKI, erlotinib. This figure 
includes the images from Figure 1C (as denoted on the left side of the image) and as well as additional images showing 
response to erlotinib at other disease sites. This figure corresponds to Supplementary Figure 3 from Konduri, Gallant et 
al., Cancer Discovery, 2016 (1).
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Figure S2.4: Additional clinical information for Patient 4. 
Serial PET scans from patient 4 documenting response to the EGFR TKI, erlotinib. The images show response to erlotinib 
at disease sites other than those shown in Figure 1C. This figure corresponds to Supplementary Figure 4 from Konduri, 
Gallant et al., Cancer Discovery, 2016 (1).
pre-treatment 2 months erlotinib 
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Figure S2.5: Characterization of EGFR-RAD51 in NR6 cells. 
A, NR6 lines stably expressing pMSCV (vector only), EGFR-WT, EGFR-L858R or EGFR–RAD51 were subjected to 
western blot analysis with the indicated antibodies. EGFR-RAD51 fusion is detected with both the N-terminal EGFR 
antibody [EGFR(N)] and with the RAD51 antibody. There is no cross reactivity between wild-type RAD51 protein, which 
has MW ~35kD, and the EGFR-RAD51 fusion. B, NR6 expressing EGFR variants were serum starved for 16 hours, 
treated with 100 nM afatinib for 1 hour followed by 50 ng/mL EGF for 5 minutes, and subjected to western blot analysis 
with the indicated antibodies. C, NR6 cells stably expressing the indicated constructs (empty = no cells; pMSCV = vector 
only) were plated in triplicate in soft agar, grown for three weeks, and quantified for colony formation. ***, P < 0.0001.  D, 
representative 4x microphotographs of soft agar assays showing empty wells (no cells) and NR6 cells transduced with 
pMSCV vector, EGFR-WT, EGFR-RAD51, and EGFR-L858R after three weeks of growth in soft agar. This figure 
corresponds to Supplementary Figure 5 from Konduri, Gallant et al., Cancer Discovery, 2016 (1).
N
R
6 
  +
pM
S
C
V 
  +
E
G
FR
-W
T 
  +
E
G
FR
-L
85
8R
 
  +
E
G
FR
-R
AD
51
 
EGFR (N) 
RAD51 (C) 
actin 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
Em
pty
Pa
ren
tal
pM
SC
V
EG
FR
-W
T
EG
FR
-R
AD
51
EG
FR
-L8
58
R
0
200
400
600
800
1000
C
ol
on
y 
nu
m
be
r 
*** 
*** 
 empty NR6 parental 
pMSCV EGFR-WT 
EGFR-RAD51 EGFR-L858R 
  p
M
S
C
V 
  E
G
FR
-L
85
8R
 
  E
G
FR
-R
AD
51
 
- - + - + - + - + 
- - - + + - - + + 
          
afatinib 
EGF 
pEGFR Y869 (light) 
pEGFR Y869 (dark) 
EGFR (N) 
EGFR (C) 
RAD51 (C) 
pAKT S473 
AKT 
pERK T202/Y204 
ERK 
actin 
A                                                    B
C                                                    D
96 
Figure S2.6: Relative stability of EGFR-WT, -L858R, and -RAD51. 
A, Ba/F3 cells harboring indicated EGFR variants were serum starved overnight and then treated with the combination of 
50 ng/mL EGF and 50 μg/mL cyclohexamide (CHX) at time = 0. Cells were lysed for western blot analysis with indicated 
antibodies at various timepoints. B, Quantification of N-EGFR western blot signal (using FiJi) relative to time = 0 (and 
normalized to actin) for each of the EGFR variants. Intensity was plotted into Prism and the receptor half-life determined 
by asymmetric sigmoidal interpolation. This figure corresponds to Supplementary Figure 6 from Konduri, Gallant et al., 
Cancer Discovery, 2016 (1).
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Figure S2.7: Structural model of an EGFR-RAD51 filament. 
Space-filling model of the EGFR-RAD51 kinase domains illustrating hypothetical filament based on the RAD51 filament 
structure. Purple = first EGFR kinase domain; green = second EGFR kinase domain; red = first RAD51 partner; blue = 
second RAD51 partner. This figure corresponds to Supplementary Figure 7 from Konduri, Gallant et al., Cancer 
Discovery, 2016 (1).
Key 
purple = EGFR kinase #1 
green = EGFR kinase #2 
red = RAD51 #1 
blue = RAD51 #2 
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Table S2.3 Results of MTT curve fitting from Prism.  
These data correspond to the graphs shown in Figure 2.3A. This table corresponds to Supplementary Table 3 from 
Konduri, Gallant et al., Cancer Discovery, 2016 (1).
EGFR-L858R EGFR-RAD51 difference 
IC50  
(nM) 
erlotinib 5.11 ± 1.35 2.65 ± 1.91 n.s. p=0.23 
afatinib ≤ 1.5 8.47 ± 5.04 n.s. p=0.17 
osimertinib 3.51 ± 1.05 3.52 ± 1.49 n.s. p=0.08 
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Figure S2.8: On-target inhibition of EGFR-RAD51 by EGFR-TKI. 
Ba/F3 cells stably expressing EGFR-WT, EGFR-L858R and EGFR-RAD51 were serum starved for 16 hours, treated with 
100 nM afatinib for 1 hour followed by 50 ng/mL EGF for 5 minutes, and subjected to western blot analysis with the 
indicated antibodies. This figure corresponds to Supplementary Figure 8 from Konduri, Gallant et al., Cancer Discovery, 
2016 (1).
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Figure S2.9: Cetuximab inhibits ligand-induced activation of downstream signaling pathways in cells expressing 
EGFR-RAD51. 
Ba/F3 cells stably expressing EGFR-L858R and EGFR-RAD51 were serum starved for 16 hours, treated with 5 μg/mL 
cetuximab for 8 hours followed by 50 ng/mL EGF for 5 minutes, and subjected to western blot analysis with the indicated 
antibodies. This figure corresponds to Supplementary Figure 9 from Konduri, Gallant et al., Cancer Discovery, 2016 (1).
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Figure S2.10: cDNA sequence of EGFR-RAD51. 
Sequence of the EGFR-RAD51 fusion based on EGFR NM_005228 (ENST00000275493) and RAD51 NM_002875 (ENST00000267868). Exons 1-24 of EGFR 
are highlighted in blue and written in lower case. Exons 4-10 of RAD51 are highlighted in orange and written in capital letters. This figure corresponds to 
Supplementary Figure 10 from Konduri, Gallant et al., Cancer Discovery, 2016 (1).
EGFR exons 1-24 (lower case)  
RAD51 exons 4-10 (capitalized) 
1    atgcgaccct ccgggacggc cggggcagcg ctcctggcgc tgctggctgc gctctgcccg gcgagtcggg ctctggagga aaagaaagtt tgccaaggca cgagtaacaa gctcacgcag 
121  ttgggcactt ttgaagatca ttttctcagc ctccagagga tgttcaataa ctgtgaggtg gtccttggga atttggaaat tacctatgtg cagaggaatt atgatctttc cttcttaaag 
241  accatccagg aggtggctgg ttatgtcctc attgccctca acacagtgga gaggattcct ttggaaaacc tgcagatcat cagaggaaat atgtactacg aaaattccta tgccttagca 
361  gtcttatcta actatgatgc aaataaaacc ggactgaagg agctgcccat gagaaattta caggaaatcc tgcatggcgc cgtgcggttc agcaacaacc ctgccctgtg caacgtggag 
481  agcatccagt ggcgggacat agtcagcagt gactttctca gcaacatgtc gatggacttc cagaaccacc tgggcagctg ccaaaagtgt gatccaagct gtcccaatgg gagctgctgg 
601  ggtgcaggag aggagaactg ccagaaactg accaaaatca tctgtgccca gcagtgctcc gggcgctgcc gtggcaagtc ccccagtgac tgctgccaca accagtgtgc tgcaggctgc 
721  acaggccccc gggagagcga ctgcctggtc tgccgcaaat tccgagacga agccacgtgc aaggacacct gccccccact catgctctac aaccccacca cgtaccagat ggatgtgaac 
841  cccgagggca aatacagctt tggtgccacc tgcgtgaaga agtgtccccg taattatgtg gtgacagatc acggctcgtg cgtccgagcc tgtggggccg acagctatga gatggaggaa 
961  gacggcgtcc gcaagtgtaa gaagtgcgaa gggccttgcc gcaaagtgtg taacggaata ggtattggtg aatttaaaga ctcactctcc ataaatgcta cgaatattaa acacttcaaa 
1081 aactgcacct ccatcagtgg cgatctccac atcctgccgg tggcatttag gggtgactcc ttcacacata ctcctcctct ggatccacag gaactggata ttctgaaaac cgtaaaggaa 
1201 atcacagggt ttttgctgat tcaggcttgg cctgaaaaca ggacggacct ccatgccttt gagaacctag aaatcatacg cggcaggacc aagcaacatg gtcagttttc tcttgcagtc 
1321 gtcagcctga acataacatc cttgggatta cgctccctca aggagataag tgatggagat gtgataattt caggaaacaa aaatttgtgc tatgcaaata caataaactg gaaaaaactg 
1441 tttgggacct ccggtcagaa aaccaaaatt ataagcaaca gaggtgaaaa cagctgcaag gccacaggcc aggtctgcca tgccttgtgc tcccccgagg gctgctgggg cccggagccc 
1561 agggactgcg tctcttgccg gaatgtcagc cgaggcaggg aatgcgtgga caagtgcaac cttctggagg gtgagccaag ggagtttgtg gagaactctg agtgcataca gtgccaccca 
1681 gagtgcctgc ctcaggccat gaacatcacc tgcacaggac ggggaccaga caactgtatc cagtgtgccc actacattga cggcccccac tgcgtcaaga cctgcccggc aggagtcatg 
1801 ggagaaaaca acaccctggt ctggaagtac gcagacgccg gccatgtgtg ccacctgtgc catccaaact gcacctacgg atgcactggg ccaggtcttg aaggctgtcc aacgaatggg 
1921 cctaagatcc cgtccatcgc cactgggatg gtgggggccc tcctcttgct gctggtggtg gccctgggga tcggcctctt catgcgaagg cgccacatcg ttcggaagcg cacgctgcgg 
2041 aggctgctgc aggagaggga gcttgtggag cctcttacac ccagtggaga agctcccaac caagctctct tgaggatctt gaaggaaact gagttcaaaa agatcaaagt gctgggctcc 
2161 ggtgcgttcg gcacggtgta taagggactc tggatcccag aaggtgagaa agttaaaatt cccgtcgcta tcaaggaatt aagagaagca acatctccga aagccaacaa ggaaatcctc 
2281 gatgaagcct acgtgatggc cagcgtggac aacccccacg tgtgccgcct gctgggcatc tgcctcacct ccaccgtgca gctcatcacg cagctcatgc ccttcggctg cctcctggac 
2401 tatgtccggg aacacaaaga caatattggc tcccagtacc tgctcaactg gtgtgtgcag atcgcaaagg gcatgaacta cttggaggac cgtcgcttgg tgcaccgcga cctggcagcc 
2521 aggaacgtac tggtgaaaac accgcagcat gtcaagatca cagattttgg gctggccaaa ctgctgggtg cggaagagaa agaataccat gcagaaggag gcaaagtgcc tatcaagtgg 
2641 atggcattgg aatcaatttt acacagaatc tatacccacc agagtgatgt ctggagctac ggggtgactg tttgggagtt gatgaccttt ggatccaagc catatgacgg aatccctgcc 
2761 agcgagatat cctccatcct ggagaaagga gaacgcctcc ctcagccacc catatgtacc atcgatgtct acatgatcat ggtcaagtgc tggatgatag acgcagatag tcgcccaaag 
2881 ttccgtgagt tgatcatcga gttctccaaa atggcccgag acccccagcg ctaccttgtc attcagGCTG AGGCAGCTAA ATTAGTTCCA ATGGGTTTCA CCACTGCAAC TGAGTTCCAC 
3001 CAAAGGCGGT CAGAGATCAT ACAGATTACT ACTGGCTCCA AAGAGCTTGA CAAACTACTT CAAGGTGGAA TTGAGACTGG ATCTATCACA GAAATGTTTG GAGAGTTCCG AACTGGGAAG 
3121 ACCCAGATAT GTCATACGCT AGCTGTCACC TGCCAGCTTC CCATTGACCG GGGTGGAGGT GAAGGAAAGG CCATGTACAT TGACACTGAG GGTACCTTTA GGCCAGAACG GCTGCTGGCA 
3241 GTGGCTGAGA GGTATGGTCT CTCTGGCAGT GATGTCCTGG ATAATGTAGC ATATGCTCGA GCGTTCAACA CAGACCACCA GACCCAGCTC CTTTATCAAG CATCAGCCAT GATGGTAGAA 
3361 TCTAGGTATG CACTGCTTAT TGTAGACAGT GCCACCGCCC TTTACAGAAC AGACTACTCG GGTCGAGGTG AGCTTTCAGC CAGGCAGATG CACTTGGCCA GGTTTCTGCG GATGCTTCTG 
3481 CGACTCGCTG ATGAGTTTGG TGTAGCAGTG GTAATCACTA ATCAGGTGGT AGCTCAAGTG GATGGAGCAG CGATGTTTGC TGCTGATCCC AAAAAACCTA TTGGAGGAAA TATCATCGCC 
3601 CATGCATCAA CAACCAGATT GTATCTGAGG AAAGGAAGAG GGGAAACCAG AATCTGCAAA ATCTACGACT CTCCCTGTCT TCCTGAAGCT GAAGCTATGT TCGCCATTAA TGCAGATGGA 
3721 GTGGGAGATG CCAAAGACTG A 
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Figure S3.1: Sequencing reads of EGFR-KDD in index patient with lung adenocarcinoma. 
A, NGS reads surrounding the genomic breakpoint of the EGFR-KDD as detected by the FoundationOne assay. B, paired 
NGS reads of tumor and matched whole blood from MSK-IMPACT™. This figure corresponds to Supplementary Figure 1 
from Gallant et al. Cancer Discovery, 2015 (2).
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Figure S3.2: cDNA sequence of the EGFR-KDD. 
Sequence of the EGFR exons 18-25 kinase domain duplication (EGFR-KDD). The first repeat of EGFR exons 18–25 is capitalized and highlighted with blue. The 
second (tandem) repeat of EGFR exons 18–25 is capitalized and highlighted with green. This figure corresponds to Supplementary Figure 2 from Gallant et al. 
Cancer Discovery, 2015 (2).
Exons 18–25 #1 (capitalized)  
Exons 18–25 #2 (capitalized) 
1      atgcgaccct ccgggacggc cggggcagcg ctcctggcgc tgctggctgc gctctgcccg gcgagtcggg ctctggagga aaagaaagtt tgccaaggca cgagtaacaa gctcacgcag 
121   ttgggcactt ttgaagatca ttttctcagc ctccagagga tgttcaataa ctgtgaggtg gtccttggga atttggaaat tacctatgtg cagaggaatt atgatctttc cttcttaaag 
241   accatccagg aggtggctgg ttatgtcctc attgccctca acacagtgga gcgaattcct ttggaaaacc tgcagatcat cagaggaaat atgtactacg aaaattccta tgccttagca 
361   gtcttatcta actatgatgc aaataaaacc ggactgaagg agctgcccat gagaaattta caggaaatcc tgcatggcgc cgtgcggttc agcaacaacc ctgccctgtg caacgtggag 
481   agcatccagt ggcgggacat agtcagcagt gactttctca gcaacatgtc gatggacttc cagaaccacc tgggcagctg ccaaaagtgt gatccaagct gtcccaatgg gagctgctgg 
601   ggtgcaggag aggagaactg ccagaaactg accaaaatca tctgtgccca gcagtgctcc gggcgctgcc gtggcaagtc ccccagtgac tgctgccaca accagtgtgc tgcaggctgc 
721   acaggccccc gggagagcga ctgcctggtc tgccgcaaat tccgagacga agccacgtgc aaggacacct gccccccact catgctctac aaccccacca cgtaccagat ggatgtgaac 
841   cccgagggca aatacagctt tggtgccacc tgcgtgaaga agtgtccccg taattatgtg gtgacagatc acggctcgtg cgtccgagcc tgtggggccg acagctatga gatggaggaa 
961   gacggcgtcc gcaagtgtaa gaagtgcgaa gggccttgcc gcaaagtgtg taacggaata ggtattggtg aatttaaaga ctcactctcc ataaatgcta cgaatattaa acacttcaaa 
1081   aactgcacct ccatcagtgg cgatctccac atcctgccgg tggcatttag gggtgactcc ttcacacata ctcctcctct ggatccacag gaactggata ttctgaaaac cgtaaaggaa 
1201   atcacagggt ttttgctgat tcaggcttgg cctgaaaaca ggacggacct ccatgccttt gagaacctag aaatcatacg cggcaggacc aagcaacatg gtcagttttc tcttgcagtc 
1321   gtcagcctga acataacatc cttgggatta cgctccctca aggagataag tgatggagat gtgataattt caggaaacaa aaatttgtgc tatgcaaata caataaactg gaaaaaactg 
1441   tttgggacct ccggtcagaa aaccaaaatt ataagcaaca gaggtgaaaa cagctgcaag gccacaggcc aggtctgcca tgccttgtgc tcccccgagg gctgctgggg cccggagccc 
1561   agggactgcg tctcttgccg gaatgtcagc cgaggcaggg aatgcgtgga caagtgcaac cttctggagg gtgagccaag ggagtttgtg gagaactctg agtgcataca gtgccaccca 
1681   gagtgcctgc ctcaggccat gaacatcacc tgcacaggac ggggaccaga caactgtatc cagtgtgccc actacattga cggcccccac tgcgtcaaga cctgcccggc aggagtcatg 
1801   ggagaaaaca acaccctggt ctggaagtac gcagacgccg gccatgtgtg ccacctgtgc catccaaact gcacctacgg atgcactggg ccaggtcttg aaggctgtcc aacgaatggg 
1921   cctaagatcc cgtccatcgc cactgggatg gtgggggccc tcctcttgct gctggtggtg gccctgggga tcggcctctt catgcgaagg cgccacatcg ttcggaagcg cacgctgcgg
2041   aggctgctgc aggagaggga gCTTGTGGAG CCTCTTACAC CCAGTGGAGA AGCTCCCAAC CAAGCTCTCT TGAGGATCTT GAAGGAAACT GAATTCAAAA AGATCAAAGT GCTGGGCTCC 
2161   GGTGCGTTCG GCACGGTGTA TAAGGGACTC TGGATCCCAG AAGGTGAGAA AGTTAAAATT CCCGTCGCTA TCAAGGAATT AAGAGAAGCA ACATCTCCGA AAGCCAACAA GGAAATCCTC 
2281   GATGAAGCCT ACGTGATGGC CAGCGTGGAC AACCCCCACG TGTGCCGCCT GCTGGGCATC TGCCTCACCT CCACCGTGCA GCTCATCACG CAGCTCATGC CCTTCGGCTG CCTCCTGGAC 
2401   TATGTCCGGG AACACAAAGA CAATATTGGC TCCCAGTACC TGCTCAACTG GTGTGTGCAG ATCGCAAAGG GCATGAACTA CTTGGAGGAC CGTCGCTTGG TGCACCGCGA CCTGGCAGCC 
2521   AGGAACGTAC TGGTGAAAAC ACCGCAGCAT GTCAAGATCA CAGATTTTGG GCTGGCCAAA CTGCTGGGTG CGGAAGAGAA AGAATACCAT GCAGAAGGAG GCAAAGTGCC TATCAAGTGG 
2641   ATGGCATTGG AATCAATTTT ACACAGAATC TATACCCACC AGAGTGATGT CTGGAGCTAC GGGGTGACTG TTTGGGAGTT GATGACCTTT GGATCCAAGC CATATGACGG AATCCCTGCC 
2761   AGCGAGATCT CCTCCATCCT GGAGAAAGGA GAACGCCTCC CTCAGCCACC CATATGTACC ATCGATGTCT ACATGATCAT GGTCAAGTGC TGGATGATAG ACGCAGATAG TCGCCCAAAG 
2881   TTCCGTGAGT TGATCATCGA ATTCTCCAAA ATGGCCCGAG ACCCCCAGCG CTACCTTGTC ATTCAGGGGG ATGAAAGAAT GCATTTGCCA AGTCCTACAG ACTCCAACTT CTACCGTGCC 
3001   CTGATGGATG AAGAAGACAT GGACGACGTG GTGGATGCCG ACGAGTACCT CATCCCACAG CAGGGCTTCT TCAGCAGCCC CTCCACGTCA CGGACTCCCC TCCTGAGCTC TCTGCTTGTG 
3121   GAGCCTCTTA CACCCAGTGG AGAAGCTCCC AACCAAGCTC TCTTGAGGAT CTTGAAGGAA ACTGAATTCA AAAAGATCAA AGTGCTGGGC TCCGGTGCGT TCGGCACGGT GTATAAGGGA 
3241   CTCTGGATCC CAGAAGGTGA GAAAGTTAAA ATTCCCGTCG CTATCAAGGA ATTAAGAGAA GCAACATCTC CGAAAGCCAA CAAGGAAATC CTCGATGAAG CCTACGTGAT GGCCAGCGTG 
3361   GACAACCCCC ACGTGTGCCG CCTGCTGGGC ATCTGCCTCA CCTCCACCGT GCAGCTCATC ACGCAGCTCA TGCCCTTCGG CTGCCTCCTG GACTATGTCC GGGAACACAA AGACAATATT 
3481   GGCTCCCAGT ACCTGCTCAA CTGGTGTGTG CAGATCGCAA AGGGCATGAA CTACTTGGAG GACCGTCGCT TGGTGCACCG CGACCTGGCA GCCAGGAACG TACTGGTGAA AACACCGCAG 
3601   CATGTCAAGA TCACAGATTT TGGGCTGGCC AAACTGCTGG GTGCGGAAGA GAAAGAATAC CATGCAGAAG GAGGCAAAGT GCCTATCAAG TGGATGGCAT TGGAATCAAT TTTACACAGA 
3721   ATCTATACCC ACCAGAGTGA TGTCTGGAGC TACGGGGTGA CCGTTTGGGA GTTGATGACC TTTGGATCCA AGCCATATGA CGGAATCCCT GCCAGCGAGA TCTCCTCCAT CCTGGAGAAA 
3841   GGAGAACGCC TCCCTCAGCC ACCCATATGT ACCATCGATG TCTACATGAT CATGGTCAAG TGCTGGATGA TAGACGCAGA TAGTCGCCCA AAGTTCCGTG AGTTGATCAT CGAATTCTCC 
3961   AAAATGGCCC GAGACCCCCA GCGCTACCTT GTCATTCAGG GGGATGAAAG AATGCATTTG CCAAGTCCTA CAGACTCCAA CTTCTACCGT GCCCTGATGG ATGAAGAAGA CATGGACGAC 
4081   GTGGTGGATG CCGACGAGTA CCTCATCCCA CAGCAGGGCT TCTTCAGCAG CCCCTCCACG TCACGGACTC CCCTCCTGAG CTCTCTGagt gcaaccagca acaattccac cgtggcttgc 
4201   attgatagaa atgggctgca aagctgtccc atcaaggaag acagcttctt gcagcgatac agctcagacc ccacaggcgc cttgactgag gacagcatag acgacacctt cctcccagtg 
4321   cctgaataca taaaccagtc cgttcccaaa aggcccgctg gctctgtgca gaatcctgtc tatcacaatc agcctctgaa ccccgcgccc agcagagacc cacactacca ggacccccac 
4441   agcactgcag tgggcaaccc cgagtatctc aacactgtcc agcccacctg tgtcaacagc acattcgaca gccctgccca ctgggcccag aaaggcagcc accaaattag cctggacaac 
4561   cctgactacc agcaggactt ctttcccaag gaagccaagc caaatggcat ctttaagggc tccacagctg aaaatgcaga atacctaagg gtcgcgccac aaagcagtga atttattgga 
4681   gcatga
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Figure S3.3: Sequencing reads identifying EGFR-KDD in a lung adenocarcinoma tumor from TCGA.  
A, next-generation sequencing (NGS) reads of RNA-seq of EGFR exons 16–20 and B, 23–28 of TCGA-49-4512. C, 
whole-genome sequencing reads from exons 18–19 and D, 25–26 of TCGA-49-4512. Paired reads with a pattern of 
tandem duplication are pictured in green, and breakpoint-spanning (soft-clipped) reads are pictured as colored base pair 
mismatches. The boundaries of the EGFR-KDD are visible at the RNA level in EGFR exon 18 and exon 25 with 
corresponding intronic DNA breakpoints between exons 17 and 18 and exons 25 and 26. The data were visualized using 
the Integrative Genomics Viewer (3). This figure corresponds to Supplementary Figure 3 from Gallant et al. Cancer 
Discovery, 2015 (2).
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Figure S3.4: Autophosphorylation of endogenous EGFR-KDD in A1235 cells. 
II-18 (EGFR-L858R) and A1235 (EGFR-KDD) cell lines were grown in the presence or absence of serum (FBS), or 
treated with 1 or 50 ng/mL EGF for 5 minutes after 16 hours of serum starvation, and then lysed for western blot analysis 
with the indicated antibodies. This figure corresponds to Supplementary Figure 4 from Gallant et al. Cancer Discovery, 
2015 (2).
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Figure S3.5: Colony formation of NR6 cells expressing EGFR variants. 
A, representative 5x microscopy photographs of NR6 cells transduced with pMSCV vector, B, EGFR-WT, C, EGFR-
L858R, or D, EGFR-KDD after 15 days of growth in soft agar. This figure corresponds to Supplementary Figure 5 from 
Gallant et al. Cancer Discovery, 2015 (2).
A       B
C       D
           
 
 
 
 
 
 
 
 
 
             
107 
Figure S3.6: Efficacy of EGFR TKIs in endogenous and ectopic models of the EGFR-KDD. 
A, 293T cells transfected with EGFR-KDD were treated with increasing doses of erlotinib or afatinib for 2 hours and lysed 
for western blot analysis. B, A1235 cells, which harbor endogenous EGFR-KDD, were treated with increasing doses of 
erlotinib, afatinib, or AZD9291 for 2 hours and lysed for western blot analysis. C, A1235 cells were treated with increasing 
doses of erlotinib, afatinib, or AZD9291 for 72 hours. Cell titer blue assays were performed to assess cell viability. Each 
point represents quadruple replicates. Data are presented as the percentage of viable cells compared to vehicle control. 
This figure corresponds to Supplementary Figure 6 from Gallant et al. Cancer Discovery, 2015 (2).
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Table S3.1: Results of MTT curve fitting from Prism. 
These data correspond to the graphs shown in Figure 3.2B. This table corresponds to Supplementary Table 1 from 
Gallant et al. Cancer Discovery, 2015 (2).
BA/F3 - EGFR-KDD 
erlotinib afatinib AZD9291 
EC50 (nM) 109.5 3.1 28.5 
Goodness of fit (R2) 0.88 0.80 0.92 
BA/F3 - EGFR-L858R 
erlotinib afatinib AZD9291 
EC50 (nM) 6.1 0.02 4.0 
Goodness of fit (R2) 0.89 0.84 0.80 
sgRNA cloning oligos 
Target and name Forward primer (5’→ 3’) Reverse primer (5’→ 3’) 
EGFR gRNA#1 caccgGATAGGTGGATCGGCTGCCT aaacAGGCAGCCGATCCACCTATCc 
EGFR gRNA#2 caccgTGGCTAGCCGGACAGTGAGG aaacCCACACTGTCCGGCTAGCCAc 
RAD51 gRNA#1 caccgGACAATCACTTGAACCCGGA aaacTCCGGGTTCAAGTGATTGTCc 
RAD51 gRNA#2 caccgCAAAAATTAGCCACGTGTGG aaacCCACACGTGGCTAATTTTTGc 
EGFR-RAD51 gRNA#1 aaaggacgaaacaccgGATAGGTGGATCGGCTGCCTgttttagagctagaaatagcaag ttctagctctaaaacTCCGGGTTCAAGTGATTGTCggatccaaggtgtctcatac 
EGFR-RAD51 gRNA#2 aaaggacgaaacaccgTGGCTAGCCGGACAGTGAGGgttttagagctagaaatagcaag ttctagctctaaaacCCACACGTGGCTAATTTTTGggatccaaggtgtctcatac 
Primers to amplify targeted regions for SURVEYOR assay 
Target Forward primer (5’→ 3’) Reverse primer (5’→ 3’) 
EGFR GTTTTCCCAGTCACGACaattgcagtctgtgcttcca CAGGAAACAGCTATGACctggtgcagagattttgagg 
RAD51 GTTTTCCCAGTCACGACtctgttttcgctttttgggta CAGGAAACAGCTATGACccatgggagctcaaggaata 
Primers to amplify genomic breakpoint regions for RT-PCR 
EGFR-RAD51 GTTTTCCCAGTCACGACaattgcagtctgtgcttcca CAGGAAACAGCTATGACccatgggagctcaaggaata 
Primers to amplify genomic breakpoint regions for PCR and sequencing 
EGFR-RAD51 GTTTTCCCAGTCACGACgccacatcgtgaactaagca CAGGAAACAGCTATGACactttgggaggctgaggtg 
Table S4.1: Primers used for EGFR-RAD51 cell line engineering using the CRISPR-Cas9 system. 
For sgRNA cloning oligos: cloning sites colored blue; U6 promoter enhancer colored green; sgRNA capitalized with PAM in red. For primers to amplify regions for 
SURVEYOR assay, RT/PCR, and sequencing: M13 sequencing primers are capitalized and the binding portion of the oligo is in lower case.
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Figure S4.1: Comparison of EGFR-KDD sequences. 
Left: published EGFR-KDD sequence (2). Right: EGFR-KDD with degenerate kinase sequences. Red: coding sequence 
outside of exons 18–25. Aqua: first exon 18–25 repeat; first kinase sequence. Dark green: second exons 18–25 repeat; 
second kinase sequence.
EGFR-KDD CCDS (verified and ordered previously)
1      ATGCGACCCT CCGGGACGGC CGGGGCAGCG CTCCTGGCGC TGCTGGCTGC GCTCTGCCCG 
61     GCGAGTCGGG CTCTGGAGGA AAAGAAAGTT TGCCAAGGCA CGAGTAACAA GCTCACGCAG 
121    TTGGGCACTT TTGAAGATCA TTTTCTCAGC CTCCAGAGGA TGTTCAATAA CTGTGAGGTG 
181    GTCCTTGGGA ATTTGGAAAT TACCTATGTG CAGAGGAATT ATGATCTTTC CTTCTTAAAG 
241    ACCATCCAGG AGGTGGCTGG TTATGTCCTC ATTGCCCTCA ACACAGTGGA GCGAATTCCT 
301    TTGGAAAACC TGCAGATCAT CAGAGGAAAT ATGTACTACG AAAATTCCTA TGCCTTAGCA 
361    GTCTTATCTA ACTATGATGC AAATAAAACC GGACTGAAGG AGCTGCCCAT GAGAAATTTA 
421    CAGGAAATCC TGCATGGCGC CGTGCGGTTC AGCAACAACC CTGCCCTGTG CAACGTGGAG 
481    AGCATCCAGT GGCGGGACAT AGTCAGCAGT GACTTTCTCA GCAACATGTC GATGGACTTC 
541    CAGAACCACC TGGGCAGCTG CCAAAAGTGT GATCCAAGCT GTCCCAATGG GAGCTGCTGG 
601    GGTGCAGGAG AGGAGAACTG CCAGAAACTG ACCAAAATCA TCTGTGCCCA GCAGTGCTCC 
661    GGGCGCTGCC GTGGCAAGTC CCCCAGTGAC TGCTGCCACA ACCAGTGTGC TGCAGGCTGC 
721    ACAGGCCCCC GGGAGAGCGA CTGCCTGGTC TGCCGCAAAT TCCGAGACGA AGCCACGTGC 
781    AAGGACACCT GCCCCCCACT CATGCTCTAC AACCCCACCA CGTACCAGAT GGATGTGAAC 
841    CCCGAGGGCA AATACAGCTT TGGTGCCACC TGCGTGAAGA AGTGTCCCCG TAATTATGTG 
901    GTGACAGATC ACGGCTCGTG CGTCCGAGCC TGTGGGGCCG ACAGCTATGA GATGGAGGAA 
961    GACGGCGTCC GCAAGTGTAA GAAGTGCGAA GGGCCTTGCC GCAAAGTGTG TAACGGAATA 
1021   GGTATTGGTG AATTTAAAGA CTCACTCTCC ATAAATGCTA CGAATATTAA ACACTTCAAA 
1081   AACTGCACCT CCATCAGTGG CGATCTCCAC ATCCTGCCGG TGGCATTTAG GGGTGACTCC 
1141   TTCACACATA CTCCTCCTCT GGATCCACAG GAACTGGATA TTCTGAAAAC CGTAAAGGAA 
1201   ATCACAGGGT TTTTGCTGAT TCAGGCTTGG CCTGAAAACA GGACGGACCT CCATGCCTTT 
1261   GAGAACCTAG AAATCATACG CGGCAGGACC AAGCAACATG GTCAGTTTTC TCTTGCAGTC 
1321   GTCAGCCTGA ACATAACATC CTTGGGATTA CGCTCCCTCA AGGAGATAAG TGATGGAGAT 
1381   GTGATAATTT CAGGAAACAA AAATTTGTGC TATGCAAATA CAATAAACTG GAAAAAACTG 
1441   TTTGGGACCT CCGGTCAGAA AACCAAAATT ATAAGCAACA GAGGTGAAAA CAGCTGCAAG 
1501   GCCACAGGCC AGGTCTGCCA TGCCTTGTGC TCCCCCGAGG GCTGCTGGGG CCCGGAGCCC 
1561   AGGGACTGCG TCTCTTGCCG GAATGTCAGC CGAGGCAGGG AATGCGTGGA CAAGTGCAAC 
1621   CTTCTGGAGG GTGAGCCAAG GGAGTTTGTG GAGAACTCTG AGTGCATACA GTGCCACCCA 
1681   GAGTGCCTGC CTCAGGCCAT GAACATCACC TGCACAGGAC GGGGACCAGA CAACTGTATC 
1741   CAGTGTGCCC ACTACATTGA CGGCCCCCAC TGCGTCAAGA CCTGCCCGGC AGGAGTCATG 
1801   GGAGAAAACA ACACCCTGGT CTGGAAGTAC GCAGACGCCG GCCATGTGTG CCACCTGTGC 
1861   CATCCAAACT GCACCTACGG ATGCACTGGG CCAGGTCTTG AAGGCTGTCC AACGAATGGG 
1921   CCTAAGATCC CGTCCATCGC CACTGGGATG GTGGGGGCCC TCCTCTTGCT GCTGGTGGTG 
1981   GCCCTGGGGA TCGGCCTCTT CATGCGAAGG CGCCACATCG TTCGGAAGCG CACGCTGCGG 
2041   AGGCTGCTGC AGGAGAGGGA GCTTGTGGAG CCTCTTACAC CCAGTGGAGA AGCTCCCAAC 
2101   CAAGCTCTCT TGAGGATCTT GAAGGAAACT GAATTCAAAA AGATCAAAGT GCTGGGCTCC 
2161   GGTGCGTTCG GCACGGTGTA TAAGGGACTC TGGATCCCAG AAGGTGAGAA AGTTAAAATT 
2221   CCCGTCGCTA TCAAGGAATT AAGAGAAGCA ACATCTCCGA AAGCCAACAA GGAAATCCTC 
2281   GATGAAGCCT ACGTGATGGC CAGCGTGGAC AACCCCCACG TGTGCCGCCT GCTGGGCATC 
2341   TGCCTCACCT CCACCGTGCA GCTCATCACG CAGCTCATGC CCTTCGGCTG CCTCCTGGAC 
2401   TATGTCCGGG AACACAAAGA CAATATTGGC TCCCAGTACC TGCTCAACTG GTGTGTGCAG 
2461   ATCGCAAAGG GCATGAACTA CTTGGAGGAC CGTCGCTTGG TGCACCGCGA CCTGGCAGCC 
2521   AGGAACGTAC TGGTGAAAAC ACCGCAGCAT GTCAAGATCA CAGATTTTGG GCTGGCCAAA 
2581   CTGCTGGGTG CGGAAGAGAA AGAATACCAT GCAGAAGGAG GCAAAGTGCC TATCAAGTGG 
2641   ATGGCATTGG AATCAATTTT ACACAGAATC TATACCCACC AGAGTGATGT CTGGAGCTAC 
2701   GGGGTGACTG TTTGGGAGTT GATGACCTTT GGATCCAAGC CATATGACGG AATCCCTGCC 
2761   AGCGAGATCT CCTCCATCCT GGAGAAAGGA GAACGCCTCC CTCAGCCACC CATATGTACC 
2821   ATCGATGTCT ACATGATCAT GGTCAAGTGC TGGATGATAG ACGCAGATAG TCGCCCAAAG 
2881   TTCCGTGAGT TGATCATCGA ATTCTCCAAA ATGGCCCGAG ACCCCCAGCG CTACCTTGTC 
2941   ATTCAGGGGG ATGAAAGAAT GCATTTGCCA AGTCCTACAG ACTCCAACTT CTACCGTGCC 
3001   CTGATGGATG AAGAAGACAT GGACGACGTG GTGGATGCCG ACGAGTACCT CATCCCACAG 
3061   CAGGGCTTCT TCAGCAGCCC CTCCACGTCA CGGACTCCCC TCCTGAGCTC TCTGCTTGTG 
3121   GAGCCTCTTA CACCCAGTGG AGAAGCTCCC AACCAAGCTC TCTTGAGGAT CTTGAAGGAA 
3181   ACTGAATTCA AAAAGATCAA AGTGCTGGGC TCCGGTGCGT TCGGCACGGT GTATAAGGGA 
3241   CTCTGGATCC CAGAAGGTGA GAAAGTTAAA ATTCCCGTCG CTATCAAGGA ATTAAGAGAA 
3301   GCAACATCTC CGAAAGCCAA CAAGGAAATC CTCGATGAAG CCTACGTGAT GGCCAGCGTG 
3361   GACAACCCCC ACGTGTGCCG CCTGCTGGGC ATCTGCCTCA CCTCCACCGT GCAGCTCATC 
3421   ACGCAGCTCA TGCCCTTCGG CTGCCTCCTG GACTATGTCC GGGAACACAA AGACAATATT 
3481   GGCTCCCAGT ACCTGCTCAA CTGGTGTGTG CAGATCGCAA AGGGCATGAA CTACTTGGAG 
3541   GACCGTCGCT TGGTGCACCG CGACCTGGCA GCCAGGAACG TACTGGTGAA AACACCGCAG 
3601   CATGTCAAGA TCACAGATTT TGGGCTGGCC AAACTGCTGG GTGCGGAAGA GAAAGAATAC 
3661   CATGCAGAAG GAGGCAAAGT GCCTATCAAG TGGATGGCAT TGGAATCAAT TTTACACAGA 
3721   ATCTATACCC ACCAGAGTGA TGTCTGGAGC TACGGGGTGA CCGTTTGGGA GTTGATGACC 
3781   TTTGGATCCA AGCCATATGA CGGAATCCCT GCCAGCGAGA TCTCCTCCAT CCTGGAGAAA 
3841   GGAGAACGCC TCCCTCAGCC ACCCATATGT ACCATCGATG TCTACATGAT CATGGTCAAG 
3901   TGCTGGATGA TAGACGCAGA TAGTCGCCCA AAGTTCCGTG AGTTGATCAT CGAATTCTCC 
3961   AAAATGGCCC GAGACCCCCA GCGCTACCTT GTCATTCAGG GGGATGAAAG AATGCATTTG 
4021   CCAAGTCCTA CAGACTCCAA CTTCTACCGT GCCCTGATGG ATGAAGAAGA CATGGACGAC 
4081   GTGGTGGATG CCGACGAGTA CCTCATCCCA CAGCAGGGCT TCTTCAGCAG CCCCTCCACG 
4141   TCACGGACTC CCCTCCTGAG CTCTCTGAGT GCAACCAGCA ACAATTCCAC CGTGGCTTGC 
4201   ATTGATAGAA ATGGGCTGCA AAGCTGTCCC ATCAAGGAAG ACAGCTTCTT GCAGCGATAC 
4261   AGCTCAGACC CCACAGGCGC CTTGACTGAG GACAGCATAG ACGACACCTT CCTCCCAGTG 
4321   CCTGAATACA TAAACCAGTC CGTTCCCAAA AGGCCCGCTG GCTCTGTGCA GAATCCTGTC 
4381   TATCACAATC AGCCTCTGAA CCCCGCGCCC AGCAGAGACC CACACTACCA GGACCCCCAC 
4441   AGCACTGCAG TGGGCAACCC CGAGTATCTC AACACTGTCC AGCCCACCTG TGTCAACAGC 
4501   ACATTCGACA GCCCTGCCCA CTGGGCCCAG AAAGGCAGCC ACCAAATTAG CCTGGACAAC 
4561   CCTGACTACC AGCAGGACTT CTTTCCCAAG GAAGCCAAGC CAAATGGCAT CTTTAAGGGC 
4621   TCCACAGCTG AAAATGCAGA ATACCTAAGG GTCGCGCCAC AAAGCAGTGA ATTTATTGGA 
4681   GCATGA 
Use degeneracy of genetic 
code to create 59% dissimilar 
first kinase sequence
Reconstruct new EGFR-KDD sequence with silent mutations in 18
 1 ATGCGACCCT CCGGGACGGC CGGGGCAGCG CTCCTGGCGC TGCTGGCTGC GCTCTGCCCG 
 61 GCGAGTCGGG CTCTGGAGGA AAAGAAAGTT TGCCAAGGCA CGAGTAACAA GCTCACGCAG 
 121 TTGGGCACTT TTGAAGATCA TTTTCTCAGC CTCCAGAGGA TGTTCAATAA CTGTGAGGTG 
 181 GTCCTTGGGA ATTTGGAAAT TACCTATGTG CAGAGGAATT ATGATCTTTC CTTCTTAAAG 
 241 ACCATCCAGG AGGTGGCTGG TTATGTCCTC ATTGCCCTCA ACACAGTGGA GCGAATTCCT 
 301 TTGGAAAACC TGCAGATCAT CAGAGGAAAT ATGTACTACG AAAATTCCTA TGCCTTAGCA 
 361 GTCTTATCTA ACTATGATGC AAATAAAACC GGACTGAAGG AGCTGCCCAT GAGAAATTTA 
 421 CAGGAAATCC TGCATGGCGC CGTGCGGTTC AGCAACAACC CTGCCCTGTG CAACGTGGAG 
 481 AGCATCCAGT GGCGGGACAT AGTCAGCAGT GACTTTCTCA GCAACATGTC GATGGACTTC 
 541 CAGAACCACC TGGGCAGCTG CCAAAAGTGT GATCCAAGCT GTCCCAATGG GAGCTGCTGG 
 601 GGTGCAGGAG AGGAGAACTG CCAGAAACTG ACCAAAATCA TCTGTGCCCA GCAGTGCTCC 
 661 GGGCGCTGCC GTGGCAAGTC CCCCAGTGAC TGCTGCCACA ACCAGTGTGC TGCAGGCTGC 
 721 ACAGGCCCCC GGGAGAGCGA CTGCCTGGTC TGCCGCAAAT TCCGAGACGA AGCCACGTGC 
 781 AAGGACACCT GCCCCCCACT CATGCTCTAC AACCCCACCA CGTACCAGAT GGATGTGAAC 
 841 CCCGAGGGCA AATACAGCTT TGGTGCCACC TGCGTGAAGA AGTGTCCCCG TAATTATGTG 
 901 GTGACAGATC ACGGCTCGTG CGTCCGAGCC TGTGGGGCCG ACAGCTATGA GATGGAGGAA 
 961 GACGGCGTCC GCAAGTGTAA GAAGTGCGAA GGGCCTTGCC GCAAAGTGTG TAACGGAATA 
 1021 GGTATTGGTG AATTTAAAGA CTCACTCTCC ATAAATGCTA CGAATATTAA ACACTTCAAA 
 1081 AACTGCACCT CCATCAGTGG CGATCTCCAC ATCCTGCCGG TGGCATTTAG GGGTGACTCC 
 1141 TTCACACATA CTCCTCCTCT GGATCCACAG GAACTGGATA TTCTGAAAAC CGTAAAGGAA 
 1201 ATCACAGGGT TTTTGCTGAT TCAGGCTTGG CCTGAAAACA GGACGGACCT CCATGCCTTT 
 1261 GAGAACCTAG AAATCATACG CGGCAGGACC AAGCAACATG GTCAGTTTTC TCTTGCAGTC 
 1321 GTCAGCCTGA ACATAACATC CTTGGGATTA CGCTCCCTCA AGGAGATAAG TGATGGAGAT 
 1381 GTGATAATTT CAGGAAACAA AAATTTGTGC TATGCAAATA CAATAAACTG GAAAAAACTG 
 1441 TTTGGGACCT CCGGTCAGAA AACCAAAATT ATAAGCAACA GAGGTGAAAA CAGCTGCAAG 
 1501 GCCACAGGCC AGGTCTGCCA TGCCTTGTGC TCCCCCGAGG GCTGCTGGGG CCCGGAGCCC 
 1561 AGGGACTGCG TCTCTTGCCG GAATGTCAGC CGAGGCAGGG AATGCGTGGA CAAGTGCAAC 
 1621 CTTCTGGAGG GTGAGCCAAG GGAGTTTGTG GAGAACTCTG AGTGCATACA GTGCCACCCA 
 1681 GAGTGCCTGC CTCAGGCCAT GAACATCACC TGCACAGGAC GGGGACCAGA CAACTGTATC 
 1741 CAGTGTGCCC ACTACATTGA CGGCCCCCAC TGCGTCAAGA CCTGCCCGGC AGGAGTCATG 
 1801 GGAGAAAACA ACACCCTGGT CTGGAAGTAC GCAGACGCCG GCCATGTGTG CCACCTGTGC 
 1861 CATCCAAACT GCACCTACGG ATGCACTGGG CCAGGTCTTG AAGGCTGTCC AACGAATGGG 
 1921 CCTAAGATCC CGTCCATCGC CACTGGGATG GTGGGGGCCC TCCTCTTGCT GCTGGTGGTG 
 1981 GCCCTGGGGA TCGGCCTCTT CATGCGAAGG CGCCACATCG TTCGGAAGCG CACGCTGCGG 
 2041 AGGCTGCTGC AGGAGAGGGA Gttggtcgaa ccgttgaccc cgtcgggcga ggcgccgaat 
 2101 caggcgttgc tccgcatact caaagagacg gagtttaaga aaataaaggt cttagggagt 
 2161 ggggcctttg ggaccgtcta caaaggcttg tggatacccg agggggaaaa ggtgaagata 
 2221 ccggtggcga taaaagagct ccgcgaggcc accagcccca aggcgaataa agagatattg 
 2281 gacgaggcgt atgtcatggc gtcggtcgat aatccgcatg tctgtaggtt attagggata 
 2341 tgtttgacga gtacggtcca attgataacc caattgatgc cgtttgggtg tttgttagat 
 2401 tacgtgagag agcataagga taacataggg agtcaatatt tattgaattg gtgcgtccaa 
 2461 atagccaaag ggatgaatta tctcgaagat aggaggctcg tccataggga tttagccgcg 
 2521 cgcaatgtct tagtcaagac cccccaacac gtgaaaataa ccgacttcgg cttagcgaag 
 2581 ttattagggg ccgaggaaaa ggagtatcac gccgagggcg ggaaggtccc gataaaatgg 
 2641 atggccctcg agagcatact ccatcgcata tacacgcatc aatcggacgt gtggtcgtat 
 2701 ggcgtcacgg tgtgggaact catgacgttc ggcagtaaac cctacgatgg cataccggcg 
 2761 tcggaaataa gtagtatatt agaaaagggc gagaggttgc cgcaaccccc gatctgcacg 
 2821 atagacgtgt atatgataat ggtgaaatgt tggatgatcg atgccgactc gaggcccaaa 
 2881 tttagggaac tcataataga gtttagtaag atggcgaggg atccgcaaag gtatttggtg 
 2941 atacaaggcg acgagcgcat gcacctcccc tcgccgaccg atagtaattt ttatagggcg 
 3001 ttaatggacg aggaggatat ggatgatgtc gtcgacgcgg atgaatattt gataccccaa 
 3061 caagggtttt tttcgtcgcc gagtaccagc agaacgccgt tgttatcgag cttaCTTGTG 
 3121 GAGCCTCTTA CACCCAGTGG AGAAGCTCCC AACCAAGCTC TCTTGAGGAT CTTGAAGGAA 
 3181 ACTGAATTCA AAAAGATCAA AGTGCTGGGC TCCGGTGCGT TCGGCACGGT GTATAAGGGA 
 3241 CTCTGGATCC CAGAAGGTGA GAAAGTTAAA ATTCCCGTCG CTATCAAGGA ATTAAGAGAA 
 3301 GCAACATCTC CGAAAGCCAA CAAGGAAATC CTCGATGAAG CCTACGTGAT GGCCAGCGTG 
 3361 GACAACCCCC ACGTGTGCCG CCTGCTGGGC ATCTGCCTCA CCTCCACCGT GCAGCTCATC 
 3421 ACGCAGCTCA TGCCCTTCGG CTGCCTCCTG GACTATGTCC GGGAACACAA AGACAATATT 
 3481 GGCTCCCAGT ACCTGCTCAA CTGGTGTGTG CAGATCGCAA AGGGCATGAA CTACTTGGAG 
 3541 GACCGTCGCT TGGTGCACCG CGACCTGGCA GCCAGGAACG TACTGGTGAA AACACCGCAG 
 3601 CATGTCAAGA TCACAGATTT TGGGCTGGCC AAACTGCTGG GTGCGGAAGA GAAAGAATAC 
 3661 CATGCAGAAG GAGGCAAAGT GCCTATCAAG TGGATGGCAT TGGAATCAAT TTTACACAGA 
 3721 ATCTATACCC ACCAGAGTGA TGTCTGGAGC TACGGGGTGA CCGTTTGGGA GTTGATGACC 
 3781 TTTGGATCCA AGCCATATGA CGGAATCCCT GCCAGCGAGA TCTCCTCCAT CCTGGAGAAA 
 3841 GGAGAACGCC TCCCTCAGCC ACCCATATGT ACCATCGATG TCTACATGAT CATGGTCAAG 
 3901 TGCTGGATGA TAGACGCAGA TAGTCGCCCA AAGTTCCGTG AGTTGATCAT CGAATTCTCC 
 3961 AAAATGGCCC GAGACCCCCA GCGCTACCTT GTCATTCAGG GGGATGAAAG AATGCATTTG 
 4021 CCAAGTCCTA CAGACTCCAA CTTCTACCGT GCCCTGATGG ATGAAGAAGA CATGGACGAC 
 4081 GTGGTGGATG CCGACGAGTA CCTCATCCCA CAGCAGGGCT TCTTCAGCAG CCCCTCCACG 
 4141 TCACGGACTC CCCTCCTGAG CTCTCTGAGT GCAACCAGCA ACAATTCCAC CGTGGCTTGC 
 4201 ATTGATAGAA ATGGGCTGCA AAGCTGTCCC ATCAAGGAAG ACAGCTTCTT GCAGCGATAC 
 4261 AGCTCAGACC CCACAGGCGC CTTGACTGAG GACAGCATAG ACGACACCTT CCTCCCAGTG 
 4321 CCTGAATACA TAAACCAGTC CGTTCCCAAA AGGCCCGCTG GCTCTGTGCA GAATCCTGTC 
 4381 TATCACAATC AGCCTCTGAA CCCCGCGCCC AGCAGAGACC CACACTACCA GGACCCCCAC 
 4441 AGCACTGCAG TGGGCAACCC CGAGTATCTC AACACTGTCC AGCCCACCTG TGTCAACAGC 
 4501 ACATTCGACA GCCCTGCCCA CTGGGCCCAG AAAGGCAGCC ACCAAATTAG CCTGGACAAC 
 4561 CCTGACTACC AGCAGGACTT CTTTCCCAAG GAAGCCAAGC CAAATGGCAT CTTTAAGGGC 
 4621 TCCACAGCTG AAAATGCAGA ATACCTAAGG GTCGCGCCAC AAAGCAGTGA ATTTATTGGA 
 4681 GCATGA 
EGFR-KDD 
(identical kinase domain sequences)
EGFR-KDD 
(degenerate kinas  s quences)
Figure S4.2: Lack of protein expression from degenerate EGFR-KDD constructs. 
A, representative western blot (of N=4) of NR6 cells stably expressing EGFR-KDD and the indicated mutants. Tandem = identical kinase sequences (2); 
degenerate = two different kinase sequences. B, representative western blot (of N=4) of Ba/F3 cells stably expressing EGFR-KDD and the indicated mutants. 
Tandem = identical kinase sequences; degenerate = two different kinase sequences. C, western blot of CHO cells stably expressing EGFR-KDD and the indicated 
mutants. Tandem = identical kinase sequences; degenerate = two different kinase sequences. D, codon adaptation index of the tandem vs. degenerate EGFR-
KDD sequences. Proteins with a codon adaptation > 80 should express; those with a codon adaptation below 60 (at any point) may not express (4). E, tandem 
rare codons through the sequence of the degenerate EGFR-KDD sequence. Tandem rare codons can cause ribosomal slippage and poor protein expression (5). 
The tandem EGFR-KDD had no tandem rare codons; the degenerate EGFR-KDD sequence had 4 pairs, as shown.
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Figure S4.3: Creation of EGFR-KDD single mutants from a construct with two identical kinase domains. 
A, workflow for creation of single EGFR-KDD mutants. i, overview of the construct demonstrating the location of each 
mutation and the ClaI restriction sites. ii, sample multi-site directed mutagenesis, here for tandem TM (threonine to 
methionine; T790M and T1141M) mutations. iii, ClaI digest of TM mutated EGFR-KDD plasmid is recombined with a ClaI–
ClaI segment from unmutated EGFR-KDD. iv, ClaI digest of unmutated EGFR-KDD plasmid is recombined with a ClaI–
ClaI segment from TM mutated EGFR-KDD. B, Ba/F3 cells lines stably expressing EGFR constructs. Note the difference 
in expression levels between the EGFR-KDD (degenerate) construct and the EGFR-KDD tandem (two identical kinase 
domains) construct.
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Mutation Forward primer (5’⟶  3’) Reverse primer (5’⟶  3’) 
I706Q cccaaccaagctctcttgaggcagttgaaggaaactgagttcaaa tttgaactcagtttccttcaactgcctcaagagagcttggttggg 
K745M aaagttaaaattcccgtcgctatcatggaattaagagaagcaac gttgcttctcttaattccatgatagcgacgggaattttaacttt 
D837N cttggtgcaccgcaacctggcagccag ctggctgccaggttgcggtgcaccaag 
Y869F gctgggtgcggaagagaaagaattccatgcagaagg ccttctgcatggaattctttctcttccgcacccagc 
Y915F tgacctttggatccaagccatttgacggaatccctg cagggattccgtcaaatggcttggatccaaaggtca 
Y944F atatgtaccatcgatgtcttcatgatcatggtcaagtgc gcacttgaccatgatcatgaagacatcgatggtacatat 
V948R cgatgtctacatgatcatgcgcaagtgctggatgatagac gtctatcatccagcacttgcgcatgatcatgtagacatcg 
Y978F cgagacccccagcgcttccttgtcattcag ctgaatgacaaggaagcgctgggggtctcg 
F993E ctgaggcagctaaattagttccaatgggtgagaccactgcaactgag ctcagttgcagtggtctcacccattggaactaatttagctgcctcag 
F993R ctaaattagttccaatgggtcgcaccactgcaactgagttcc ggaactcagttgcagtggtgcgacccattggaactaatttag 
A996W ttagttccaatgggtttcaccacttggactgagttccaccaaagg cctttggtggaactcagtccaagtggtgaaacccattggaactaa 
A996R tccaatgggtttcaccactagaactgagttccaccaaagg cctttggtggaactcagttctagtggtgaaacccattgga 
F993R+A996R gctaaattagttccaatgggtcgcaccactagaactgagttccaccaaaggcg cgcctttggtggaactcagttctagtggtgcgacccattggaactaatttagc 
A1097W tggcagtgatgtcctggataatgtatggtatgctcgagcgttcaa ttgaacgctcgagcataccatacattatccaggacatcactgcca 
A1099W gcagtgatgtcctggataatgtagcatattggcgagcgttcaacaca tgtgttgaacgctcgccaatatgctacattatccaggacatcactgc 
A1097W+A1099W tctctctggcagtgatgtcctggataatgtatggtattggcgagcgttcaacacagaccac gtggtctgtgttgaacgctcgccaataccatacattatccaggacatcactgccagagaga 
Y1222F ggaaaccagaatctgcaaaatcttcgactctccctg cagggagagtcgaagattttgcagattctggtttcc 
Δint24+ ccagcgctaccttgtcatttaggctgaggc gcctcagcctaaatgacaaggtagcgctgg 
stop/tag cloning gagtgggagatgccaaagacagaattcattaattaactgg ccagttattaatgaattctgtctttggcatctcccactc 
Table S4.2: Site-directed mutagenesis primers for use with EGFR-RAD51.
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Mutation Forward primer (5’⟶  3’) Reverse primer (5’⟶  3’) 
Site-directed mutagenesis primers for use with multi-site directed mutagenesis 
IQ cccaaccaagctctcttgaggcagttgaaggaaactgagttcaaa tttgaactcagtttccttcaactgcctcaagagagcttggttggg 
KM aaagttaaaattcccgtcgctatcatggaattaagagaagcaac gttgcttctcttaattccatgatagcgacgggaattttaacttt 
TM ccaccgtgcagctcatcatgcagctcatgc gcatgagctgcatgatgagctgcacggtgg 
DN cttggtgcaccgcaacctggcagccag ctggctgccaggttgcggtgcaccaag 
LR tcacagattttgggcgggccaaactgctggg cccagcagtttggcccgcccaaaatctgtga 
VR cgatgtctacatgatcatgcgcaagtgctggatgatagac gtctatcatccagcacttgcgcatgatcatgtagacatcg 
Site-directed mutagenesis primers for use with EGFR-KDD degenerate construct 
I706Q cgaatcaggcgttgctccgccagctcaaagagacggagtttaa ttaaactccgtctctttgagctggcggagcaacgcctgattcg 
K745M gtgaagataccggtggcgataatggagctccgcgag ctcgcggagctccattatcgccaccggtatcttcac 
T790M gagtacggtccaattgataatgcaattgatgccgtttgggtg cacccaaacggcatcaattgcattatcaattggaccgtactc 
D837N ggctcgtccataggaatttagccgcgcgc gcgcgcggctaaattcctatggacgagcc 
L858R gaaaataaccgacttcggcagagcgaagttattaggggcc ggcccctaataacttcgctctgccgaagtcggttattttc 
V948R cgatagacgtgtatatgataatgaggaaatgttggatgatcgatgccg cggcatcgatcatccaacatttcctcattatcatatacacgtctatcg 
I1057Q cccaaccaagctctcttgaggcagttgaaggaaactgagttcaaa tttgaactcagtttccttcaactgcctcaagagagcttggttggg 
K1096M aaagttaaaattcccgtcgctatcatggaattaagagaagcaac gttgcttctcttaattccatgatagcgacgggaattttaacttt 
T1141M ccaccgtgcagctcatcatgcagctcatgc gcatgagctgcatgatgagctgcacggtgg 
D1188N cttggtgcaccgcaacctggcagccag ctggctgccaggttgcggtgcaccaag 
L1209R tcacagattttgggcgggccaaactgctggg cccagcagtttggcccgcccaaaatctgtga 
V1299R cgatgtctacatgatcatgcgcaagtgctggatgatagac gtctatcatccagcacttgcgcatgatcatgtagacatcg 
Table S4.3: Site-directed mutagenesis primers for use with EGFR-KDD constructs.
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